Complementary peptide ligands generated from microbial genome sequences

ABSTRACT

In the current invention the application of our novel informatics approach to the databases containing nucleotide and peptide sequences from pathogens generates the sequence of many peptides which form the basis of an innovative and novel approach to developing anti-infective drugs.  
     This invention claims the use of specific complementary peptide to the proteins encoded in the genomes of known pathogens as reagents and drugs for drug discovery programmes.

[0001] At present more than 20 microbial genomes have been sequenced and over 80 are on going sequencing projects. Many of the microbes that have been selected are human pathogens and are responsible for a large proportion of the global burden of infectious disease.

BACKGROUND

[0002] Specific protein interactions are critical events in most biological processes and a clear idea of the way proteins interact, their three dimensional structure and the types of molecules which might block or enhance interaction are critical aspects of the science of drug discovery in the pharmaceutical industry.

[0003] Proteins are made up of strings of amino acids and each amino acid in a string is coded for by a triplet of nucleotides present in DNA sequences (Stryer 1997). The linear sequence of DNA code is read and translated by a cell's synthetic machinery to produce a linear sequence of amino acids that then fold to form a complex three-dimensional protein.

[0004] In general it is held that the primary structure of a protein determines its tertiary structure. A large volume of work supports this view and many sources of software are available to the scientists in order to produce models of protein structures (Sansom 1998). In addition, a considerable effort is underway in order to build on this principle and generate a definitive database demonstrating the relationships between primary and tertiary protein structures. This endeavour is likened to the human genome project and is estimated to have a similar cost (Gaasterland 1998).

[0005] The binding of large proteinaceous signalling molecules (such as hormones) to cellular receptors regulates a substantial portion of the control of cellular processes and functions. These protein-protein interactions are distinct from the interaction of substrates to enzymes or small molecule ligands to seven-transmembrane receptors. Protein-protein interactions occur over relatively large surface areas, as opposed to the interactions of small molecule ligands with serpentine receptors, or enzymes with their substrates, which usually occur in focused “pockets” or “clefts”. Thus, protein-protein targets are non-traditional and the pharmaceutical community has had very limited success in developing drugs that bind to them using currently available approaches to lead discovery. High throughput screening technologies in which large (combinatorial) libraries of synthetic compounds are screened against a target protein(s) have failed to produce a significant number of lead compounds.

[0006] Many major diseases result from the inactivity or hyperactivity of large protein signalling molecules. For example, diabetes mellitus results from the absence or ineffectiveness of insulin, and dwarfism from the lack of growth hormone. Thus, simple replacement therapy with recombinant forms of insulin or growth hormone heralded the beginnings of the biotechnology industry. However, nearly all drugs that target protein-protein interactions or that mimic large protein signalling molecules are also large proteins. Protein drugs are expensive to manufacture, difficult to formulate, and must be given by injection or topical administration.

[0007] It is generally believed that because the binding interfaces between proteins are very large, traditional approaches to drug screening or design have not been successful. In fact, for most protein-protein interactions, only small subsets of the overall intermolecular surfaces are important in defining binding affinity. “One strongly suspects that the many crevices, canyons, depressions and gaps, that punctuate any protein surface are places that interact with numerous micro- and macro-molecular ligands inside the cell or in the extra-cellular spaces, the identity of which is not known” (Goldstein 1998).

[0008] Despite these complexities, recent evidence suggests that protein-protein interfaces are tractable targets for drug design when coupled with suitable functional analysis and more robust molecular diversity methods. For example, the interface between hGH and its receptor buries ˜1300 Sq. Angstroms of surface area and involves 30 contact side chains across the interface. However, alanine-scanning mutagenesis shows that only eight side-chains at the centre of the interface (covering an area of about 350 Sq. Angstroms) are crucial for affinity. Such “hot spots” have been found in numerous other protein-protein complexes by alanine-scanning, and their existence is likely to be a general phenomenon.

[0009] The problem therefore is to define the small subset of regions that define the binding or functionality of the protein.

[0010] The important commercial reason for this is that a more efficient way of doing this would greatly accelerate the process of drug development.

[0011] These complexities are not insoluble problems and newer theoretical methods should not be ignored in the drug design process. Nonetheless, in the near future there are no good algorithms that allow one to predict protein binding affinities quickly, reliably, and with high precision (Sunesis website www.sunesis.com 17/9/99).

[0012] A process for the analysis of whole genome databases has been developed. Significant utility can be achieved within the pharmaceutical industry by searching and analysing protein and nucleotide sequence databases to identify complementary peptides which interact with their relevant target proteins.

[0013] These novel peptides can be used as lead ligands to facilitate drug design and development. This invention describes the application of this process to the databases containing nucleotide and protein sequence data from known pathogens (microbes, viruses, fungi and protozoa).

[0014] The process has been described in patent application number GB 9927485.4, filed 19th November 1999 for use in analysing, and manipulating the sequence data (both DNA and protein) found in large databases and its utility in conducting systematic searches to identify the sequences which code for the key intermolecular surfaces or “hot spots” on specific protein targets.

THE INVENTION

[0015] In the current invention the application of our novel informatics approach to the databases containing nucleotide and peptide sequences from pathogens generates the sequence of many peptides which form the basis of an innovative and novel approach to developing anti-infective drugs.

[0016] This invention claims the use of specific complementary peptide to the proteins encoded in the genomes of known pathogens as reagents and drugs for drug discovery programmes.

[0017] The Need For New Approaches to Anti-Infective Drugs

[0018] For many bacterial and viral infectious diseases, the remarkable genetic variability and adaptability of microorganisms constitutes a major problem for clinicians and patients (see EXAMPLE 1). In developed countries people living in poor socioeconomic conditions and expanding elderly populations are increasingly susceptible to relatively innocuous infectious agents. Resistance is an ongoing problem in intensive care units where high levels of antibiotics are used to combat infections. Consequently, there is a pressing need to understand how bacteria acquire resistance to antibiotics and to develop new agents to combat them.

[0019] The need for new antibiotics is urgent as nearly 9 million people in the United States are affected by drug-resistant bacterial infections each year and are the cause of death for approximately 60,000 of these individuals.

[0020] The development of antibiotics was a major advance in combating bacterial infections. However, antiviral agents have not been nearly as effective. Since viruses are totally dependent on their host cells and carry little that is unique to them, it has proved difficult to obtain inhibitory agents which will not adversely affect the normal functions of the cell. Selected stages of the replication cycle are potentially vulnerable to inhibition by suitable agents and a few are in clinical use.

[0021] Applications of genomic research and systematic DNA sequence analysis will open new avenues for research in immunology, therapeutics and drug development, including vaccines and new antibiotics.

[0022] For instance, two peptide therapies have been developed for the treatment of HIV. One, T-20, inhibits the fusion of HIV with the host cell. Fusion of the viral envelope with a target cell membrane is required for the initiation of infection and therefore, virus replication.

[0023] A synthetic version of the naturally occurring peptide thymosin alpha 1 has been developed to treat Hepatitis B and C infections. The peptide, Zadaxin, works by boosting the body's immune's ability to produce T cells that are the body's most potent defence against infectious diseases. It promotes the maturation of disease fighting T cells, which are involved in the control of various immune responses.

APPLICATION OF THE DATA MINING PROCESS TO THE ANALYSIS OF PATHOGEN GENOMES

[0024] We have applied our computational approach with its novel algorithms for generating complementary peptides to the known pathogen nucleotide and peptide sequence databases.

[0025] There are over 20 completed pathogen genomes in public databases (GOLD, Genomes On Line Database, http://geta.life.uiuc.edu/˜nikos/genomes.html, 25/10/99). Of these, there are 16 eubacterium, 6 archeabacterium and 1 unicellular eukaryote (in addition the genome of the nematode worm C. elegans is complete). At least another 84 prokaryote and 27 eukaryote genomes are partially sequenced and many are nearing completion, including the human genome. High-throughput genome sequencing is now making it possible to compare organisms at the level of whole genomes. This will allow important clinically relevant differences between man and viral/bacterial and fungal pathogens to be made.

[0026] Whole genome sequences represent a huge resource of data for the discovery and utilisation of biologically important complementary peptides. The catalogues detailed in this patent cover all available pathogen genomes. A series of Tables (Tables 1 to 5) detailing the various pathogens and their genomic databases which have been processed using our method are shown below.

[0027] Sequence data from completed genomes is downloaded from the NCBI (National Centre for Biotechnology Information), http://www.ncbi.nlm.nih.gov/Entrez/Genome/org.html, and analysed for complementary peptide sequences both intra-molecular (within a protein) and inter-molecular (between proteins) as described in patent application number GB 9927485.4 filed 19th November 1999.

[0028] A set of inter-molecular complementary peptide sequences, frame size 10, was generated for each gene within a pathogen genome (see EXAMPLE 2).

[0029] Sets of shorter ‘daughter’ sequences of frame size 5,6,7,8 or 9 can also be derived from these sequences (EXAMPLE 3).

[0030] A catalogue of complementary intra molecular peptides frame size 10 (average 3 per gene) was generated for each gene within a pathogen genome (see EXAMPLE 4).

[0031] Sets of shorter ‘daughter’ sequences of frame size 5,6,7,8 or 9 can also be derived from these sequences (EXAMPLE 5).

[0032] Each complementary peptide sequence has a unique identifying number in the catalog and peptides are categorised as either inter-molecular or intra-molecular peptides within each genome as shown in the table below (and in EXAMPLES 2,4 and in the genomes noted in EXAMPLES 6 and 7): Inter-molecular Intra-molecular Genome peptides peptides Borrelia burgdorferi Chlamydia Pneumoniae Chlamydia Trachomatis Echerichia Coli Haemophilus Influenzae Helicobacter Pylori Mycobacterium tuberculosis Mycoplasma genitalium 1-754 755-804 Mycoplasma pneumoniae Rickettsia Prowazekii Treponema Pallidum

[0033] Utilizing our novel approach we were able to establish the sequences of complementary peptides that have the potential to interact with and alter the functionality of the relevant protein coded for by its gene. Furthermore the second analysis provides information as to the regions on other proteins which might interact with the first protein (its ‘molecular partners’ in physiological functions).

[0034] The peptide sequences described herein can be readily made into peptides by a multitude of methods. The peptides made from the sequences described in this patent will have considerable utility as tools for functional genomics studies, reagents for the configuration of high-throughput screens, a starting point for medicinal chemistry manipulation, peptide mimetics, and therapeutic agents in their own right.

[0035] The generation of complementary peptides to nucleotide and protein sequences from pathogen genomes offers a substantial opportunity for delivering novel and innovative leads to drug development programmes in the area of anti-infective medicine.

[0036] The process of patent application number GB9927485.4 will now be described below. The examples of this present application are the result of applying that process to a selected microbial database :- it will readily be appreciated that use of the process on other microbial databases will yield peptide sequences and catalogues of intra- and inter-molecular complementary peptides specific to the other microbial databases (e.g. the microbial databases tabulated above, and in Tables 1 to 5).

[0037] The current problems associated with design of complementary peptides are:

[0038] A lack of understanding of the forces of recognition between complementary peptides

[0039] An absence of software tools to facilitate searching and selecting complementary peptide pairs from within a protein database

[0040] A lack of understanding of statistical relevance/distribution of naturally encoded complementary peptides and how this corresponds to functional relevance.

[0041] Based on these shortfalls, our process provides the following technological advances in this field:

[0042] A mini library approach to define forces of recognition between human Interleukin (IL) 1βand its complementary peptides.

[0043] A high throughput computer system to analyse an entire database for intra/inter-molecular complementary regions.

[0044] Studies into preferred complementary peptide pairings between IL-1βand its complementary ligand reveal the importance of both the genetic code and complementary hydropathy for recognition. Specifically, for our example, the genetic code for a region of protein codes for the complementary peptide with the highest affinity. An important observation is that this complementary peptide maps spatially and by residue hydropathic character to the interacting portion of the IL-1R receptor, as elucidated by the X-ray crystal structure Brookhaven reference pdb2itb.ent.

[0045] Using these novel observations as guiding principles for analysis, we have developed a computational analysis system to evaluate the statistical and functional relevance of intra/inter- molecular complementary sequences.

[0046] This process provides significant benefits for those interested in:

[0047] The analysis and acquisition of peptide sequences to be used in the understanding of protein-protein interactions.

[0048] The development of peptides or small molecules which could be used to manipulate these interactions.

[0049] The advantages of this process to previous work in this field include:

[0050] Using a valid statistical model. Previously, complementary mappings within protein structures has been statistically validated by assuming that the occurrence of individual amino acids is equally weighted at 1/20 (Baranyi, 1995). Our statistical model takes into account the natural occurrence of amino acids and thus generates probabilities dependent on sequence rather than content per se.

[0051] Facilitation of batch searching of an entire database. Previously, investigations into the, significance of naturally encoded complementary related sequences have been limited to small sample sizes with non-automated methods. The invention allows for analysis of an entire database at a time, overcoming the sampling problem, and providing for the first time an overview or ‘map’ of complementary peptide sequences within known protein sequences.

[0052] The ability to map complementary sequences as a function of frame size and percentage antisense amino acid content. Previously, no consideration has been given to the significance of the frame length of complementary sequences. Our process produces a statistical map as a function of frame size and percentage complementary residue content such that the statistical importance of how nature selects these frames may be evaluated.

BRIEF DESCRIPTION OF DRAWINGS

[0053] The process is described with reference to accompanying drawings. In the drawings, like reference numbers indicate identical or functionally similar elements.

[0054] FIG (1) shows a block diagram illustrating one embodiment of a method of the present invention

[0055] FIG (2) shows a block diagram illustrating one embodiment for carrying out Step 4 in FIG (1)

[0056] FIG (3) shows a block diagram illustrating one embodiment for carrying out Step 5 in FIG (1)

[0057] FIG (4) shows a block diagram illustrating one embodiment for carrying out Step 8 in FIG (2) and (3)

[0058] FIG (5) shows a block diagram illustrating one embodiment for carrying out Step 8 in FIG (2) and (3)

[0059] FIG (6) shows a block diagram illustrating one embodiment for carrying out Step 6 in FIG (1)

A description of the analytical process

[0060] The software, ALS (antisense ligand searcher), performs the following tasks:

[0061] Given the input of two amino acid sequences, calculates the position, number and probability of the existence of intra- (within a protein) and inter- (between proteins) molecular antisense regions. ‘Antisense’ refers to relationships between amino acids specified in EXAMPLES 8 and 9 (both 5′−>3′ derived and 3′>−5′ derived coding schemes).

[0062] Allows sequences to be inputted manually through a suitable user interface (UI) and also through a connection to a database such that automated, or batch, processing can be facilitated.

[0063] Provides a suitable database to store results and an appropriate interface to allow manipulation of this data.

[0064] Allows generation of random sequences to function as experimental controls.

[0065] Diagrams describing the algorithms involved in this software are shown in FIGS. 1-5.

DETAILED DESCRIPTION

[0066] 1. Overview

[0067] The present process is directed toward a computer-based process, a computer-based system and/or a computer program product for analysing antisense relationships between protein or DNA sequences. The method of the embodiment provides a tool for the analysis of protein or DNA sequences for antisense relationships. This embodiment covers analysis of DNA or protein sequences for intramolecular (within the same sequence) antisense relationships or inter-molecular (between 2 different sequences) antisense relationships. This principle applies whether the sequence contains amino acid information (protein) or DNA information, since the former may be derived from the latter.

[0068] The overall process is to facilitate the batch analysis of an entire genome (collection of genes/and or protein sequences) for every possible antisense relationship of both inter- and intra-molecular nature. For the purpose of example it will be described here how a protein sequence database may be analysed by the methods described.

[0069] The program runs in two modes. The first mode (Intermolecular) is to select the first protein sequence in the databases and then analyse the antisense relationships between this sequence and all other protein sequences, one at a time. The program then selects the second sequence and repeats this process. This continues until all of the possible relationships have been analysed. The second mode (Intramolecular) is where each protein sequence is analysed for antisense relationships within the same protein and thus each sequence is loaded from the database and analysed in turn for these properties. Both operational modes use the same core algorithms for their processes. The core algorithms are described in detail below.

[0070] An example of the output from this process is a list of proteins in the database that contain highly improbable numbers of intramolecular antisense frames of size 10 (frame size is a section of the main sequence, it is described in more detail below).

[0071] 2. Method

[0072] For the purpose of example protein sequence 1 is ATRGRDSRDERSDERTD and protein sequence 2 is GTFRTSREDSTYSGDTDFDE (universal 1 letter amino acid codes used).

[0073] In step 1 (see FIG. 1), a protein sequence, sequence 1, is loaded. The protein sequence consists of an array of universally recognised amino acid one letter codes, e.g. ‘ADTRGSRD’. The source of this sequence can be a database, or any other file type. Step 2, is the same operation as for step 1, except sequence 2 is loaded. Decision step 3 involves comparing the two sequences and determining whether they are identical, or whether they differ. If they differ, processing continues to step 4, described in FIG. 2, otherwise processing continues to step 5, described in FIG. 3.

[0074] Step 6 analyses the data resulting from either step 4, or step 5, and involves an algorithm described in FIG. 6.

[0075] Description of parameters used in FIG. 2 Name Description N Framesize - the number of amino acids that make up each ‘frame’ X Score threshold - the number of amino acids that have to fulfil the antisense criteria within a given frame for that frame to be stored for analysis Y Score of individual antisense comparison (either 1 or 0) IS Running score for frame - (sum of y for frame) ip1 Position marker for Sequence 1 - used to track location of selected frame for sequence 1 ip2 Position marker for Sequence 2 - used to track location of selected frame for sequence 1 F Current position in frame

[0076] In Step 7, a ‘frame’ is selected for each of the proteins selected in steps 1 and 2. A ‘frame’ is a specific section of a protein sequence. For example, for sequence 1, the first frame of length ‘5’ would correspond to the characters ‘ATRGR’. The user of the program decides the frame length as. an input value. This value corresponds to parameter ‘n’ in FIG. 2. A frame is selected from each of the protein sequences (sequence 1 and sequence 2). Each pair of frames that are selected are aligned and frame position parameter f is set to zero. The first pair of amino acids are ‘compared’ using the algorithm shown in FIG. 4/FIG 5. The score output from this algorithm (y, either one or zero) is added to a aggregate score for the frame iS. In decision step 9 it is determined whether the aggregate score iS is greater than the Score threshold value (x). If it is then the frame is stored for further analyisis. If it is not then decision step 10 is implemented. In decision step 10, it is determined whether it is possible for the frame to yield the score threshold (x). If it can, the frame processing continues and f is incremented such that the next pair of amino acids are compared. If it cannot, the loop exits and the next frame is selected. The position that the frame is selected from the protein sequences is determined by the parameter ip1 for sequence 1 and ip2 for sequence 2 (refer to FIG. 2). Each time steps 7 to 10 or 7 to 11 are completed, the value of ip1 is zeroed and then incremented until all frames of sequence 1 have been analysed against the chosen frame of sequence 2. When this is done, ip2 is then incremented and the value of ip1 is incremented until all frames of sequence 1 have been analysed against the chosen frame of sequence 2. This process repeats and terminates when ip2 is equal to the length of sequence 2. Once this process is complete, sequence 1 is reversed programmatically and the same analysis as described above is repeated. The overall effect of repeating steps 7 to 11 using each possible frame from both sequences is to facilitate step 8, the antisense scoring matrix for each possible combination of linear sequences at a given frame length.

[0077]FIG. 3 shows a block diagram of the algorithmic process that is carried out in the conditions described in FIG. 1. Step 12 is the only difference between the algorithms FIG. 2 and FIG. 3. In step 12, the value of ip2 (the position of the frame in sequence 2) is set to at least the value of ip1 at all times since as sequence I and sequence 2 are identical, if ip2 is less than ip1 then the same sequences are being searched twice.

[0078]FIGS. 4 and 5 describe the process in which a pair of amino acids (FIG. 4) or a pair of triplet codons are assessed for an antisense relationship. The antisense relationships are listed in EXAMPLES 8 and 9. In step 13, the currently selected amino acid from the current frame of sequence 1 and the currently selected amino acid from the current frame of sequence 2 (determined by parameter ‘f’ in FIG. 2/3) are selected. For example, the first amino acid from the first frame of sequence 1 would be ‘A’ and the first amino acid from the first frame of sequence 2 would be ‘G’. In step 14, the ASCII character codes for the selected single uppercase characters are determined and multiplied and, in step 15, the product compared with a list of precalculated scores, which represent the antisense relationships in EXAMPLES 8 and 9. If the amino acids are deemed to fulfil the criteria for an antisense relationship (the product matches a value in the precalculated list) then an output parameter ‘T’ is set to 1, otherwise the output parameter is set to zero.

[0079] Steps 16-21 relate to the case where the input sequences are DNA/RNA code rather the protein sequence. For example sequence 1 could be AAATTTAGCATG and sequence 2 could be TTTAAAGCATGC. The domain of the current invention includes both of these types of information as input values, since the protein sequence can be decoded from the DNA sequence, in accordance with the genetic code. Steps 16-21 determine antisense relationships for a given triplet codon. In step 16, the currently selected triplet codon for both sequences is ‘read’. For example, for sequence 1 the first triplet codon of the first frame would be ‘AAA’, and for sequence 2 this would be ‘TTT’. In step 17, the second character of each of these strings is selected. In step 18, the ASCII codes are multiplied and compared, in decision step 19, to a list to find out if the bases selected are ‘complementary’, in accordance with the rules of the genetic code. If they are, the first bases are compared in step 20, and subsequently the third bases are compared in step 21. Step 18 then determines whether the bases are ‘complementary’ or not. If the comparison yields a ‘non-complementary’ value at any step the routine terminates and the output score ‘T’ is set to zero. Otherwise the triplet codons are complementary and the output score T=1.

[0080]FIG. 6 illustrates the process of rationalising the results after the comparison of 2 protein or 2 DNA sequences. In step 22, the first ‘result’ is selected. A result consists of information on a pair of frames that were deemed ‘antisense’ in FIG's 2 or 3. This information includes location, length, score (i.e the sum of scores for a frame) and frame type (forward or reverse, depending on orientation of sequences with respect to one another). In step 23, the frame size, the score values and the length of the parent sequence are then used to calculate the probability of that frame existing. The statistics, which govern the probability of any frame existing, are described in the next section and refer to equations 1-4. If the probability is less than a user chosen value ‘p’, then the frame details are ‘stored’ for inclusion in the final result set (step 24).

Statistical Basis of Program Operation

[0081] The number of complementary frames in a protein sequence can be predicted from appropriate use of statistical theory.

[0082] The probability of any one residue fitting the criteria for a complementary relationship with any other is defined by the groupings illustrated in EXAMPLE 8. Thus, depending on the residue in question, there are varying probabilities for the selection of a complementary amino acid. This is a result of an uneven distribution of possible partners. For example possible complementary partners for a tryptophan residue include only proline whilst glycine, serine, cysteine and arginine all fulfil the criteria as complementary partners for threonine. The probabilities for these residues aligning with a complementary match are thus 0.05 and 0.2 respectively. The first problem in fitting an accurate equation to describe the expected number of complementary frames within any sequence is integrating these uneven probabilities into the model. One solution is to use an average value of the relative abundance of the different amino acids in natural sequences. This is calculated by equation 1

v=ΣR*N 1

[0083] Where v =probability sum, R =fractional abundance of amino acid in e.coli proteins, N=number of complementary partners specified by genetic code.

[0084] This value (p) is calculated as 2.98. The average probability (p) of selecting a complementary amino acid is thus 2.98/20 =0.149.

[0085] For a single ‘frame’ of size (n) the probability (C) of pairing a number of complementary amino acids (r) can be described by the binomial distribution (equation 2) $\begin{matrix} {C = {\frac{n!}{{\left( {n - r} \right)!}{r!}}{p^{r}\left( {1 - p} \right)}^{n - r}}} & 2 \end{matrix}$

[0086] With this information we can predict that the expected number (Ex) of complementary frames in a protein to be: $\begin{matrix} {{Ex} = {2\left( {S - n} \right)^{2}\frac{n!}{{\left( {n - r} \right)!}{r!}}{p^{r}\left( {1 - p} \right)}^{n - r}}} & 3 \end{matrix}$

[0087] Where S =protein length, n =frame size, r =number of complementary residues required for a frame and p =0.149. If r =n, representing that all amino acids in a frame have to fulfil a complementary relationship, the above equation simplifies to:

Ex =2(S - n)²p^(n) 4

[0088] For a population of randomly assembled amino acid chains of a predetermined length we would expect the number of frames fulfilling the complementary c riteria in the search algorithm to vary in accordance with a normal distribution.

[0089] Importantly, it is possible to standardise results such that given a calculated mean (μ) and standard deviation (σ) for a population it is possible to determine the probability of any specific result occurring. Standardisation of the distribution model is facilitated by the following relation: - $\begin{matrix} {Z = \frac{X - \mu}{\sigma}} & 5 \end{matrix}$

[0090] Where Xis an single value (result) in a population. If we are considering complementary frames with a single protein structure then the above statistical model requires further analysis. In particular, the possibility exists that a region may be complementary to itself, as indicated in the diagram below.

[0091] Reverse turn motifs within proteins. A region of protein may be complementary to itself. In this scenario, A-S, L-K and V-D are complementary partners. A six amino acid wide frame would thus be reported (in reverse orientation). A frame of this type is only specified by half of the residues in the frame. Such a frame is called a reverse turn.

[0092] In this scenario, once half of the frame length has been selected with complementary partners, there is a finite probability that those partners are the sequential neighbouring amino acids to those already selected. The probability of this occurring in any protein of any sequence is:

Ex =pf¹²(S-f)   7

[0093] Where f is the frame size for analysis, and S is the sequence length and p is the average probability of choosing an antisense amino acid.

[0094] The software of the embodiment incorporates all of the statistical models reported above such that it may assess whether a frame qualifies as a forward frame, reverse frame, or is reverse turn. TABLE ONE Published microbial genomes (taken from http://www.tigr.org/tdb/mdb/mdb.html, 25/10/99), all completed sequences can be accessed via http://www.ncbi.nlm.nih.gov/Entrez/Genome/org.html Key: A; Archaea, B; Eubacteria, E; Eukaryote enome Strain Key Disease Web link Publication Aeropyrum pernix K1 A aerobic hyper-thermophilic http://www.mild.nite.go.jp/APE Kawarabayasi et Genome Size (Mb) 1.67 crenarchaeon K1/index.html al., DNA Research 6: 83- 101 (1999) Aquifex aeolicus VF5 B Hyperthermophilic http://www.ncgr.org/microbe/aq Deckert et al., Genome Size (Mb) 1.50 chemolithoautotroph uifextxt.html Nature 392:353 (1998) Archaeoglobus fulgidus DSM4304 A Hyperthermophilic marine http://www.tigr.org/tdb/CMR/ga Klenk et Genome Size (Mb) 2.18 Sulphate reducing f/htmls/SplashPage.html al., Nature bacterium 390:364-370 (1997) Bacillus subtilis 168 B Common environmental http://bioweb.pasteur.fr/GenoLis Kunst et.al., Genome Size (Mb) 4.20 Organism t/SubtiList/ Nature 390: 249- 256(1997) Borrelia burgdorferi B31 B Lyme disease http://www.tigr.org/tdb/CMR/gb Fraser et al., Genome Size (Mb) 1.44 b/htmls/SplashPage.html Nature, 390: 580-586 (1997) Chlamydia pneumoniae CWL029 B Acute respiratory infections http://chlamydia- Kalman et al., Genome Size (Mb) 1.23 and atherosclerosis. www.berkeley.edu:4231/ Nat Genet 21: 385-389 (1999) Chlamydia trachomatis serovar D B Obligate pathogen. http://chlamydia- Stephens et al., Genome Size (Mb) 1.05 (D/UW- Inclusion conjunctivitis and www.berkeley.edu:4231/ Science 282: 3/Cx) genital infections 754-759 (1998) Escherichia coil K-12 B Commensal organism, http://www.genetics.wisc.edu/ Blattner et. al., Genome Size (Mb) 4.60 Presence of virulence Science determinants 277:1453-1474 Can cause infections and (1997) diarrhoea Haemophilus influenzae Rd KW20 B Otitis media, respiratory http://www.tigr.org/tdb/CMR/gh Fleischmann et. (non-pathogenic strain) infection and meningitis i/htmls/SplashPage.html al., Science Genome Size (Mb) 1.83 269:496-512 (1995) Helicobacter pylori 26695 B Chronic active gastritis, http://www.tigr.org/tdb/CMR/gh Tomb et. Al., Genome Size (Mb) 1.66 peptic ulceration and p/htmls/SplashPage.html Nature 388:539- mucosa-associated 547 (1997) lymphoid tissue lymphomas. Helicobacter pylori J99 B See H pylori strain 26695 http://www.astra- Alm et.al., Genome Size (Mb) 1.64 above boston.com/hpylori/ Nature, 397:176- 180 (1999) Methanobacterium delta H A Autotrophic methanogenic http://www.genomecorp.com/se Smith et al., J. thermoautotrophicum Bacterium quence center/bacterial genome Bacteriology, Genome Size (Mb) 1.75 s/ 179:7135-7155 (1997) Methanococcus jannaschii DSM 2661 A Autotrophic methanogenic http://www.tigr.org/tdb/CMR/ar Bult et. al., Genome Size (Mb) 1.66 Bacterium g/htmls/SplashPage.html Science 273:1058-1073 (1996) Mycobacterium H37Rv B Tuberculosis. http://www.sanger.ac.uk/Project Cole et al., tuberculosis (lab strain) s/M tuberculosis/ Nature 393:537 Genome Size (Mb) 4.40 (1998) Mycoplasma genitalium G-37 B Urethritis. http://www.tigr.org/tdb/CMR/g Fraser et. Al., Genome Size (Mb) 0.58 mg/htmls/SplashPage.html Science 270:397-403 (1995) Mycoplasma pneumoniae M129 B Respiratory infections http://www.zmbh.uni- Himmeireich et. Genome Size (Mb) 0.81 heidelberg de/M pneumoniae/g al. Nuc. Acid enone/Results.html Res. 24:4420- 4449 (1996) Pyrococcus abyssi GE5 A Hyperthermophilic http://www.genoscope.cns.fr/Pa Genome Size (Mb) 1.8 Archaebacterium b/ Pyrococcus horikoshii OT3 A Hyper-thermophilic http://www.bio.nite.go.jp/ot3db Kawarabayasi et Genome Size (Mb) 1.80 Archaebacterium index.html al., DNA Research 5: 55- 76 (1998) Rickettsia prowazekii Madrid E B Epidemic typhus. http://evolution.bmc.uu.se/˜siv/ Andersson et al., Genome Size (Mb) 1.10 gnomics/Rickettsia.html Nature 396:133- 140 (1998) Synechocystis sp. FCC 6803 B Unicellular cyanobacterium http://www.kazusa.or.jp/cyano/c Kaneko et. al., Genome Size (Mb) 3.57 yano.html DNA Res. 3: 109-136 (1996) Thermotoga mantima MSB8 B Thermophile http://www.tigr.org/tdb/CMR/bt Nelson et al., Genome Size (Mb) 1.80 m/htmls/SplashPage.html Nature 399: 323- 329 (1999) Treponema pallidum Nichols B Syphilis http://www.tigr.org/tdb/CMR/gt Fraser et al., Genome Size (Mb) 1.14 p/htmls/SplashPage.html Science 281: 375-388(1998)

[0095] TABLE TWO List of microbial genomes, sequencing in progress (25/10/1999). Sequence data can be accessed via http://www.ncbi.nlm.nih.gov/BLAST/unfinishedgenome.html#GENOMES Genome Genome Genome Actinobacillus Klebsiella pneumoniae Rhodobacter capsulatus actinomycetemcomitans Bacillus anthracis Lactobadilus acidophilus Rhodobacter sphaeroides Bacillus halodurans Lactococcus lactis Rickettsia conorii Bacillus stearothermophilus Legionella pneumophila Salmonella paratyphi A Bartonella henselae Leptospira interrogans Salmonella typhi serovar icterohaemorrhagiae Bordetella bronchiseptica Listeria monocytogenes Salmonella typhimurium Bordetella parapertussis Methanosarcina mazel Shewanella putrefaciens Bordetella pertussis Mycobacterium avium Shigella flexneri 2a Campylobacter jejuni Mycobacterium bovis Staphylococcus aureus Caulobacter crescentus Mycobacterium leprae Staphylococcus aureus Chlamydia muridarum Mycobacterium tuberculosis Streptococcus mutans Chlamydia pneumoniae Mycoplasma mycoides Streptococcus pneumoniae subsp. Mycoides SC Chlamydia trachomatis Mycoplasma pulmonis Streptococcus pyogenes Chlorobium tepidum Neisseria gonorrhoeae Streptomyces coelicolor Clostridium acetobutylicum Neisseria meningitidis Sulfolobus solfataricus Clostridium diffidile Neisseria meningitidis Thermoplasma acidophilum Corynebacterium diphtheriae Pasteurella haemolytica Thermus thermophilus Corynebacterium glutamicum Pasteurella multocida Thiobacillus ferrooxidans Dehalococcoides Photorhabdus luminescens Treponema denticola ethenogenes Deinococcus radiodurans Porphyromonas gingivalis Ureaplasma urealyticum Desulfovibrio vulgaris Pseudomonas aeruginosa Vibrio cholerae Enterococcus faecalis Pseudomonas putida Xanthomonas citri Francisella tularensis Pyrobaculum aerophilum Xylella fastidiosa Halobacterium salinarium Pyrococcus furiosus Yersinia pestis Halobacterium sp. Raistonia solanacearum

[0096] TABLE THREE First Completed Viral Genomes, taken from GOLD, Genomes On Line Database, (http://geta.life.uiuc.edu/˜nikos/genomes.html, 25/10/99). Viral Genome Size (Kb) Publication Bacteriophage fX174 5.38 Sanger F et al., 1977 SV40 5.224 Fiers W et al., 1978 Hepatitis B 3.18 Galibert F et al., 1979 Bacteriophage Lambda 48.5 Sanger F et al.,, 1982 Rous Sarcoma Virus 9.31 Schwartz DE et a., 1983 Epstein-Barr Virus 172.28 Baer R et al., 1984 AIDS virus LAV 9.19 Wain-Hobson S et al., 1985 Vaccinia Virus 191.63 Goebel SJ et al., 1990 Cytomegalovirus (CMV) 229 Bankier AT et al., 1991 SmallPox Virus (variolla) 186.102 Massung RE et al., 1994

[0097] TABLE FOUR List of viral genomes, sequencing completed or in progress (from http://www- fp.mcs.anl.gov/%7Egaasterland/genomes.html, 25/10/99) Genome Genome Genome Genome Abelson murine leukemia Cucumber green mottle Jembrana disease virus Rabies virus virus mosaic virus Adeno-associated virus 2 Cucumber mosaic virus Kennedya yellow mosaic virus Rice tungro spherical virus Adeno-associated virus 3 Cucumber necrosis virus Lactate dehydrogenase- Rice yellow mottle virus elevating virus African swine fever virus Dengue virus 3 Leishmania RNA virus Ross River virus Alfalfa mosaic virus Dengue virus type 1 Leishmania RNA virus 1 Rous sarcoma virus Apple chlorotic leaf spot virus Dengue virus type 2 Lucerne transient streak virus Rubella virus Apple stem grooving virus Digitaria streak virus Maize streak virus Sacoharomyces cerevisiae virus La Arabis mosaic virus satellite Duck hepatitis B virus Marburg virus Saguaro cactus virus Arctic ground squirrel hepatitis Ebola virus (contructed) Mason-Pfizer monkey virus satellite tobacco necrosis B virus virus Artichoke mottled crinkle virus Eggplant mosaic virus Measles virus Sendai virus Autographa californica Encephalomyocarditis virus Melon necrotic spot virus Simian foamy virus nuclear polyhedrosis virus Avian carcinoma virus Equine infectious anemia Mice minute virus Simian immunodeficiency virus virus Avian infectious bronchitis Feline immunodeficiency virus Molluscum contagiosum virus Simian sarcoma virus virus subtype 1 Avian leukosis virus Foxtail mosaic virus Moloney murine sarcoma Simian virus 40 virus Avian sarcoma virus Friend murine leukemia virus Mouse mammary tumor virus Sindbis virus BK virus Friend spleen focus-forming Murine leukemia virus Sindbis-like virus virus Baboon endogenous virus Fujinami sarcoma virus Murine osteosarcoma virus Sonchus yellow net virus Baboon endogenous virus Ground squirrel hepatitis virus Murine sarcoma virus Southern bean mosaic (BaEV) virus Bamboo mosaic virus Hepatitis A virus Mushroom bacilliform virus Soybean chlorotic mottle virus Barley yellow dwarf virus Hepatitis B virus Narcissus mosaic virus Spiroplasma virus Barmah Forest virus Hepatitis C virus Onyong-nyong virus Strawberry vein banding virus Bean golden mosaic virus Hepatitis D virus Odontoglossum ringspot virus Sulfolobus virus-like particle ssv1 Beet curly top virus Hepatitis E virus Olive latent virus 1 Swine vesicular disease virus Beet yellows virus Hepatitis G virus Ononis yellow mosaic virus Theiler's encephalomyelitis virus Black beetle virus Hepatitis GB virus B Ovine pulmonary Tick-borne encephalitis adenocarcinoma virus virus Bombyx mori nuclear Heron hepatitis B virus Panicum streak virus Tobacco etch virus polyhedrosis virus Border disease virus Hog cholera virus Papaya mosaic virus Tobacco mild green mosaic virus Borna disease virus Human T-cell lymphotropic Papaya ringspot virus Tobacco mosaic virus virus type 1 Bovine immunodeficiency Human T-cell lymphotropic Pea early browning virus Tobacco necrosis virus virus virus type 2 Bovine leukemia virus Human T-cell lymphotropic Pea seed-borne mosaic virus Tobacco vein mottling virus type I (curated proviral) virus Bovine viral diarrhea virus Human adenovirus type 12 Peanut chlorotic streak virus Tomato bushy stunt virus Brome mosaic virus Human adenovirus type 2 Peanut stripe virus Tomato golden mosaic virus Cacao swollen shoot virus Human foamy virus Peanut stunt virus Tomato leaf curl virus Caprine arthritis-encephalitis Human herpesvirus 1 Pepper huasteco virus Tomato yellow leaf curl virus virus Cardamine chlorotic fleck Human herpesvirus 3 Pepper mottle virus Turnip vein-clearing virus virus Carrot mottle virus A Human herpesvirus 4 Plum pox virus Turnip yellow mosaic virus Cassava common mosaic Human immunodeficiency Polyomavirus strain a2 Vaccinia virus virus virus type 1 Cassava latent virus Human immunodeficiency Polyomavirus strain a3 Variola virus virus type 2 Cassava vein mosaic virus Human parainfluenza virus 3 Potato leaf roll virus Venezuelan equine encephalitis virus Cauliflower mosaic virus Human respiratory syncytial Potato mop-top virus Vesicular stomatitis virus virus Chicken anemia virus Infectious hematopoietic Potato virus A Visna virus necrosis virus Chloris striate mosaic virus Influenza A virus Potato virus M West Nile virus Citrus tristeza virus Influenza B virus Potato virus X Woodchuck hepatitis B virus Clover yellow mosaic virus Influenza C virus Potato virus Y Woodchuck hepatitis virus Coconut foliar decay virus JC virus Punta Toro virus Y73 sarcoma virus Commelina yellow mottle Japanese encephalitis virus Rabbit hemorrhagic disease Yellow fever virus virus virus

[0098] TABLE FIVE List of eukaryotic pathogens, sequencing in progress, taken from GOLD, Genomes On Line Database, (http://geta.life.uiuc.edu/˜nikos/genomes.html, 25/10/99). 1. Protozoa Genome Strain Disease/Description Web site Publication Leishmania major Friedlin Cutaneous leishmaniasis http://www.sbri.org/Labs/myler.html, Chromosome http://www.sanger.ac.uk/Projects/L_major/ complete beowulf_index.shtml Myler et al., http://204.203.14.2/LmjF/chr3.html Natl Acad Science http://204.203.14.2/LmjF/chr35.html 96: 2902-29 (1999) Plasmodium falciparum 3D3 Human malaria http://www.tigr.org/tdb/edb/pfdb/pfdb.html Chromosome http://www.ncbi.nlm.nih.gov/Malaria/ 3 complete http://www.sanger.ac.uk/Projects/ 282,1126-1 P_falciparum/ (1998) Cryptosporidium parvum Diarrhoea http://www.mrc- lmb.cam.ac.uk/happy/CRYPTO/crypto- genome.html Dictyostelium AX4 A soil-living amoeba http://www.sanger.ac.uk/Projects/D_discoideu discoideum m/ Giardia lamblia WB Diarrhoea http://evol3.mbl.edu/Giardia- HTML/giardia_data.html Shistosoma mansoni Shistosomiasis http://www.nhm.ac.uk/hosted_sites/schisto/ind ex.html Shistosoma japonicum Shistosomiasis http://www.nhm.ac.uk/hosted_sites/schisto/ind ex.html Trypanosoma brucei Trypanosomiasis http://www.sanger.ac.uk/Projects/T_brucei/ (West African sleeping sickness), Trypanosoma b. TREU Rhodesian http://www.tigr.org/tdb/mdb/tbdb/ rhodesiense 927/4 trypanosomiasis http://www.tigr.org/cgi- in/BlastSearch/blast.cgi?organism=t_brucei Trypanosoma cruzi Chagas' disease http://www.tigr.org/ 2. Microsporidia Genome Disease/Description Web site Encephalitozoon cuniculi Intracellular parasite http://www.genoscope.cns.fr/externe/English/Projets/Projet_ AD/AD.html 3. Fungi Genome Disease/Description Web site Schizosaccharomyces Fission yeast http://genome- pombe www.stanford.edu/Saccharomyces/VL-yeast.html and http//www.sanger.ac.uk/Projects/S_pombe/ Neurospora crassa A genus of fungi used as a http://www.genome.ou.edu/fungal.html strain 74-OR23-IVA model organism in genetic research Neurospora Genome Project http://biology.unm.edu/˜ngp/home.html Aspergillus ridulans Mycelial fungus, may cause aspergillosis http://fungus.genetics.uga.edu:5080/ Candida albicans 1161 Common human pathogen http://www.sanger.ac.uk/Projects/C_albicans/ Candida albicans http://sequence- SC5314 www.stanford.edu/group/candida/index.html Pneumocystis carinii Extracellular lung pathogens that can http://www.uky.edu/Projects/Pneumocystis/ f. sp. Carinii lead to development of a lethal pneumonia. Pneumocystis carinii http//www.uky.edu/Projects/Pneumocystis/ f. sp. Hominis Ustilago maydis ‘Corn smut’, allergen. http://www3.ncbi.nlm.nih.gov/htbin- post/Taxonomy/wgetorg?id=5270&1v1=3

EXAMPLE 1 SOME BACTERIAL AND VIRAL PATHOGENS

[0099] Haemophilus influenzae

[0100]H. influenzae was the first free-living unicellular organism to be completely sequenced in 1995. It is a small, nonmotile, Gram-negative bacterium whose only natural host is human.

[0101] These bacteria were first identified during the influenza (‘flu’) pandemic of 1890. At the time it was believed to be the cause of the disease which is now known to be viral in origin. It is an obligate parasite, having an absolute requirement for exogenously supplied heme for aerobic growth. There are six antigenically distinct capsular types of H. infiuenzae, designated a to f. Non-typeable strains also exist and are distinguished by their lack of detectable capsular polysaccharide. They are frequent constituents of the upper respiratory mucosa of healthy children and adults. Serious invasive infection is caused almost exclusively by type b strains; these include meningitis, sepsis, epiglottitis, pneumonia and inner-ear infections.

[0102] Bacterial meningitis and epiglottitis due to H. infiuenzae are lfe-threateming diseases with a 5-25% lethality. These statistics make the study of H. influenzae a very important area of medical research.

[0103] The H. influenzae bacillus is also exhibiting increased antibiotic resistance. The first finding of ampicillin resistance dates to 1984. As a result, current pharmacological research is focusing on the development of antibiotics that specifically target this microorganism. There is also a clear association between infection by H. influenzae and infection by the human immunodeficiency virus (HIV).

[0104] The strain from which the complete genome sequence has been determined is the non-pathogenic H. influenzae Rd strain KW20. The only difference between noninfectious Rd and infectious type b strains of H. influenzae is the presence in type b of a set of eight, tandemly arrayed genes that encode fimbrial proteins. Fimbriae are colonization factors that mediate bacterial adherence to human cells. These genes have also been screened for complementary peptides.

[0105] The sequencing of the H. influenzae chromosome is a very important landmark in biological research since this is the first complete genome sequence of a free-living organism (Fleischmann et al., 1995). The circular chromosome of this microorganism is 1.83 Mb long, with an overall G+C content of approximately 38%. The authors identified 1743 open reading frames (ORFs) in the sequence. Sixty-three of these ORFs contain frameshifts or stop codons when compared to homologues from other species. A total of 1,007 genes have been matched to the biological database; 347 matched hypothetical proteins already in the database, and 389 did not have any matches.

[0106] Recently, the H. influenzae genome sequence has been re-analyzed, resulting in a new set of predicted genes among ORFs without homologs (Tatusov et al., 1996). The H. influenzae sequences found in GenBank have been re-annotated based on this analysis.

[0107] Borrelia burgdorferi

[0108] The genus Borrelia is one of the four genera of the family Spirochaetaceae and comprises pathogenic bacteria that are transmitted by arthropod vectors. Borrelia species utilize glucose as the major energy source, and lactic acid is the predominant metabolic end product.

[0109]B. burgdorferi is the causative agent of Lyme borreliosis, a disease transmitted by ticks. The disease is named after the town Old Lyme, Connecticut, USA, where a mysterious cluster of arthritis cases occurred among children in the early 1970s. The illness was recognized as a distinctive disease and called Lyme disease. The most common symptoms of Lyme disease are rash, muscle and joint aches, headache and stiff neck, fatigue, facial paralysis, and meningitis. During more advanced stages of the disease, infected individuals experience arthritis, intermittent or chronic. Lyme disease is difficult to diagnose because many of its symptoms mimic those of other disorders. Almost all Lyme disease patients can be effectively treated with antibiotic therapy, such as doxycycline or amoxicillin.

[0110] The DNA organization of the Borrelia appears to be unique in the spirochete family in having linear DNA plasmids, a form of DNA that was previously thought to be unique to eukaryotes. Borrelia species also contain circular plasmids. The entire genome of B. burgdorferi is 1.0 Mb in length and was completely sequenced in 1997 (Fraser et al., 1997).

[0111] Hepatitis B

[0112] Hepatitis B is the second most common chronic infectious disease worldwide. When adults are infected, about 90% of them are able to defeat the hepatitis B virus on its own but in 10 % of cases, the disease wins out over the immune system and the condition becomes chronic. Individuals who suffer from chronic hepatitis B are at high risk of developing cirrhosis of the liver and liver cancer. According to the World Health Report published by the World Health Organization in 1997, 2 billion people have evidence of past or current infection with the !I hepatitis B virus, and 350 million are chronically infected.

[0113] In Western countries, Hepatitis B virus is transmitted prinicpally via blood products, intravenous drug use, or sexually. In other parts of the world, particularly in Asia, the major route of transmission is from infected mother to child at birth. Children are particularly susceptible to the virus; as many as 50-70% of those exposed to the virus become chronic carriers.

[0114] Hepatitis C

[0115] Hepatitis C is one of the world's most prevalent chronic infectious diseases. In approximately 85 % of all cases, the body is not able to fight off the infection and the infected individual becomes a chronic hepatitis C carrier. The World Health Organization estimates that more than 170 million people are infected worldwide with the hepatitis C virus.

[0116] The hepatitis C virus was not specifically identified until 1989. Approximately 20% of infected persons develop cirrhosis of the liver within 10-20 years after infection. For others, the rate of disease progression is much slower and may extend over 20 to 40 years or more

[0117] Aside from the fact that it is a blood borne disease, the mechanism of spread of hepatitis C within a population is poorly understood. Hepatitis C virus is transmitted via blood products, intravenous drug use, and sexually but, in some cases, its origin remains unknown. Healthcare workers are particularly susceptible to hepatitis C infection.

EXAMPLE 2

[0118] The complete genome of Mycoplasma genitalium which is 0.58 Mb in size and codes for an estimated 479 genes was screened for intermolecular peptides using the method described in patent application number GB 9927485.4, filed 19th November 1999. The gene, database accession number, its predicted interacting peptides and their position within the coding sequence of the gene are shown in the attached sequence listing: SEQ ID Nos. [1-754].

EXAMPLE 3

[0119] Derivation of ‘Child’ Sequences from Parent Sequences

[0120] For each pair of ‘frames’ of amino acids which are deemed a ‘hit’ by the algorithm of the current invention includes derived pairs of composite ‘child’ sequences of shorter frame lengths which automatically fulfil the same ‘complementary’ relationship.

[0121] For example, there is a complementary frame of size 10 between genes (inter-molecular) MG002 and MG004 of mycoplasma genitalium.: GENE1 GENE2 Sequence 1 Location Sequence 2 Location Score MG002 MG004 AYSILSDPNQ 47-56 LLSVGQNGIG 720-729 10

[0122] One embodiment of the invention covers the derivation of the following sequences at frame length of 5: Se- quence GENE GENE2 1 Location Sequence 2 Location Score MG002 MG004 AYSIL 47-51 LLSVG 720-724 5 MG002 MG004 YSILS 48-52 LSVGQ 721-725 5 MG002 MG004 SILSD 49-53 SVGQN 722-726 5 MG002 MG004 ILSDP 50-54 VGQNG 723-727 5 MG002 MG004 LSDPN 51-55 GQNGI 724-728 5 MG002 MG004 SDPNQ 52-56 QNGIG 725-729 5

[0123] One embodiment of the invention covers the derivation of the following sequences at frame length of 6: Sequence Sequence GENE GENE2 1 Location 2 Location Score MG002 MG004 AYSILS 47-52 LLSVGQ 720-725 6 MG002 MG004 YSILSD 48-53 LSVGQN 721-726 6 MG002 MG004 SILSDP 49-54 SVGQNG 722-727 6 MG002 MG004 ILSDPN 50-55 VGQNGI 723-728 6 MG002 MG004 LSDPNQ 51-56 GQNGIG 724-729 6

[0124] One embodiment of the invention covers the derivation of the following sequences at frame length of 7: Sequence Loca- GENE GENE2 1 tion Sequence 2 Location Score MG002 MG004 AYSILSD 47-53 LLSVGQN 720-726 7 MG002 MG004 YSILSDP 48-54 LSVGQNG 721-727 7 MG002 MG004 SILSDPN 49-55 SVGQNGI 722-728 7 MG002 MG004 ILSDPNQ 50-56 VGQNGIG 723-729 7

[0125] One embodiment of the invention covers the derivation of the following sequences at frame length of 8: Loca- Loca- GENE GENE2 Sequence 1 tion Sequence 2 tion Score MG002 MG004 AYSILSDP 47-54 LLSVGQNG 720- 8 727 MG002 MG004 YSILSDPN 48-55 LSVGQNGI 721- 8 728 MG002 MG004 SILSDPNQ 49-56 SVGQNGIG 722- 8 729

[0126] One embodiment of the invention covers the derivation of the following sequences at frame length of 9: GENE GENE2 Sequence 1 Location Sequence 2 Location Score MG002 MG004 AYSILSDPN 47-55 LLSVGQNGI 720-728 9 MG002 MG004 YSILSDPNQ 48-56 LSVGQNGIG 721-729 9

EXAMPLE 4

[0127] The complete genome of Mycoplasma genitalium which is 0.58 Mb in size and codes for

[0128] an estimated 479 genes was screened for intramolecular peptides using the method described in patent application number GB 9927485.4, filed 19th Nov. 1999. The gene, database accession number, peptide sequences and their position within the coding sequence of the gene are shown in the attached sequence listing: SEQ ID Nos. [755-804].

EXAMPLE5

[0129] Derivation of ‘Child’ Sequences from Parent Sequences

[0130] For each pair of ‘framnes’ of amino acids which are deemed a ‘hit’ by the algorithm of the current invention includes derived pairs of composite ‘child’ sequences of shorter frame lengths which automatically fuilfil the same ‘complementary’ relationship.

[0131] For example, gene MG015 in Mycoplasma Genitalium contains the following intra-molecular complementary relationship of frame length 10: GENE Sequence 1 Location Sequence 2 Location Score MG015 SFAFLKKSKT 184-193 SFAFLKKSKT 184-193 10

[0132] One embodiment of the invention covers the derivation of the following sequences at frame lengthof 5: GENE Sequence 1 Location Sequence 2 Location Score 1787318 SFAFL 184-188 TKSKK 193-189 5 1787318 FAFLK 185-189 KSKKL 192-188 5 1787318 AFLKK 186-190 SKKLF 191-187 5 1787318 FLKKS 187-191 KKLFA 190-186 5 1787318 LKKSK 188-192 KLFAF 189-185 5 1787318 KKSKT 189-193 LFAFS 188-184 5

[0133] One embodiment of the invention covers the derivation of the following sequences at of 6: GENE Sequence 1 Location Sequence 2 Location Score 1787318 SFAFLK 184-189 TKSKKL 193-188 6 1787318 FAFLKK 185-190 KSKKLF 192-187 6 1787318 AFLKKS 186-191 SKKLFA 191-186 6 1787318 FLKKSK 187-192 KKLFAF 190-185 6 1787318 LKKSKT 188-193 KLFAFS 189-184 6

[0134] One embodiment of the invention covers the derivation of the following sequences at of 7: GENE Sequence 1 Location Sequence 2 Location Score 1787318 SFAFLKK 184-190 TKSKKLF 193-187 7 1787318 FAFLKKS 185-191 KSKKLFA 192-186 7 1787318 AFLKKSK 186-192 SKKLFAF 191-185 7 1787318 FLKKSKT 187-193 KKLFAFS 190-184 7

[0135] One embodiment of the invention covers the derivation of the following sequences at of 8: GENE Sequence 1 Location Sequence 2 Location Score 1787318 SFAFLKKS 184-191 TKSKKLFA 193-186 8 1787318 FAFLKKSK 185-192 KSKKLFAF 192-185 8 1787318 AFLKKSKT 186-193 SKKLFAFS 191-184 8

[0136] Loca- GENE Sequence 1 Location Sequence 2 tion Score 1787318 SFAFLKKSK 184-192 TKSKKLFAF 193- 9 185 1787318 FAFLKKSKT 185-193 KSKKLFAFS 192- 9 184

[0137] One embodiment of the invention covers the derivation of the following sequences at frame length of 9:

EXAMPLE 6

[0138] The genomes of the following microbes were screened for intermolecular peptides in the same way as in Example 2. Genome Number of proteins Borrelia burgdorferi 849 Chlamydia Pneumoniae 1051 Chlamydia Trachomatis 893 Echerichia Coli 4288 Haemophilus Influenzae 1708 Helicobacter Pylori 1552 Mycobacterium tuberculosis 3924 Mycoplasma genitalium 479 Mycoplasma pneumoniae 676 Rickettsia Prowazekii 833 Treponema Pallidum 1030

EXAMPLE 7

[0139] The genomes of the following microbes were screened for intramolecular peptides in the same way as in Example 4. Genome Number of proteins Borrelia burgdorferi 849 Chlamydia Pneumoniae 1051 Chlamydia Trachomatis 893 Echerichia Coli 4288 Haemophulus Influenzae 1708 Helicobacter Pylori 1552 Mycobacterium tuberculosis 3924 Mycoplasma genitalium 479 Mycoplasma pneumoniae 676 Rickettsia Prowazekii 833 Treponema Pallidum 1030

EXAMPLE 8

[0140] THE AMINO ACID PAIRINGS RESULTING FROM READING THE ANTICODON FOR NATURALLY OCCURING AMINO ACID RESIDUES IN THE 5′-3′ DIRECTION Comple- Comple- Comple- Amino mentary Complementary Amino mentary mentary Acid codon codon Amino acid Acid codon codon Amino acid Alanine GCA UGC Cysteine Serine UCA UGA Stop GCG CGC Arginine UCC GGA Glycine GCC GGC Glycine UCG CGA Arginine GGU AGC Serine UCU AGA Arginine AGC GCU Alanine AGU AGU Threonine Arginine CGG CCG Proline Glutamine CAA UUG Leucine CGA UCG Serine CAG CUG LeucINe CGC GCG Alanine CGU ACG Threonine AGG CCU Proline AGA UCU Serine Aspartic Acid GAC GUC Valine Glycine GGA UCC Serine GAU AUC Isoleucine GGC GCC Alanine GGU ACC Threonine GGG CCC Proline Asparagine AAC GUU Valine Histidine CAC GUG Valine AAU AUU Isoleucine CAU AUG Methionine Cysteine UGU AGA Threonine Isoleucine AUA UAU Tyrosine UGC GCA Alanine AUC GAU Aspartic AUU AAU acid Asparagine Glutamic GAA UUC Phenylalanine Leucine CUG CAG Glutamine Acid GAG CUC Leucine CUC GAG Glutamic CUU AAG acid UUA UAA Lysine CUA UAG Stop UUG CAA Stop CUG CAG Glutamine Glutamine Lysine AAA UUU Phenylalanine Threonine ACA UGU Cysteine AAG CUU Leucine ACG CGU Arginine ACC GGU Glycine ACU AGU Serine Methionine AUG CAU Histidine Tryptophan UGG CCA Proline Phenylalanine UUU AAA Lysine Tyrosine UAC GUA Valine UUC GAA Glutamic Acid UAU AUA Isoleucine Proline GCA UGG Tryptophan Valine GUA UAC Tyrosine CCC GGG Glycine GUG CAC Histidine CCU AGG Arginine GUC GAC Aspartic CCG CGG Arginine GUU AAC Acid Asparagine

EXAMPLE 9

[0141] The relationships between amino acids and the residues encoded in the complementary strand reading 3‘-5’ Comple- Comple- Comple- Amino mentary Complementary Amino mentary mentary Acid codon codon Amino acid Acid codon codon Amino acid Alanine GCA CGU Arginine Serine UCA AGU Serine GCG CGC UCC AGG Arginine GCC CGG UCG AGC Serine GCU CGA UCU AGA Arginine AGC UCG Serine AGU UCA Serine Arginine CGG GCC Alanine Glutamine CAA GUU Valine CGA GCU Alanine CAG GUC Valine CGC GCG Alanine CGU GCA Alanine AGG UCC Serine AGA UCU Serine Aspartic GAC GUC Valine Glycine GGA CCU Proline Acid GAU AUC Isoleucine GGC CCG Proline GGU CCA Proline GGG CCC Proline Asparagine AAC UUG Leucine Histidine CAC GUG Valine AAU UUA Leucine CAU GUA Valine Cysteine UGU ACA Threonine Isoleucine AUA UAU Tyrosine UGC ACG Threonine AUC UAG Stop AUU UAA Stop Glutamic GAA CUU Leucine Leucine CUG GAC Asp Acid GAG CUG Leucine CUC GAG Glutamic CUU GAA acid UUA AAU Glutamic CUA GAU Acid UUG AAC Asparagine CUG GAC Aspartic Acid Asparagine Aspartic Acid Lysine AAA UUU Phenylalanine Threonine ACA UGU Cysteine AAG UUC Phenylalanine ACG UGC Cysteine ACC UGG Tryptophan ACU UGA Stop Methionine AUG UAC Tyrosine Tryptophan UGG ACC Threonine Phenylalanine UUU AAA Lysine Tyrosine UAC AUG Methionine UUC AAG Lysine UAU AUA Isoleucine Proline CCA GGU Glycine Valine GUA CAU Histidine CCC GGG Glycine GUG CAC Histidine CCU GGA Glycine GUC CAG Glutamine CCG GGC Glycine GUU CAA Glutamine

REFERENCES

[0142] All publications, patents, and patent applications cited are hereby incorporated by reference in their entirety.

[0143] Baranyi L, Campbell W, Ohshima K, Fujimoto S, Boros M and Okada H. 1995. The antisense homology box: a new motif within proteins that encodes biologically active peptides. NatureMedicine. 1:894-901.

[0144] Fleischmann RD, Adams MD, White 0, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al. 1995. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496-512.

[0145] Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, White O, Ketchum KA, Dodson R, Hickey EK, Gwinn M, Dougherty B, Tomb JF, Fleischmann RD, Richardson D, Peterson J, Kerlavage AR, Quackenbush J, Salzberg S, Hanson M, van Vugt R, Palmer N, Adams MD, Gocayne J, Venter JC, et al. 1997. Genomic sequence of a Lyme disease is spirochaete, Borrelia burgdorferi. Nature 390:580-6.

[0146] Gaasterland T. Structural genomics: Bioinformatics in the driver's seat. Nature Biotechnology 16: 645-627, 1998.

[0147] Goldstein DJ. 1998. An unacknowledged problem for structural genomics? Nature Biotechnology 16: 696-697.

[0148] Sansom C. 1998. Extending the boundaries of molecular modelling. Nature Biotechnology 16: 917-918.

[0149] Stryer L. Biochmistry. 4th Edition. Freeman and Company, New York 1997.

[0150] Tatusov RL, Mushegian AR, Bork P, Brown NP, Hayes WS, Borodovsky M, Rudd KE and Koonin EV. 1996. Metabolism and evolution of Haemophilus influenzae deduced from a whole-genome comparison with Escherichia coli. Curr Biol. 6:279-91.

1 804 1 10 PRT mycoplasma genitalium Sequence located in MG002 at 269-278 and may interact with Sequence 2 in this patent. 1 Arg Leu Arg Ile Phe Ser Ser Phe Phe Glu 1 5 10 2 10 PRT mycoplasma genitalium Sequence located in MG081 at 82-91 and may interact with Sequence 1 in this patent. 2 Leu Glu Lys Gly Ala Lys Asn Ala Lys Thr 1 5 10 3 10 PRT mycoplasma genitalium Sequence located in MG003 at 281-290 and may interact with Sequence 4 in this patent. 3 Gln Ser Ile Phe Ser Phe Cys Asn Asn Ile 1 5 10 4 10 PRT mycoplasma genitalium Sequence located in MG305 at 516-525 and may interact with Sequence 3 in this patent. 4 Leu Arg Asn Glu Gly Glu Gly Ile Val Asn 1 5 10 5 10 PRT mycoplasma genitalium Sequence located in MG003 at 172-181 and may interact with Sequence 6 in this patent. 5 Ile Val Glu Phe Val Pro Asp Phe Ser Val 1 5 10 6 10 PRT mycoplasma genitalium Sequence located in MG122 at 396-405 and may interact with Sequence 5 in this patent. 6 Asn Asp Leu Lys Asn Gly Val Lys Arg Asp 1 5 10 7 10 PRT mycoplasma genitalium Sequence located in MG004 at 440-449 and may interact with Sequence 8 in this patent. 7 Arg Ser Leu Ser Val Leu Glu Val Asn Lys 1 5 10 8 10 PRT mycoplasma genitalium Sequence located in MG051 at 196-205 and may interact with Sequence 7 in this patent. 8 Phe Ile Asp Leu Lys Tyr Gly Lys Gly Ala 1 5 10 9 10 PRT mycoplasma genitalium Sequence located in MG004 at 318-327 and may interact with Sequence 10 in this patent. 9 Lys Arg Asp Thr Val Pro Glu Val Leu Leu 1 5 10 10 10 PRT mycoplasma genitalium Sequence located in MG036 at 137-146 and may interact with Sequence 9 in this patent. 10 Leu Ala Ile Arg Asn Trp Phe Asn Gln Gln 1 5 10 11 10 PRT mycoplasma genitalium Sequence located in MG004 at 229-238 and may interact with Sequence 12 in this patent. 11 Phe Pro Thr Gly Ala Asn Ile Ile Tyr Thr 1 5 10 12 10 PRT mycoplasma genitalium Sequence located in MG231 at 688-697 and may interact with Sequence 11 in this patent. 12 Lys Gly Cys Ser Ser Ile Tyr Tyr Val Arg 1 5 10 13 10 PRT mycoplasma genitalium Sequence located in MG004 at 741-750 and may interact with Sequence 14 in this patent. 13 Lys Arg Asn Ala Lys Gly Val Lys Thr Leu 1 5 10 14 10 PRT mycoplasma genitalium Sequence located in MG414 at 433-442 and may interact with Sequence 13 in this patent. 14 Leu Pro Ile Ser Phe Ser Asn Leu Ser Lys 1 5 10 15 10 PRT mycoplasma genitalium Sequence located in MG007 at 166-175 and may interact with Sequence 16 in this patent. 15 Glu Gln Ile Glu Ala Ile Glu Asn Gly Ser 1 5 10 16 10 PRT mycoplasma genitalium Sequence located in MG241 at 66-75 and may interact with Sequence 15 in this patent. 16 Leu Leu Asn Phe Ser Asp Phe Val Ser Gly 1 5 10 17 10 PRT mycoplasma genitalium Sequence located in MG007 at 165-174 and may interact with Sequence 18 in this patent. 17 Asp Glu Gln Ile Glu Ala Ile Glu Asn Gly 1 5 10 18 10 PRT mycoplasma genitalium Sequence located in MG241 at 65-74 and may interact with Sequence 17 in this patent. 18 Val Leu Leu Asn Phe Ser Asp Phe Val Ser 1 5 10 19 10 PRT mycoplasma genitalium Sequence located in MG008 at 399-408 and may interact with Sequence 20 in this patent. 19 Lys Lys Tyr Leu Phe Phe Asp Val Leu Val 1 5 10 20 10 PRT mycoplasma genitalium Sequence located in MG031 at 44-53 and may interact with Sequence 19 in this patent. 20 Asn Lys Tyr Ile Glu Glu Lys Val Phe Leu 1 5 10 21 10 PRT mycoplasma genitalium Sequence located in MG009 at 168-177 and may interact with Sequence 22 in this patent. 21 Leu Leu Ser Leu Lys Asp Leu Asn Ile Asp 1 5 10 22 10 PRT mycoplasma genitalium Sequence located in MG028 at 154-163 and may interact with Sequence 21 in this patent. 22 Ile Asp Ile Glu Ile Leu Lys Ala Lys Lys 1 5 10 23 10 PRT mycoplasma genitalium Sequence located in MG014 at 7-16 and may interact with Sequence 24 in this patent. 23 Glu Phe Asn Asn Lys Ile Arg Thr Ala Leu 1 5 10 24 10 PRT mycoplasma genitalium Sequence located in MG156 at 98-107 and may interact with Sequence 23 in this patent. 24 Lys Arg Ser Ser Asn Leu Val Ile Lys Leu 1 5 10 25 10 PRT mycoplasma genitalium Sequence located in MG015 at 184-193 and may interact with Sequence 26 in this patent. 25 Ser Phe Ala Phe Leu Lys Lys Ser Lys Thr 1 5 10 26 10 PRT mycoplasma genitalium Sequence located in MG015 at 184-193 and may interact with Sequence 25 in this patent. 26 Ser Phe Ala Phe Leu Lys Lys Ser Lys Thr 1 5 10 27 10 PRT mycoplasma genitalium Sequence located in MG015 at 148-157 and may interact with Sequence 28 in this patent. 27 Ala Ile Gln Ser Leu Phe Asn Ile Leu Thr 1 5 10 28 10 PRT mycoplasma genitalium Sequence located in MG247 at 88-97 and may interact with Sequence 27 in this patent. 28 Gly Tyr Leu Thr Glu Lys Val Tyr Gln Ser 1 5 10 29 10 PRT mycoplasma genitalium Sequence located in MG015 at 147-156 and may interact with Sequence 30 in this patent. 29 Gln Ala Ile Gln Ser Leu Phe Asn Ile Leu 1 5 10 30 10 PRT mycoplasma genitalium Sequence located in MG025 at 18-27 and may interact with Sequence 29 in this patent. 30 Gln Tyr Ile Lys Lys Ala Leu Asp Ser Leu 1 5 10 31 10 PRT mycoplasma genitalium Sequence located in MG015 at 148-157 and may interact with Sequence 32 in this patent. 31 Ala Ile Gln Ser Leu Phe Asn Ile Leu Thr 1 5 10 32 10 PRT mycoplasma genitalium Sequence located in MG025 at 17-26 and may interact with Sequence 31 in this patent. 32 Cys Gln Tyr Ile Lys Lys Ala Leu Asp Ser 1 5 10 33 10 PRT mycoplasma genitalium Sequence located in MG015 at 149-158 and may interact with Sequence 34 in this patent. 33 Ile Gln Ser Leu Phe Asn Ile Leu Thr Thr 1 5 10 34 10 PRT mycoplasma genitalium Sequence located in MG025 at 16-25 and may interact with Sequence 33 in this patent. 34 Cys Cys Gln Tyr Ile Lys Lys Ala Leu Asp 1 5 10 35 10 PRT mycoplasma genitalium Sequence located in MG015 at 294-303 and may interact with Sequence 36 in this patent. 35 Leu Ser Tyr Ile Ala Ser Leu Arg Gln Ile 1 5 10 36 10 PRT mycoplasma genitalium Sequence located in MG075 at 390-399 and may interact with Sequence 35 in this patent. 36 Glu Gly Ile Asn Ser Ala Glu Ser Leu Tyr 1 5 10 37 10 PRT mycoplasma genitalium Sequence located in MG017 at 167-176 and may interact with Sequence 38 in this patent. 37 Leu Thr Thr Val Tyr Pro His Arg Tyr Thr 1 5 10 38 10 PRT mycoplasma genitalium Sequence located in MG066 at 19-28 and may interact with Sequence 37 in this patent. 38 Lys Gly Gly His Val Gly Met Ala Ile Gly 1 5 10 39 10 PRT mycoplasma genitalium Sequence located in MG017 at 15-24 and may interact with Sequence 40 in this patent. 39 Phe Leu Ser Leu Val Lys Glu Val Lys Lys 1 5 10 40 10 PRT mycoplasma genitalium Sequence located in MG266 at 671-680 and may interact with Sequence 39 in this patent. 40 Phe Leu Asn Phe Leu Tyr Lys Thr Lys Lys 1 5 10 41 10 PRT mycoplasma genitalium Sequence located in MG017 at 165-174 and may interact with Sequence 42 in this patent. 41 Asn Thr Leu Thr Thr Val Tyr Pro His Arg 1 5 10 42 10 PRT mycoplasma genitalium Sequence located in MG429 at 218-227 and may interact with Sequence 41 in this patent. 42 Thr Val Gly Ile Asn Gly Arg Lys Gly Ile 1 5 10 43 10 PRT mycoplasma genitalium Sequence located in MG032 at 191-200 and may interact with Sequence 44 in this patent. 43 Leu Val Ser Glu Asn Asp Ile Ile Lys His 1 5 10 44 10 PRT mycoplasma genitalium Sequence located in MG119 at 99-108 and may interact with Sequence 43 in this patent. 44 Val Leu Asp Asn Ile Ile Leu Gly Asn Glu 1 5 10 45 10 PRT mycoplasma genitalium Sequence located in MG040 at 397-406 and may interact with Sequence 46 in this patent. 45 Ala Leu Asp Val Ala Val Glu Ser Ile Leu 1 5 10 46 10 PRT mycoplasma genitalium Sequence located in MG286 at 86-95 and may interact with Sequence 45 in this patent. 46 Gly Glu Ile Asn Arg Tyr Leu Arg Asn Glu 1 5 10 47 10 PRT mycoplasma genitalium Sequence located in MG040 at 366-375 and may interact with Sequence 48 in this patent. 47 Ala Gln Glu Leu Leu Asp Ile Asn Ile Asp 1 5 10 48 10 PRT mycoplasma genitalium Sequence located in MG239 at 680-689 and may interact with Sequence 47 in this patent. 48 Ser Leu Phe Lys Lys Ile Asp Ile Asn Ile 1 5 10 49 10 PRT mycoplasma genitalium Sequence located in MG040 at 435-444 and may interact with Sequence 50 in this patent. 49 Gly Val Ser Glu Ala Gly Tyr Glu Phe Leu 1 5 10 50 10 PRT mycoplasma genitalium Sequence located in MG440 at 40-49 and may interact with Sequence 49 in this patent. 50 Lys Glu Leu Val Thr Ser Leu Arg Asp Ser 1 5 10 51 10 PRT mycoplasma genitalium Sequence located in MG040 at 517-526 and may interact with Sequence 52 in this patent. 51 Arg Asn Gly Ser Ser Asp Ser Asn Gln Gln 1 5 10 52 10 PRT mycoplasma genitalium Sequence located in MG468 at 1096-1105 and may interact with Sequence 51 in this patent. 52 Leu Leu Ile Gly Ile Ala Gly Thr Ile Pro 1 5 10 53 10 PRT mycoplasma genitalium Sequence located in MG048 at 134-143 and may interact with Sequence 54 in this patent. 53 Val Gly Leu Asp Ile Tyr Arg Pro Ala Ala 1 5 10 54 10 PRT mycoplasma genitalium Sequence located in MG039 at 318-327 and may interact with Sequence 53 in this patent. 54 Gly Ser Arg Ala Ile Asp Ile Glu Thr Asn 1 5 10 55 10 PRT mycoplasma genitalium Sequence located in MG048 at 239-248 and may interact with Sequence 56 in this patent. 55 Lys Leu Thr Gly Phe Ile Ile Ser Lys Leu 1 5 10 56 10 PRT mycoplasma genitalium Sequence located in MG136 at 433-442 and may interact with Sequence 55 in this patent. 56 Gln Leu Gly Asn Asp Glu Thr Ser Glu Leu 1 5 10 57 10 PRT mycoplasma genitalium Sequence located in MG049 at 102-111 and may interact with Sequence 58 in this patent. 57 Gly Asp Pro Leu Arg Ala Lys Trp Ile Ala 1 5 10 58 10 PRT mycoplasma genitalium Sequence located in MG049 at 102-111 and may interact with Sequence 57 in this patent. 58 Gly Asp Pro Leu Arg Ala Lys Trp Ile Ala 1 5 10 59 10 PRT mycoplasma genitalium Sequence located in MG049 at 2-11 and may interact with Sequence 60 in this patent. 59 Val Cys Pro Thr Val Leu Ser Leu Ile Ala 1 5 10 60 10 PRT mycoplasma genitalium Sequence located in MG154 at 56-65 and may interact with Sequence 59 in this patent. 60 His Gly Gly Arg His Lys Arg Lys Tyr Arg 1 5 10 61 10 PRT mycoplasma genitalium Sequence located in MG049 at 1-10 and may interact with Sequence 62 in this patent. 61 Met Val Cys Pro Thr Val Leu Ser Leu Ile 1 5 10 62 10 PRT mycoplasma genitalium Sequence located in MG154 at 55-64 and may interact with Sequence 61 in this patent. 62 His His Gly Gly Arg His Lys Arg Lys Tyr 1 5 10 63 10 PRT mycoplasma genitalium Sequence located in MG050 at 97-106 and may interact with Sequence 64 in this patent. 63 Ala Glu Phe Lys Lys Arg Cys Ala Cys Val 1 5 10 64 10 PRT mycoplasma genitalium Sequence located in MG209 at 220-229 and may interact with Sequence 63 in this patent. 64 Ser Leu Glu Leu Leu Thr Gly Arg Thr His 1 5 10 65 10 PRT mycoplasma genitalium Sequence located in MG050 at 200-209 and may interact with Sequence 66 in this patent. 65 Ala Ser Arg Ile Gly Thr Ser Asn Ala Val 1 5 10 66 10 PRT mycoplasma genitalium Sequence located in MG348 at 169-178 and may interact with Sequence 65 in this patent. 66 Arg Arg Ser Asp Ala Ser Ala Val Arg Tyr 1 5 10 67 10 PRT mycoplasma genitalium Sequence located in MG054 at 119-128 and may interact with Sequence 68 in this patent. 67 Gly Ile Val Gly Ser Ser Gly Arg Gly Ala 1 5 10 68 10 PRT mycoplasma genitalium Sequence located in MG095 at 178-187 and may interact with Sequence 67 in this patent. 68 Ala Asn Asn Thr Ala Thr Ser Ser Thr Arg 1 5 10 69 10 PRT mycoplasma genitalium Sequence located in MG054 at 63-72 and may interact with Sequence 70 in this patent. 69 Pro Arg Ser Leu Lys Asn Thr Thr Phe Asn 1 5 10 70 10 PRT mycoplasma genitalium Sequence located in MG163 at 80-89 and may interact with Sequence 69 in this patent. 70 Arg Ala Gly Gln Leu Ile Gly Cys Lys Val 1 5 10 71 10 PRT mycoplasma genitalium Sequence located in MG058 at 167-176 and may interact with Sequence 72 in this patent. 71 Pro Ser His Asn Val Ala Glu Ser Ile Asn 1 5 10 72 10 PRT mycoplasma genitalium Sequence located in MG285 at 118-127 and may interact with Sequence 71 in this patent. 72 Ile Asn Arg Phe Ser Asn Val Val Ala Arg 1 5 10 73 10 PRT mycoplasma genitalium Sequence located in MG061 at 64-73 and may interact with Sequence 74 in this patent. 73 Asp Gly Thr Ser Val Glu Leu Ile Lys Gly 1 5 10 74 10 PRT mycoplasma genitalium Sequence located in MG037 at 221-230 and may interact with Sequence 73 in this patent. 74 Val Ala Arg Ala His Leu Gln Tyr Phe Thr 1 5 10 75 10 PRT mycoplasma genitalium Sequence located in MG061 at 346-355 and may interact with Sequence 76 in this patent. 75 Tyr Glu Phe Lys Asp Tyr Lys Lys Asn Glu 1 5 10 76 10 PRT mycoplasma genitalium Sequence located in MG225 at 391-400 and may interact with Sequence 75 in this patent. 76 Phe Val Phe Phe Ile Ile Phe Lys Phe Ile 1 5 10 77 10 PRT mycoplasma genitalium Sequence located in MG062 at 625-634 and may interact with Sequence 78 in this patent. 77 Leu Leu Lys Thr Thr Leu Gln Gly Ile Glu 1 5 10 78 10 PRT mycoplasma genitalium Sequence located in MG279 at 99-108 and may interact with Sequence 77 in this patent. 78 Leu Asn Ala Leu Glu Gly Ser Leu Lys Lys 1 5 10 79 10 PRT mycoplasma genitalium Sequence located in MG062 at 626-635 and may interact with Sequence 80 in this patent. 79 Leu Lys Thr Thr Leu Gln Gly Ile Glu Gly 1 5 10 80 10 PRT mycoplasma genitalium Sequence located in MG279 at 98-107 and may interact with Sequence 79 in this patent. 80 Ser Leu Asn Ala Leu Glu Gly Ser Leu Lys 1 5 10 81 10 PRT mycoplasma genitalium Sequence located in MG062 at 627-636 and may interact with Sequence 82 in this patent. 81 Lys Thr Thr Leu Gln Gly Ile Glu Gly Ala 1 5 10 82 10 PRT mycoplasma genitalium Sequence located in MG279 at 97-106 and may interact with Sequence 81 in this patent. 82 Ser Ser Leu Asn Ala Leu Glu Gly Ser Leu 1 5 10 83 10 PRT mycoplasma genitalium Sequence located in MG062 at 46-55 and may interact with Sequence 84 in this patent. 83 Phe Glu Ala Leu Lys Lys Arg Glu Glu Glu 1 5 10 84 10 PRT mycoplasma genitalium Sequence located in MG108 at 59-68 and may interact with Sequence 83 in this patent. 84 Leu Phe Leu Ser Leu Phe Glu Gly Phe Glu 1 5 10 85 10 PRT mycoplasma genitalium Sequence located in MG065 at 104-113 and may interact with Sequence 86 in this patent. 85 Glu Thr Val Ile Ala Ser Tyr Asn Ser Phe 1 5 10 86 10 PRT mycoplasma genitalium Sequence located in MG065 at 104-113 and may interact with Sequence 85 in this patent. 86 Glu Thr Val Ile Ala Ser Tyr Asn Ser Phe 1 5 10 87 10 PRT mycoplasma genitalium Sequence located in MG065 at 303-312 and may interact with Sequence 88 in this patent. 87 Leu Asn Asp Arg Lys Leu Thr Lys Phe Arg 1 5 10 88 10 PRT mycoplasma genitalium Sequence located in MG261 at 381-390 and may interact with Sequence 87 in this patent. 88 Gln Ile Val Thr Phe Gln Arg Phe Lys Thr 1 5 10 89 10 PRT mycoplasma genitalium Sequence located in MG065 at 302-311 and may interact with Sequence 90 in this patent. 89 Cys Leu Asn Asp Arg Lys Leu Thr Lys Phe 1 5 10 90 10 PRT mycoplasma genitalium Sequence located in MG261 at 380-389 and may interact with Sequence 89 in this patent. 90 Ala Gln Ile Val Thr Phe Gln Arg Phe Lys 1 5 10 91 10 PRT mycoplasma genitalium Sequence located in MG065 at 393-402 and may interact with Sequence 92 in this patent. 91 Phe Gly Asp Glu Pro Thr Gly Ala Leu Asp 1 5 10 92 10 PRT mycoplasma genitalium Sequence located in MG301 at 99-108 and may interact with Sequence 91 in this patent. 92 Ile Glu Ser Thr Gly Arg Phe Val Ser Glu 1 5 10 93 10 PRT mycoplasma genitalium Sequence located in MG066 at 615-624 and may interact with Sequence 94 in this patent. 93 Gly Ala Phe Ser Phe Gly Glu Ser Asp Asp 1 5 10 94 10 PRT mycoplasma genitalium Sequence located in MG072 at 104-113 and may interact with Sequence 93 in this patent. 94 Thr Gly Glu Gly Lys Thr Leu Thr Ile Val 1 5 10 95 10 PRT mycoplasma genitalium Sequence located in MG066 at 49-58 and may interact with Sequence 96 in this patent. 95 Lys Trp Ile Asn Arg Asp Arg Phe Val Leu 1 5 10 96 10 PRT mycoplasma genitalium Sequence located in MG328 at 309-318 and may interact with Sequence 95 in this patent. 96 Gln Asn Lys Pro Val Ala Ile Asn Pro Leu 1 5 10 97 10 PRT mycoplasma genitalium Sequence located in MG066 at 167-176 and may interact with Sequence 98 in this patent. 97 Leu Tyr Lys Leu Asn Lys Leu Ile Val Leu 1 5 10 98 10 PRT mycoplasma genitalium Sequence located in MG341 at 238-247 and may interact with Sequence 97 in this patent. 98 Glu Ile Leu Lys Ile Phe Lys Asn Asn Glu 1 5 10 99 10 PRT mycoplasma genitalium Sequence located in MG066 at 594-603 and may interact with Sequence 100 in this patent. 99 Glu Ala Ser Ser Ser Tyr Glu Trp Phe Cys 1 5 10 100 10 PRT mycoplasma genitalium Sequence located in MG450 at 114-123 and may interact with Sequence 99 in this patent. 100 Thr Lys Pro Leu Val Ala Gly Gly Arg Leu 1 5 10 101 10 PRT mycoplasma genitalium Sequence located in MG067 at 95-104 and may interact with Sequence 102 in this patent. 101 Thr Ile Ala Ser Ser Ser Ile Ile Ser Ser 1 5 10 102 10 PRT mycoplasma genitalium Sequence located in MG274 at 239-248 and may interact with Sequence 101 in this patent. 102 Ala Ala Asn Tyr Ala Arg Gly Gly Asn Gly 1 5 10 103 10 PRT mycoplasma genitalium Sequence located in MG067 at 96-105 and may interact with Sequence 104 in this patent. 103 Ile Ala Ser Ser Ser Ile Ile Ser Ser Val 1 5 10 104 10 PRT mycoplasma genitalium Sequence located in MG274 at 238-247 and may interact with Sequence 103 in this patent. 104 Asp Ala Ala Asn Tyr Ala Arg Gly Gly Asn 1 5 10 105 10 PRT mycoplasma genitalium Sequence located in MG069 at 4-13 and may interact with Sequence 106 in this patent. 105 Ser Leu Val Lys Ile Arg Asn Lys Phe Lys 1 5 10 106 10 PRT mycoplasma genitalium Sequence located in MG072 at 722-731 and may interact with Sequence 105 in this patent. 106 Thr Glu His Leu Asp Ser Val Phe Lys Leu 1 5 10 107 10 PRT mycoplasma genitalium Sequence located in MG069 at 339-348 and may interact with Sequence 108 in this patent. 107 Phe Leu Ser Trp Lys Glu Leu Val Asp Gly 1 5 10 108 10 PRT mycoplasma genitalium Sequence located in MG290 at 17-26 and may interact with Sequence 107 in this patent. 108 Lys Lys Ala Pro Leu Leu Gln Asn Ile Ser 1 5 10 109 10 PRT mycoplasma genitalium Sequence located in MG069 at 479-488 and may interact with Sequence 110 in this patent. 109 Ala Pro Lys Gly Arg Arg Lys Glu Ala Ser 1 5 10 110 10 PRT mycoplasma genitalium Sequence located in MG098 at 80-89 and may interact with Sequence 109 in this patent. 110 Gly Gly Leu Thr Ala Ala Leu Phe Arg Gly 1 5 10 111 10 PRT mycoplasma genitalium Sequence located in MG069 at 317-326 and may interact with Sequence 112 in this patent. 111 Ala Thr Thr Thr Gly Gln Asp Ser Thr Ser 1 5 10 112 10 PRT mycoplasma genitalium Sequence located in MG191 at 992-1001 and may interact with Sequence 111 in this patent. 112 Ser Ser Ser Ser Thr Leu Val Gly Ser Gly 1 5 10 113 10 PRT mycoplasma genitalium Sequence located in MG069 at 316-325 and may interact with Sequence 114 in this patent. 113 Gly Ala Thr Thr Thr Gly Gln Asp Ser Thr 1 5 10 114 10 PRT mycoplasma genitalium Sequence located in MG191 at 991-1000 and may interact with Sequence 113 in this patent. 114 Ser Ser Ser Ser Ser Thr Leu Val Gly Ser 1 5 10 115 10 PRT mycoplasma genitalium Sequence located in MG069 at 281-290 and may interact with Sequence 116 in this patent. 115 Gly Ser Asp Tyr Val Thr Arg Val Ile Gly 1 5 10 116 10 PRT mycoplasma genitalium Sequence located in MG346 at 16-25 and may interact with Sequence 115 in this patent. 116 Pro Asn Asn Thr Gly Asn Ile Val Arg Ser 1 5 10 117 10 PRT mycoplasma genitalium Sequence located in MG070 at 43-52 and may interact with Sequence 118 in this patent. 117 Arg Lys His Asn Asn Asp Leu Leu Lys Leu 1 5 10 118 10 PRT mycoplasma genitalium Sequence located in MG223 at 72-81 and may interact with Sequence 117 in this patent. 118 Lys Leu Glu Lys Val Val Val Val Leu Ala 1 5 10 119 10 PRT mycoplasma genitalium Sequence located in MG071 at 403-412 and may interact with Sequence 120 in this patent. 119 Glu Lys Ala Phe Asp Ser Ile Arg Lys Leu 1 5 10 120 10 PRT mycoplasma genitalium Sequence located in MG181 at 259-268 and may interact with Sequence 119 in this patent. 120 Glu Leu Ala Tyr Gly Ile Glu Arg Leu Leu 1 5 10 121 10 PRT mycoplasma genitalium Sequence located in MG071 at 217-226 and may interact with Sequence 122 in this patent. 121 Gly Lys Ile Ala Lys Thr Val Asp Asp Ser 1 5 10 122 10 PRT mycoplasma genitalium Sequence located in MG241 at 485-494 and may interact with Sequence 121 in this patent. 122 Thr Val Ile Asn Arg Leu Arg Tyr Leu Ser 1 5 10 123 10 PRT mycoplasma genitalium Sequence located in MG071 at 174-183 and may interact with Sequence 124 in this patent. 123 Asp Lys Thr Ile Asp Ser Asn Glu Lys Ala 1 5 10 124 10 PRT mycoplasma genitalium Sequence located in MG334 at 659-668 and may interact with Sequence 123 in this patent. 124 Val Leu Ser Asn Ile Ala Ile Leu Leu Ser 1 5 10 125 10 PRT mycoplasma genitalium Sequence located in MG072 at 326-335 and may interact with Sequence 126 in this patent. 125 Glu Gly Arg Ser Tyr Ser Asn Gly Leu Gln 1 5 10 126 10 PRT mycoplasma genitalium Sequence located in MG195 at 485-494 and may interact with Sequence 125 in this patent. 126 Leu Lys Pro Ile Gly Ile Thr Ser Ser Phe 1 5 10 127 10 PRT mycoplasma genitalium Sequence located in MG073 at 365-374 and may interact with Sequence 128 in this patent. 127 Ile Asp Tyr Gly Phe Arg Leu Pro Ser Ala 1 5 10 128 10 PRT mycoplasma genitalium Sequence located in MG140 at 316-325 and may interact with Sequence 127 in this patent. 128 Gly Thr Gly Lys Ser Glu Thr Ile Val Asn 1 5 10 129 10 PRT mycoplasma genitalium Sequence located in MG073 at 236-245 and may interact with Sequence 130 in this patent. 129 Lys Ile Leu Asn Gln Leu Phe Glu Ile Lys 1 5 10 130 10 PRT mycoplasma genitalium Sequence located in MG462 at 295-304 and may interact with Sequence 129 in this patent. 130 Phe Asn Leu Lys Gln Leu Ile Glu Asn Phe 1 5 10 131 10 PRT mycoplasma genitalium Sequence located in MG074 at 3-12 and may interact with Sequence 132 in this patent. 131 Gln Phe Ile Lys Leu Ser Leu Leu Val Phe 1 5 10 132 10 PRT mycoplasma genitalium Sequence located in MG239 at 223-232 and may interact with Sequence 131 in this patent. 132 Lys Asn Lys Glu Thr Glu Phe Asp Lys Leu 1 5 10 133 10 PRT mycoplasma genitalium Sequence located in MG077 at 109-118 and may interact with Sequence 134 in this patent. 133 Leu Ile Gly Ser Leu Leu Gly Ile Phe Leu 1 5 10 134 10 PRT mycoplasma genitalium Sequence located in MG037 at 187-196 and may interact with Sequence 133 in this patent. 134 Glu Lys Tyr Ala Lys Glu Thr Ala Asp Glu 1 5 10 135 10 PRT mycoplasma genitalium Sequence located in MG077 at 369-378 and may interact with Sequence 136 in this patent. 135 Tyr Lys Thr Lys Thr Val Gln Leu Thr Thr 1 5 10 136 10 PRT mycoplasma genitalium Sequence located in MG147 at 152-161 and may interact with Sequence 135 in this patent. 136 Arg Ser Glu Leu Tyr Arg Leu Cys Leu Val 1 5 10 137 10 PRT mycoplasma genitalium Sequence located in MG077 at 370-379 and may interact with Sequence 138 in this patent. 137 Lys Thr Lys Thr Val Gln Leu Thr Thr Glu 1 5 10 138 10 PRT mycoplasma genitalium Sequence located in MG147 at 151-160 and may interact with Sequence 137 in this patent. 138 Phe Arg Ser Glu Leu Tyr Arg Leu Cys Leu 1 5 10 139 10 PRT mycoplasma genitalium Sequence located in MG079 at 250-259 and may interact with Sequence 140 in this patent. 139 Leu Ile Lys Gln Leu Arg Asp Leu Leu Asn 1 5 10 140 10 PRT mycoplasma genitalium Sequence located in MG334 at 606-615 and may interact with Sequence 139 in this patent. 140 Ile Gln Lys Ile Thr Lys Leu Leu Asp Lys 1 5 10 141 10 PRT mycoplasma genitalium Sequence located in MG079 at 59-68 and may interact with Sequence 142 in this patent. 141 Glu Ser Gly Ser Gly Lys Ser Val Ser Val 1 5 10 142 10 PRT mycoplasma genitalium Sequence located in MG459 at 59-68 and may interact with Sequence 141 in this patent. 142 Phe Gly Ala Thr Ala Leu Gly Asp Gly His 1 5 10 143 10 PRT mycoplasma genitalium Sequence located in MG080 at 684-693 and may interact with Sequence 144 in this patent. 143 Glu Phe Ser Gly Gly Gln Arg Gln Arg Ile 1 5 10 144 10 PRT mycoplasma genitalium Sequence located in MG261 at 235-244 and may interact with Sequence 143 in this patent. 144 Leu Lys Ala Ala Ser Leu Ser Leu Thr Asp 1 5 10 145 10 PRT mycoplasma genitalium Sequence located in MG080 at 731-740 and may interact with Sequence 146 in this patent. 145 Ala Lys Lys His Asn Leu Thr Val Leu Phe 1 5 10 146 10 PRT mycoplasma genitalium Sequence located in MG300 at 55-64 and may interact with Sequence 145 in this patent. 146 Lys Lys Asn Cys Lys Ile Val Leu Leu Ser 1 5 10 147 10 PRT mycoplasma genitalium Sequence located in MG244 at 392-401 and may interact with Sequence 148 in this patent. 147 Gln Leu Val Lys Leu Gln Arg Val Leu Ile 1 5 10 148 10 PRT mycoplasma genitalium Sequence located in MG400 at 253-262 and may interact with Sequence 147 in this patent. 148 Asp Lys Tyr Thr Leu Gln Phe Asn Lys Leu 1 5 10 149 10 PRT mycoplasma genitalium Sequence located in MG248 at 21-30 and may interact with Sequence 150 in this patent. 149 Tyr Asp Ile Gly Cys Asp His Ser Tyr Leu 1 5 10 150 10 PRT mycoplasma genitalium Sequence located in MG335 at 107-116 and may interact with Sequence 149 in this patent. 150 Ile Val Asp Ser Gly Val Val Thr Val Gln 1 5 10 151 10 PRT mycoplasma genitalium Sequence located in MG249 at 204-213 and may interact with Sequence 152 in this patent. 151 Asp Lys Val Asp Asp Asn Val Arg Phe Phe 1 5 10 152 10 PRT mycoplasma genitalium Sequence located in MG415 at 229-238 and may interact with Sequence 151 in this patent. 152 Lys Lys Thr Asp Ile Ile Val Tyr Leu Ile 1 5 10 153 10 PRT mycoplasma genitalium Sequence located in MG256 at 202-211 and may interact with Sequence 154 in this patent. 153 Pro Val Leu Asn Phe Gln Arg Leu Tyr Val 1 5 10 154 10 PRT mycoplasma genitalium Sequence located in MG018 at 19-28 and may interact with Sequence 153 in this patent. 154 Asp Ile Lys Ala Leu Lys Ile Glu Asp Arg 1 5 10 155 10 PRT mycoplasma genitalium Sequence located in MG258 at 325-334 and may interact with Sequence 156 in this patent. 155 Leu Thr Ile Asn Lys Leu Asn Thr Val Ile 1 5 10 156 10 PRT mycoplasma genitalium Sequence located in MG085 at 14-23 and may interact with Sequence 155 in this patent. 156 Asn Asp Cys Ile Gln Leu Ile Asp Gly Lys 1 5 10 157 10 PRT mycoplasma genitalium Sequence located in MG262 at 61-70 and may interact with Sequence 158 in this patent. 157 Phe Asp Thr Lys Ala Pro Thr Phe Arg Asp 1 5 10 158 10 PRT mycoplasma genitalium Sequence located in MG266 at 178-187 and may interact with Sequence 157 in this patent. 158 Val Ser Glu Arg Gly Ser Phe Ser Val Glu 1 5 10 159 10 PRT mycoplasma genitalium Sequence located in MG270 at 219-228 and may interact with Sequence 160 in this patent. 159 Val Leu Thr Lys Asp Ala Leu Ala Lys Val 1 5 10 160 10 PRT mycoplasma genitalium Sequence located in MG445 at 158-167 and may interact with Sequence 159 in this patent. 160 Asp Gln Ser Leu Ile Cys Glu Ser Phe Asn 1 5 10 161 10 PRT mycoplasma genitalium Sequence located in MG270 at 218-227 and may interact with Sequence 162 in this patent. 161 Ile Val Leu Thr Lys Asp Ala Leu Ala Lys 1 5 10 162 10 PRT mycoplasma genitalium Sequence located in MG445 at 157-166 and may interact with Sequence 161 in this patent. 162 Asn Asp Gln Ser Leu Ile Cys Glu Ser Phe 1 5 10 163 10 PRT mycoplasma genitalium Sequence located in MG271 at 243-252 and may interact with Sequence 164 in this patent. 163 Leu Phe Tyr Thr Val Asn Gly Val Glu Gln 1 5 10 164 10 PRT mycoplasma genitalium Sequence located in MG271 at 243-252 and may interact with Sequence 163 in this patent. 164 Leu Phe Tyr Thr Val Asn Gly Val Glu Gln 1 5 10 165 10 PRT mycoplasma genitalium Sequence located in MG271 at 253-262 and may interact with Sequence 166 in this patent. 165 Ser Val Ile Gly Asp Lys Ile Leu Val Ser 1 5 10 166 10 PRT mycoplasma genitalium Sequence located in MG192 at 438-447 and may interact with Sequence 165 in this patent. 166 Gly Tyr Lys Asp Leu Val Thr Asn Asp Thr 1 5 10 167 10 PRT mycoplasma genitalium Sequence located in MG272 at 187-196 and may interact with Sequence 168 in this patent. 167 Asn Ala Thr Lys Leu Lys Gln Tyr Arg Glu 1 5 10 168 10 PRT mycoplasma genitalium Sequence located in MG322 at 102-111 and may interact with Sequence 167 in this patent. 168 Leu Ala Val Leu Leu Gln Leu Gly Gly Ile 1 5 10 169 10 PRT mycoplasma genitalium Sequence located in MG276 at 85-94 and may interact with Sequence 170 in this patent. 169 Ala Asn Lys Leu Pro Gly Gln Leu Ile Ser 1 5 10 170 10 PRT mycoplasma genitalium Sequence located in MG276 at 85-94 and may interact with Sequence 169 in this patent. 170 Ala Asn Lys Leu Pro Gly Gln Leu Ile Ser 1 5 10 171 10 PRT mycoplasma genitalium Sequence located in MG277 at 160-169 and may interact with Sequence 172 in this patent. 171 Gln Val Arg Arg Asn Ala Ile Ser Ser Val 1 5 10 172 10 PRT mycoplasma genitalium Sequence located in MG156 at 51-60 and may interact with Sequence 171 in this patent. 172 Leu Asn Ser Ala Ile Ser Asn Ala Thr Asn 1 5 10 173 10 PRT mycoplasma genitalium Sequence located in MG277 at 551-560 and may interact with Sequence 174 in this patent. 173 Ser Val Val Ser Ser Leu Val Ile Phe Ser 1 5 10 174 10 PRT mycoplasma genitalium Sequence located in MG211 at 23-32 and may interact with Sequence 173 in this patent. 174 Ala Lys Asp Asp Lys Gly Gly Tyr Asp Ala 1 5 10 175 10 PRT mycoplasma genitalium Sequence located in MG277 at 208-217 and may interact with Sequence 176 in this patent. 175 Val Asn Ser Ala Leu Thr Phe Glu Tyr Lys 1 5 10 176 10 PRT mycoplasma genitalium Sequence located in MG239 at 640-649 and may interact with Sequence 175 in this patent. 176 His Val Ala Gly Lys Gly Glu Leu Ile Leu 1 5 10 177 10 PRT mycoplasma genitalium Sequence located in MG277 at 207-216 and may interact with Sequence 178 in this patent. 177 Ser Val Asn Ser Ala Leu Thr Phe Glu Tyr 1 5 10 178 10 PRT mycoplasma genitalium Sequence located in MG239 at 639-648 and may interact with Sequence 177 in this patent. 178 Thr His Val Ala Gly Lys Gly Glu Leu Ile 1 5 10 179 10 PRT mycoplasma genitalium Sequence located in MG277 at 533-542 and may interact with Sequence 180 in this patent. 179 Leu Thr Leu Arg Tyr Lys Leu Leu Gly Leu 1 5 10 180 10 PRT mycoplasma genitalium Sequence located in MG386 at 1055-1064 and may interact with Sequence 179 in this patent. 180 Glu Ser Glu Ala Val Phe Glu Lys Pro Gln 1 5 10 181 10 PRT mycoplasma genitalium Sequence located in MG277 at 631-640 and may interact with Sequence 182 in this patent. 181 Val Ile Tyr Leu Ser Asn Tyr Gln Val Gln 1 5 10 182 10 PRT mycoplasma genitalium Sequence located in MG401 at 57-66 and may interact with Sequence 181 in this patent. 182 Asn Asn Ile Gln Gly Ile Val Leu Asn Leu 1 5 10 183 10 PRT mycoplasma genitalium Sequence located in MG278 at 172-181 and may interact with Sequence 184 in this patent. 183 Thr Leu Glu Leu Tyr Ala Lys Ile Ala Gly 1 5 10 184 10 PRT mycoplasma genitalium Sequence located in MG101 at 37-46 and may interact with Sequence 183 in this patent. 184 Arg Gln Leu Glu Ile Arg Phe Asn Ser Ser 1 5 10 185 10 PRT mycoplasma genitalium Sequence located in MG279 at 12-21 and may interact with Sequence 186 in this patent. 185 Leu Ile Ile Leu Val Gly Ile Leu Leu Leu 1 5 10 186 10 PRT mycoplasma genitalium Sequence located in MG217 at 135-144 and may interact with Sequence 185 in this patent. 186 Gln Tyr Tyr Gln Asp Pro Asn Gln Gln Gln 1 5 10 187 10 PRT mycoplasma genitalium Sequence located in MG279 at 12-21 and may interact with Sequence 188 in this patent. 187 Leu Ile Ile Leu Val Gly Ile Leu Leu Leu 1 5 10 188 10 PRT mycoplasma genitalium Sequence located in MG217 at 116-125 and may interact with Sequence 187 in this patent. 188 Gln Tyr Tyr Gln Asp Pro Asn Gln Gln Gln 1 5 10 189 10 PRT mycoplasma genitalium Sequence located in MG279 at 12-21 and may interact with Sequence 190 in this patent. 189 Leu Ile Ile Leu Val Gly Ile Leu Leu Leu 1 5 10 190 10 PRT mycoplasma genitalium Sequence located in MG217 at 97-106 and may interact with Sequence 189 in this patent. 190 Gln Tyr Tyr Gln Asp Pro Asn Gln Gln Gln 1 5 10 191 10 PRT mycoplasma genitalium Sequence located in MG279 at 12-21 and may interact with Sequence 192 in this patent. 191 Leu Ile Ile Leu Val Gly Ile Leu Leu Leu 1 5 10 192 10 PRT mycoplasma genitalium Sequence located in MG217 at 77-86 and may interact with Sequence 191 in this patent. 192 Gln Tyr Tyr Gln Asp Pro Asn Gln Gln Gln 1 5 10 193 10 PRT mycoplasma genitalium Sequence located in MG279 at 12-21 and may interact with Sequence 194 in this patent. 193 Leu Ile Ile Leu Val Gly Ile Leu Leu Leu 1 5 10 194 10 PRT mycoplasma genitalium Sequence located in MG217 at 57-66 and may interact with Sequence 193 in this patent. 194 Gln Tyr Tyr Gln Asp Pro Asn Gln Gln Gln 1 5 10 195 10 PRT mycoplasma genitalium Sequence located in MG279 at 12-21 and may interact with Sequence 196 in this patent. 195 Leu Ile Ile Leu Val Gly Ile Leu Leu Leu 1 5 10 196 10 PRT mycoplasma genitalium Sequence located in MG217 at 25-34 and may interact with Sequence 195 in this patent. 196 Gln Tyr Tyr Gln Asp Pro Asn Gln Gln Gln 1 5 10 197 10 PRT mycoplasma genitalium Sequence located in MG280 at 102-111 and may interact with Sequence 198 in this patent. 197 Ala Thr Lys Lys Asp Leu Glu Asn Ser Lys 1 5 10 198 10 PRT mycoplasma genitalium Sequence located in MG043 at 105-114 and may interact with Sequence 197 in this patent. 198 Ser Ser Phe Leu Ile Lys Leu Ile Gly Leu 1 5 10 199 10 PRT mycoplasma genitalium Sequence located in MG281 at 270-279 and may interact with Sequence 200 in this patent. 199 Gly Leu Ser Gly Asn Gly Ser Gln Leu Asn 1 5 10 200 10 PRT mycoplasma genitalium Sequence located in MG095 at 34-43 and may interact with Sequence 199 in this patent. 200 Ala Gln Thr Thr Ile Ser Thr Leu Lys Ile 1 5 10 201 10 PRT mycoplasma genitalium Sequence located in MG281 at 269-278 and may interact with Sequence 202 in this patent. 201 Arg Gly Leu Ser Gly Asn Gly Ser Gln Leu 1 5 10 202 10 PRT mycoplasma genitalium Sequence located in MG095 at 33-42 and may interact with Sequence 201 in this patent. 202 Pro Ala Gln Thr Thr Ile Ser Thr Leu Lys 1 5 10 203 10 PRT mycoplasma genitalium Sequence located in MG281 at 203-212 and may interact with Sequence 204 in this patent. 203 Thr Lys Ala Thr Thr Val Ser Thr Ser Asn 1 5 10 204 10 PRT mycoplasma genitalium Sequence located in MG169 at 20-29 and may interact with Sequence 203 in this patent. 204 Val Gly Arg Gly His Gly Ser Gly Leu Gly 1 5 10 205 10 PRT mycoplasma genitalium Sequence located in MG281 at 204-213 and may interact with Sequence 206 in this patent. 205 Lys Ala Thr Thr Val Ser Thr Ser Asn Asn 1 5 10 206 10 PRT mycoplasma genitalium Sequence located in MG169 at 19-28 and may interact with Sequence 205 in this patent. 206 Val Val Gly Arg Gly His Gly Ser Gly Leu 1 5 10 207 10 PRT mycoplasma genitalium Sequence located in MG281 at 205-214 and may interact with Sequence 208 in this patent. 207 Ala Thr Thr Val Ser Thr Ser Asn Asn Leu 1 5 10 208 10 PRT mycoplasma genitalium Sequence located in MG169 at 18-27 and may interact with Sequence 207 in this patent. 208 Lys Val Val Gly Arg Gly His Gly Ser Gly 1 5 10 209 10 PRT mycoplasma genitalium Sequence located in MG281 at 206-215 and may interact with Sequence 210 in this patent. 209 Thr Thr Val Ser Thr Ser Asn Asn Leu Thr 1 5 10 210 10 PRT mycoplasma genitalium Sequence located in MG169 at 17-26 and may interact with Sequence 209 in this patent. 210 Ser Lys Val Val Gly Arg Gly His Gly Ser 1 5 10 211 10 PRT mycoplasma genitalium Sequence located in MG281 at 429-438 and may interact with Sequence 212 in this patent. 211 Tyr Arg Glu Gly Asp Asn Thr Tyr Tyr Arg 1 5 10 212 10 PRT mycoplasma genitalium Sequence located in MG314 at 388-397 and may interact with Sequence 211 in this patent. 212 Val Pro Phe Ser Ile Ile Ser Val Ile Ala 1 5 10 213 10 PRT mycoplasma genitalium Sequence located in MG282 at 146-155 and may interact with Sequence 214 in this patent. 213 Gly Ile Glu Val Pro Tyr Arg Val Lys Ile 1 5 10 214 10 PRT mycoplasma genitalium Sequence located in MG210.1 at 23-32 and may interact with Sequence 213 in this patent. 214 Thr Asp Phe Asp Trp Val Thr Tyr Leu Asn 1 5 10 215 10 PRT mycoplasma genitalium Sequence located in MG282 at 20-29 and may interact with Sequence 216 in this patent. 215 Leu Glu Asn Leu Ile Gln Val Lys Arg Pro 1 5 10 216 10 PRT mycoplasma genitalium Sequence located in MG379 at 357-366 and may interact with Sequence 215 in this patent. 216 Lys Leu Ile Glu Asn Leu Tyr Phe Ala Gly 1 5 10 217 10 PRT mycoplasma genitalium Sequence located in MG289 at 2-11 and may interact with Sequence 218 in this patent. 217 Leu Phe Lys Lys Phe Thr Trp Val Ile Pro 1 5 10 218 10 PRT mycoplasma genitalium Sequence located in MG023 at 257-266 and may interact with Sequence 217 in this patent. 218 Gly Tyr Asp Pro Arg Lys Leu Leu Lys Glu 1 5 10 219 10 PRT mycoplasma genitalium Sequence located in MG289 at 250-259 and may interact with Sequence 220 in this patent. 219 Ala Val Val Arg Gly Arg Glu Ile Gly Ile 1 5 10 220 10 PRT mycoplasma genitalium Sequence located in MG191 at 853-862 and may interact with Sequence 219 in this patent. 220 Ser Asn Asn Ser Thr Pro Phe Asp Pro Asn 1 5 10 221 10 PRT mycoplasma genitalium Sequence located in MG290 at 222-231 and may interact with Sequence 222 in this patent. 221 Asn His Ala Leu Val Leu Asp Arg Leu Thr 1 5 10 222 10 PRT mycoplasma genitalium Sequence located in MG171 at 41-50 and may interact with Sequence 221 in this patent. 222 Arg Glu Ala Ile Lys Asn Gln Ser Val Ile 1 5 10 223 10 PRT mycoplasma genitalium Sequence located in MG290 at 223-232 and may interact with Sequence 224 in this patent. 223 His Ala Leu Val Leu Asp Arg Leu Thr Glu 1 5 10 224 10 PRT mycoplasma genitalium Sequence located in MG171 at 40-49 and may interact with Sequence 223 in this patent. 224 Phe Arg Glu Ala Ile Lys Asn Gln Ser Val 1 5 10 225 10 PRT mycoplasma genitalium Sequence located in MG290 at 224-233 and may interact with Sequence 226 in this patent. 225 Ala Leu Val Leu Asp Arg Leu Thr Glu Lys 1 5 10 226 10 PRT mycoplasma genitalium Sequence located in MG171 at 39-48 and may interact with Sequence 225 in this patent. 226 Leu Phe Arg Glu Ala Ile Lys Asn Gln Ser 1 5 10 227 10 PRT mycoplasma genitalium Sequence located in MG290 at 121-130 and may interact with Sequence 228 in this patent. 227 Lys Trp Ile Lys Asp Lys Ile Leu Ala Ile 1 5 10 228 10 PRT mycoplasma genitalium Sequence located in MG366 at 485-494 and may interact with Sequence 227 in this patent. 228 Asn Cys Glu Asn Leu Ile Phe Asp Pro Leu 1 5 10 229 10 PRT mycoplasma genitalium Sequence located in MG291 at 287-296 and may interact with Sequence 230 in this patent. 229 Arg Ile Ile Phe Ile Leu Phe Ile Val Val 1 5 10 230 10 PRT mycoplasma genitalium Sequence located in MG328 at 403-412 and may interact with Sequence 229 in this patent. 230 Ser Asn Asp Glu Asn Glu Lys Tyr Asp Asp 1 5 10 231 10 PRT mycoplasma genitalium Sequence located in MG297 at 258-267 and may interact with Sequence 232 in this patent. 231 Thr Leu Leu Val Leu Asp Gly Thr Val Gly 1 5 10 232 10 PRT mycoplasma genitalium Sequence located in MG341 at 802-811 and may interact with Sequence 231 in this patent. 232 Gly Gln Glu His Lys Ile Ala Ser Asp Ser 1 5 10 233 10 PRT mycoplasma genitalium Sequence located in MG297 at 294-303 and may interact with Sequence 234 in this patent. 233 Ser Ala Lys Gly Gly Ile Ile Leu Ala Ile 1 5 10 234 10 PRT mycoplasma genitalium Sequence located in MG393 at 29-38 and may interact with Sequence 233 in this patent. 234 Thr Ser Leu Ala Ser Asn Asp Lys Ser Asp 1 5 10 235 10 PRT mycoplasma genitalium Sequence located in MG297 at 163-172 and may interact with Sequence 236 in this patent. 235 Gln Asn Lys Arg Val Leu Leu Val Ala Gly 1 5 10 236 10 PRT mycoplasma genitalium Sequence located in MG462 at 447-456 and may interact with Sequence 235 in this patent. 236 Leu Ile Phe Thr Asn Lys Glu His Gly Pro 1 5 10 237 10 PRT mycoplasma genitalium Sequence located in MG298 at 727-736 and may interact with Sequence 238 in this patent. 237 Ile Gln Asn Ile Thr Glu Lys Ile Asn Ser 1 5 10 238 10 PRT mycoplasma genitalium Sequence located in MG122 at 533-542 and may interact with Sequence 237 in this patent. 238 Asn Leu Val Asn Arg Phe Phe Tyr Ile Thr 1 5 10 239 10 PRT mycoplasma genitalium Sequence located in MG298 at 495-504 and may interact with Sequence 240 in this patent. 239 Leu Asp Gly Phe Leu Gly Val Cys Ser Asp 1 5 10 240 10 PRT mycoplasma genitalium Sequence located in MG374 at 112-121 and may interact with Sequence 239 in this patent. 240 Lys Ile Ser Glu Glu Pro Asn Thr Thr Ile 1 5 10 241 10 PRT mycoplasma genitalium Sequence located in MG305 at 279-288 and may interact with Sequence 242 in this patent. 241 Lys Leu Thr Arg Ala Lys Phe Glu Glu Leu 1 5 10 242 10 PRT mycoplasma genitalium Sequence located in MG414 at 825-834 and may interact with Sequence 241 in this patent. 242 Leu Lys Ser Ser Ser Phe Lys Phe Leu Glu 1 5 10 243 10 PRT mycoplasma genitalium Sequence located in MG310 at 258-267 and may interact with Sequence 244 in this patent. 243 Ser Leu Val Asn Asp Phe Phe Gln Leu Ile 1 5 10 244 10 PRT mycoplasma genitalium Sequence located in MG130 at 402-411 and may interact with Sequence 243 in this patent. 244 Asp Glu Leu Lys Lys Ile Val Asp Lys Thr 1 5 10 245 10 PRT mycoplasma genitalium Sequence located in MG310 at 46-55 and may interact with Sequence 246 in this patent. 245 Tyr Ser Phe Tyr Ala Ile Asn Tyr Pro Gly 1 5 10 246 10 PRT mycoplasma genitalium Sequence located in MG421 at 226-235 and may interact with Sequence 245 in this patent. 246 Ser Arg Ile Val Asp Ser Ile Glu Thr Ile 1 5 10 247 10 PRT mycoplasma genitalium Sequence located in MG311 at 78-87 and may interact with Sequence 248 in this patent. 247 Val Leu Lys Gln Lys Gly Asn Leu Thr Val 1 5 10 248 10 PRT mycoplasma genitalium Sequence located in MG462 at 356-365 and may interact with Sequence 247 in this patent. 248 Asn Arg Glu Ile Ser Leu Leu Phe Lys Asn 1 5 10 249 10 PRT mycoplasma genitalium Sequence located in MG001 at 247-256 and may interact with Sequence 250 in this patent. 249 Phe Glu Pro Glu Thr Lys Ile Val Val Gln 1 5 10 250 10 PRT mycoplasma genitalium Sequence located in MG428 at 50-59 and may interact with Sequence 249 in this patent. 250 Glu Phe Gly Leu Ser Phe Asp Asn Tyr Leu 1 5 10 251 10 PRT mycoplasma genitalium Sequence located in MG010 at 77-86 and may interact with Sequence 252 in this patent. 251 Arg Lys Val Ser Tyr Lys Lys Glu Phe Leu 1 5 10 252 10 PRT mycoplasma genitalium Sequence located in MG414 at 538-547 and may interact with Sequence 251 in this patent. 252 Glu Glu Leu Phe Phe Ile Arg Asn Leu Pro 1 5 10 253 10 PRT mycoplasma genitalium Sequence located in MG010 at 37-46 and may interact with Sequence 254 in this patent. 253 Arg Gly Phe Asn Leu Gln Asp Phe Leu Lys 1 5 10 254 10 PRT mycoplasma genitalium Sequence located in MG433 at 2-11 and may interact with Sequence 253 in this patent. 254 Ala Thr Lys Ile Glu Leu Ile Lys Glu Leu 1 5 10 255 10 PRT mycoplasma genitalium Sequence located in MG020 at 282-291 and may interact with Sequence 256 in this patent. 255 Tyr Val Thr Asn Asn Ala Gly His Ser Gly 1 5 10 256 10 PRT mycoplasma genitalium Sequence located in MG294 at 60-69 and may interact with Sequence 255 in this patent. 256 Ala Thr Val Thr Ser Ile Ile Gly Tyr Val 1 5 10 257 10 PRT mycoplasma genitalium Sequence located in MG024 at 351-360 and may interact with Sequence 258 in this patent. 257 Asn Tyr Leu Ile Lys Asp Gly Asp Val Cys 1 5 10 258 10 PRT mycoplasma genitalium Sequence located in MG180 at 267-276 and may interact with Sequence 257 in this patent. 258 Val Ile Lys Asp Leu Ile Ala Ile Asn Ala 1 5 10 259 10 PRT mycoplasma genitalium Sequence located in MG025 at 100-109 and may interact with Sequence 260 in this patent. 259 Tyr Phe Leu Lys Asp Ser Phe Lys Lys Val 1 5 10 260 10 PRT mycoplasma genitalium Sequence located in MG095 at 385-394 and may interact with Sequence 259 in this patent. 260 Asp Phe Phe Lys Ala Ile Phe Gln Lys Val 1 5 10 261 10 PRT mycoplasma genitalium Sequence located in MG025 at 56-65 and may interact with Sequence 262 in this patent. 261 Asp Tyr Leu Ile Lys Tyr Ser Asn Ile Ser 1 5 10 262 10 PRT mycoplasma genitalium Sequence located in MG180 at 267-276 and may interact with Sequence 261 in this patent. 262 Val Ile Lys Asp Leu Ile Ala Ile Asn Ala 1 5 10 263 10 PRT mycoplasma genitalium Sequence located in MG027 at 94-103 and may interact with Sequence 264 in this patent. 263 Ser Gly Lys Lys Ile Asp Leu Leu Thr Thr 1 5 10 264 10 PRT mycoplasma genitalium Sequence located in MG027 at 94-103 and may interact with Sequence 263 in this patent. 264 Ser Gly Lys Lys Ile Asp Leu Leu Thr Thr 1 5 10 265 10 PRT mycoplasma genitalium Sequence located in MG028 at 157-166 and may interact with Sequence 266 in this patent. 265 Glu Ile Leu Lys Ala Lys Lys Gly Glu Pro 1 5 10 266 10 PRT mycoplasma genitalium Sequence located in MG335.2 at 276-285 and may interact with Sequence 265 in this patent. 266 Trp Phe Ala Leu Phe Ser Phe Glu Tyr Phe 1 5 10 267 10 PRT mycoplasma genitalium Sequence located in MG029 at 101-110 and may interact with Sequence 268 in this patent. 267 Ile Cys Asp Thr Pro Asn Val Leu Phe Lys 1 5 10 268 10 PRT mycoplasma genitalium Sequence located in MG130 at 180-189 and may interact with Sequence 267 in this patent. 268 Asn Gly Ile Ser Gly Ile Asn Lys Lys Leu 1 5 10 269 10 PRT mycoplasma genitalium Sequence located in MG030 at 195-204 and may interact with Sequence 270 in this patent. 269 Leu Gly Asp Ala Gly Asp Arg Leu Phe Gly 1 5 10 270 10 PRT mycoplasma genitalium Sequence located in MG081 at 2-11 and may interact with Sequence 269 in this patent. 270 Ala Lys Lys Thr Val Thr Arg Ile Ala Lys 1 5 10 271 10 PRT mycoplasma genitalium Sequence located in MG030 at 141-150 and may interact with Sequence 272 in this patent. 271 Ile Lys Ser Ile Lys Glu Asp Lys Pro Ile 1 5 10 272 10 PRT mycoplasma genitalium Sequence located in MG147 at 303-312 and may interact with Sequence 271 in this patent. 272 Tyr Phe Gly Tyr Phe Leu Ile Leu Gly Asn 1 5 10 273 10 PRT mycoplasma genitalium Sequence located in MG031 at 428-437 and may interact with Sequence 274 in this patent. 273 Gly Arg Tyr Asp Asp Val Ile Glu Phe Ser 1 5 10 274 10 PRT mycoplasma genitalium Sequence located in MG206 at 196-205 and may interact with Sequence 273 in this patent. 274 Pro Ser Val Val Ile Asn Tyr Leu Lys Ala 1 5 10 275 10 PRT mycoplasma genitalium Sequence located in MG031 at 31-40 and may interact with Sequence 276 in this patent. 275 Leu Asn Ser Leu Ile Glu Arg Ile Glu Ser 1 5 10 276 10 PRT mycoplasma genitalium Sequence located in MG217 at 226-235 and may interact with Sequence 275 in this patent. 276 Ala Leu Tyr Ser Leu Asp Lys Thr Ile Gln 1 5 10 277 10 PRT mycoplasma genitalium Sequence located in MG031 at 32-41 and may interact with Sequence 278 in this patent. 277 Asn Ser Leu Ile Glu Arg Ile Glu Ser Ile 1 5 10 278 10 PRT mycoplasma genitalium Sequence located in MG217 at 225-234 and may interact with Sequence 277 in this patent. 278 Asn Ala Leu Tyr Ser Leu Asp Lys Thr Ile 1 5 10 279 10 PRT mycoplasma genitalium Sequence located in MG035 at 143-152 and may interact with Sequence 280 in this patent. 279 Asp Thr Leu Leu Phe Ala Asn Ser Leu Leu 1 5 10 280 10 PRT mycoplasma genitalium Sequence located in MG107 at 43-52 and may interact with Sequence 279 in this patent. 280 Lys Lys Arg Ile Ser Glu Lys Glu Gly Ile 1 5 10 281 10 PRT mycoplasma genitalium Sequence located in MG036 at 109-118 and may interact with Sequence 282 in this patent. 281 Glu Glu Val Arg Leu Lys Tyr Arg Tyr Leu 1 5 10 282 10 PRT mycoplasma genitalium Sequence located in MG085 at 107-116 and may interact with Sequence 281 in this patent. 282 Gln Val Pro Ile Leu Lys Thr Asn Leu Phe 1 5 10 283 10 PRT mycoplasma genitalium Sequence located in MG036 at 207-216 and may interact with Sequence 284 in this patent. 283 Tyr Arg Asp Glu Asp Ser Arg Lys Asp Arg 1 5 10 284 10 PRT mycoplasma genitalium Sequence located in MG443 at 252-261 and may interact with Sequence 283 in this patent. 284 Ile Ala Ile Leu Ile Gly Ser Phe Val Ala 1 5 10 285 10 PRT mycoplasma genitalium Sequence located in MG038 at 416-425 and may interact with Sequence 286 in this patent. 285 Ala Asp Gly Gly Ile Val Lys Ser Asn Tyr 1 5 10 286 10 PRT mycoplasma genitalium Sequence located in MG462 at 191-200 and may interact with Sequence 285 in this patent. 286 Gly Val Ala Thr Tyr Asn Phe Ala Val Val 1 5 10 287 10 PRT mycoplasma genitalium Sequence located in MG042 at 237-246 and may interact with Sequence 288 in this patent. 287 Gln Tyr Gln Lys Lys Lys Thr Glu Leu Lys 1 5 10 288 10 PRT mycoplasma genitalium Sequence located in MG319 at 8-17 and may interact with Sequence 287 in this patent. 288 Phe Lys Leu Cys Phe Leu Leu Leu Val Leu 1 5 10 289 10 PRT mycoplasma genitalium Sequence located in MG042 at 81-90 and may interact with Sequence 290 in this patent. 289 Phe Ala Thr Val Phe Gln Asp Tyr Ala Leu 1 5 10 290 10 PRT mycoplasma genitalium Sequence located in MG379 at 132-141 and may interact with Sequence 289 in this patent. 290 Lys Gly Val Ile Leu Lys Asp Gly Ser Glu 1 5 10 291 10 PRT mycoplasma genitalium Sequence located in MG042 at 49-58 and may interact with Sequence 292 in this patent. 291 Leu Leu Arg Leu Leu Ala Gly Phe Glu Asp 1 5 10 292 10 PRT mycoplasma genitalium Sequence located in MG455 at 317-326 and may interact with Sequence 291 in this patent. 292 Lys Glu Ala Gln Gln Arg Ser Glu Leu Ile 1 5 10 293 10 PRT mycoplasma genitalium Sequence located in MG043 at 124-133 and may interact with Sequence 294 in this patent. 293 Leu Ser Leu Asn Arg Val Gly Asp Asn Asn 1 5 10 294 10 PRT mycoplasma genitalium Sequence located in MG195 at 140-149 and may interact with Sequence 293 in this patent. 294 Lys Thr Glu Val Ala Asp Ala Ile Ile Ile 1 5 10 295 10 PRT mycoplasma genitalium Sequence located in MG044 at 174-183 and may interact with Sequence 296 in this patent. 295 Leu Ile Leu Ala Ser Gln Asp Leu Gly Tyr 1 5 10 296 10 PRT mycoplasma genitalium Sequence located in MG110 at 55-64 and may interact with Sequence 295 in this patent. 296 Ile Thr Lys Val Leu Ala Arg Lys Asn Glu 1 5 10 297 10 PRT mycoplasma genitalium Sequence located in MG044 at 175-184 and may interact with Sequence 298 in this patent. 297 Ile Leu Ala Ser Gln Asp Leu Gly Tyr Ser 1 5 10 298 10 PRT mycoplasma genitalium Sequence located in MG110 at 54-63 and may interact with Sequence 297 in this patent. 298 Ala Ile Thr Lys Val Leu Ala Arg Lys Asn 1 5 10 299 10 PRT mycoplasma genitalium Sequence located in MG044 at 176-185 and may interact with Sequence 300 in this patent. 299 Leu Ala Ser Gln Asp Leu Gly Tyr Ser Pro 1 5 10 300 10 PRT mycoplasma genitalium Sequence located in MG110 at 53-62 and may interact with Sequence 299 in this patent. 300 Gly Ala Ile Thr Lys Val Leu Ala Arg Lys 1 5 10 301 10 PRT mycoplasma genitalium Sequence located in MG044 at 61-70 and may interact with Sequence 302 in this patent. 301 Leu Arg Leu Gly Glu Thr Asp Phe Ala Thr 1 5 10 302 10 PRT mycoplasma genitalium Sequence located in MG360 at 169-178 and may interact with Sequence 301 in this patent. 302 Gln Ala Lys Pro Phe Gly Ile Lys Ser Cys 1 5 10 303 10 PRT mycoplasma genitalium Sequence located in MG044 at 154-163 and may interact with Sequence 304 in this patent. 303 Phe Ser Val Pro Tyr Ala Leu Ile Leu Ile 1 5 10 304 10 PRT mycoplasma genitalium Sequence located in MG423 at 313-322 and may interact with Sequence 303 in this patent. 304 Asn Glu Asp Glu Arg Ile Arg Tyr Arg Lys 1 5 10 305 10 PRT mycoplasma genitalium Sequence located in MG045 at 151-160 and may interact with Sequence 306 in this patent. 305 Leu Val Phe Val Tyr Arg Gly Glu Lys Ile 1 5 10 306 10 PRT mycoplasma genitalium Sequence located in MG135 at 214-223 and may interact with Sequence 305 in this patent. 306 Glu Tyr Lys Asn Val Ala Thr Phe Leu Asn 1 5 10 307 10 PRT mycoplasma genitalium Sequence located in MG045 at 285-294 and may interact with Sequence 308 in this patent. 307 Leu Ser Glu Glu Gln Ile Pro Asp Gly Asn 1 5 10 308 10 PRT mycoplasma genitalium Sequence located in MG152 at 185-194 and may interact with Sequence 307 in this patent. 308 Val Ser Val Arg Asp Leu Leu Leu Ala Lys 1 5 10 309 10 PRT mycoplasma genitalium Sequence located in MG045 at 438-447 and may interact with Sequence 310 in this patent. 309 Val Glu Thr Ile Lys Lys Ala Tyr Thr Ile 1 5 10 310 10 PRT mycoplasma genitalium Sequence located in MG255 at 254-263 and may interact with Sequence 309 in this patent. 310 Asn Gly Val Cys Phe Phe Tyr Gly Phe Asp 1 5 10 311 10 PRT mycoplasma genitalium Sequence located in MG046 at 133-142 and may interact with Sequence 312 in this patent. 311 Gly Leu Val Ile Ser Gly Gly His Thr Ala 1 5 10 312 10 PRT mycoplasma genitalium Sequence located in MG192 at 248-257 and may interact with Sequence 311 in this patent. 312 Ala Lys Asn Asp Ala Pro Ser Val Ser Gly 1 5 10 313 10 PRT mycoplasma genitalium Sequence located in MG046 at 132-141 and may interact with Sequence 314 in this patent. 313 Leu Gly Leu Val Ile Ser Gly Gly His Thr 1 5 10 314 10 PRT mycoplasma genitalium Sequence located in MG192 at 247-256 and may interact with Sequence 313 in this patent. 314 Glu Ala Lys Asn Asp Ala Pro Ser Val Ser 1 5 10 315 10 PRT mycoplasma genitalium Sequence located in MG064 at 1096-1105 and may interact with Sequence 316 in this patent. 315 Ser Gly Ile Phe Pro Ala Thr Ser Ser Phe 1 5 10 316 10 PRT mycoplasma genitalium Sequence located in MG176 at 80-89 and may interact with Sequence 315 in this patent. 316 Lys Gly Thr Gly Arg Gly Lys Asp Thr Thr 1 5 10 317 10 PRT mycoplasma genitalium Sequence located in MG064 at 716-725 and may interact with Sequence 318 in this patent. 317 Gly Thr Thr Asp Lys Arg Ser Glu Ser Ser 1 5 10 318 10 PRT mycoplasma genitalium Sequence located in MG192 at 926-935 and may interact with Sequence 317 in this patent. 318 Pro Ser Arg Val Phe Ala Gly Phe Ala Ala 1 5 10 319 10 PRT mycoplasma genitalium Sequence located in MG064 at 605-614 and may interact with Sequence 320 in this patent. 319 Leu Lys Lys Asp Val Val Lys Ile Leu Lys 1 5 10 320 10 PRT mycoplasma genitalium Sequence located in MG199 at 60-69 and may interact with Sequence 319 in this patent. 320 Glu Leu Phe Val Asn Tyr Leu Asn Lys Leu 1 5 10 321 10 PRT mycoplasma genitalium Sequence located in MG064 at 1288-1297 and may interact with Sequence 322 in this patent. 321 Leu Asp Ala Phe Leu Ser Phe Glu Ser Ala 1 5 10 322 10 PRT mycoplasma genitalium Sequence located in MG231 at 611-620 and may interact with Sequence 321 in this patent. 322 Glu Val Arg Lys Glu Gly Lys Leu Gly Arg 1 5 10 323 10 PRT mycoplasma genitalium Sequence located in MG076 at 125-134 and may interact with Sequence 324 in this patent. 323 Tyr Leu Val Gly Ser Leu Val Ser Gly Leu 1 5 10 324 10 PRT mycoplasma genitalium Sequence located in MG346 at 85-94 and may interact with Sequence 323 in this patent. 324 Lys Ser Gly Asp Lys Thr Pro Asp Gln Ile 1 5 10 325 10 PRT mycoplasma genitalium Sequence located in MG085 at 242-251 and may interact with Sequence 326 in this patent. 325 Ser Phe Glu Arg Leu Gly Ser Asp Leu Lys 1 5 10 326 10 PRT mycoplasma genitalium Sequence located in MG457 at 221-230 and may interact with Sequence 325 in this patent. 326 Ala Lys Leu Ala Lys Ser Thr Val Lys Phe 1 5 10 327 10 PRT mycoplasma genitalium Sequence located in MG086 at 117-126 and may interact with Sequence 328 in this patent. 327 Asn Lys Thr Lys Thr Ile Ala Glu Leu Leu 1 5 10 328 10 PRT mycoplasma genitalium Sequence located in MG214 at 76-85 and may interact with Sequence 327 in this patent. 328 Lys Lys Phe Gly Asn Ser Phe Ser Leu Val 1 5 10 329 10 PRT mycoplasma genitalium Sequence located in MG086 at 46-55 and may interact with Sequence 330 in this patent. 329 Leu Gln Asp Asn Ser Phe Tyr Phe Phe Ile 1 5 10 330 10 PRT mycoplasma genitalium Sequence located in MG379 at 128-137 and may interact with Sequence 329 in this patent. 330 Asn Glu Lys Ile Lys Gly Val Ile Leu Lys 1 5 10 331 10 PRT mycoplasma genitalium Sequence located in MG088 at 3-12 and may interact with Sequence 332 in this patent. 331 Lys Asn Arg Ala Leu Lys Arg Thr Val Leu 1 5 10 332 10 PRT mycoplasma genitalium Sequence located in MG088 at 3-12 and may interact with Sequence 331 in this patent. 332 Lys Asn Arg Ala Leu Lys Arg Thr Val Leu 1 5 10 333 10 PRT mycoplasma genitalium Sequence located in MG088 at 4-13 and may interact with Sequence 334 in this patent. 333 Asn Arg Ala Leu Lys Arg Thr Val Leu Pro 1 5 10 334 10 PRT mycoplasma genitalium Sequence located in MG088 at 2-11 and may interact with Sequence 333 in this patent. 334 Arg Lys Asn Arg Ala Leu Lys Arg Thr Val 1 5 10 335 10 PRT mycoplasma genitalium Sequence located in MG090 at 112-121 and may interact with Sequence 336 in this patent. 335 Leu Thr Lys Tyr Asn Glu Ile Ile Ala Ser 1 5 10 336 10 PRT mycoplasma genitalium Sequence located in MG361 at 23-32 and may interact with Sequence 335 in this patent. 336 Lys Gly Phe Val Ile Phe Asp Tyr Ser Gly 1 5 10 337 10 PRT mycoplasma genitalium Sequence located in MG093 at 133-142 and may interact with Sequence 338 in this patent. 337 Glu Ile Thr Ala Thr Leu Thr Val Ile Val 1 5 10 338 10 PRT mycoplasma genitalium Sequence located in MG200 at 448-457 and may interact with Sequence 337 in this patent. 338 Asn Asp His Gly Lys Gly Cys Gly Asp Leu 1 5 10 339 10 PRT mycoplasma genitalium Sequence located in MG093 at 118-127 and may interact with Sequence 340 in this patent. 339 Arg Leu Gln Phe Gly Glu His Lys Leu Ile 1 5 10 340 10 PRT mycoplasma genitalium Sequence located in MG370 at 287-296 and may interact with Sequence 339 in this patent. 340 Tyr Glu Leu Val Phe Pro Lys Leu Glu Thr 1 5 10 341 10 PRT mycoplasma genitalium Sequence located in MG094 at 359-368 and may interact with Sequence 342 in this patent. 341 Glu Glu Arg Lys Asp Ser Arg Pro Ile Leu 1 5 10 342 10 PRT mycoplasma genitalium Sequence located in MG140 at 768-777 and may interact with Sequence 341 in this patent. 342 Lys Asn Arg Ser Arg Ile Leu Thr Leu Leu 1 5 10 343 10 PRT mycoplasma genitalium Sequence located in MG095 at 181-190 and may interact with Sequence 344 in this patent. 343 Thr Ala Thr Ser Ser Thr Arg Ala Ser Thr 1 5 10 344 10 PRT mycoplasma genitalium Sequence located in MG391 at 390-399 and may interact with Sequence 343 in this patent. 344 Ser Thr Ser Ala Arg Gly Ala Gly Ser Ser 1 5 10 345 10 PRT mycoplasma genitalium Sequence located in MG096 at 362-371 and may interact with Sequence 346 in this patent. 345 Ala Glu Glu Lys Arg Lys Ala Glu Glu Ala 1 5 10 346 10 PRT mycoplasma genitalium Sequence located in MG411 at 467-476 and may interact with Sequence 345 in this patent. 346 Gly Leu Phe Gly Leu Ser Phe Phe Leu Arg 1 5 10 347 10 PRT mycoplasma genitalium Sequence located in MG098 at 147-156 and may interact with Sequence 348 in this patent. 347 Ile Ala Gly Ile Leu Arg Glu Val Leu Ile 1 5 10 348 10 PRT mycoplasma genitalium Sequence located in MG372 at 115-124 and may interact with Sequence 347 in this patent. 348 Asp Lys Asn Phe Ala Glu Asn Ser Ser Asn 1 5 10 349 10 PRT mycoplasma genitalium Sequence located in MG098 at 148-157 and may interact with Sequence 350 in this patent. 349 Ala Gly Ile Leu Arg Glu Val Leu Ile Ser 1 5 10 350 10 PRT mycoplasma genitalium Sequence located in MG372 at 114-123 and may interact with Sequence 349 in this patent. 350 Arg Asp Lys Asn Phe Ala Glu Asn Ser Ser 1 5 10 351 10 PRT mycoplasma genitalium Sequence located in MG098 at 149-158 and may interact with Sequence 352 in this patent. 351 Gly Ile Leu Arg Glu Val Leu Ile Ser Thr 1 5 10 352 10 PRT mycoplasma genitalium Sequence located in MG372 at 113-122 and may interact with Sequence 351 in this patent. 352 Arg Arg Asp Lys Asn Phe Ala Glu Asn Ser 1 5 10 353 10 PRT mycoplasma genitalium Sequence located in MG099 at 139-148 and may interact with Sequence 354 in this patent. 353 Ile Ala Gly Gly Ser Ser Ser Gly Ser Ala 1 5 10 354 10 PRT mycoplasma genitalium Sequence located in MG391 at 389-398 and may interact with Sequence 353 in this patent. 354 Asn Ser Thr Ser Ala Arg Gly Ala Gly Ser 1 5 10 355 10 PRT mycoplasma genitalium Sequence located in MG099 at 138-147 and may interact with Sequence 356 in this patent. 355 Leu Ile Ala Gly Gly Ser Ser Ser Gly Ser 1 5 10 356 10 PRT mycoplasma genitalium Sequence located in MG391 at 388-397 and may interact with Sequence 355 in this patent. 356 Gln Asn Ser Thr Ser Ala Arg Gly Ala Gly 1 5 10 357 10 PRT mycoplasma genitalium Sequence located in MG101 at 73-82 and may interact with Sequence 358 in this patent. 357 Phe Val Cys Lys Asp Val Gly Phe Ser Phe 1 5 10 358 10 PRT mycoplasma genitalium Sequence located in MG140 at 8-17 and may interact with Sequence 357 in this patent. 358 Lys Asn Arg Leu Val Asn Ser Lys Thr Lys 1 5 10 359 10 PRT mycoplasma genitalium Sequence located in MG103 at 136-145 and may interact with Sequence 360 in this patent. 359 Leu Leu Lys Leu Phe Ser Phe Phe Lys Lys 1 5 10 360 10 PRT mycoplasma genitalium Sequence located in MG307 at 778-787 and may interact with Sequence 359 in this patent. 360 Gln Gln Phe Glu Lys Ala Lys Lys Leu Phe 1 5 10 361 10 PRT mycoplasma genitalium Sequence located in MG104 at 402-411 and may interact with Sequence 362 in this patent. 361 Cys Asp Glu Thr Val Ile Asn Ser Leu Lys 1 5 10 362 10 PRT mycoplasma genitalium Sequence located in MG212 at 172-181 and may interact with Sequence 361 in this patent. 362 Arg Ile Leu Ser Asn Asp Ile Gly Glu Phe 1 5 10 363 10 PRT mycoplasma genitalium Sequence located in MG104 at 619-628 and may interact with Sequence 364 in this patent. 363 Thr Glu Ile Lys Ile Ile Asn Cys Glu Arg 1 5 10 364 10 PRT mycoplasma genitalium Sequence located in MG345 at 327-336 and may interact with Sequence 363 in this patent. 364 Ala Phe Gly Ile Asp Asp Phe Tyr Leu Cys 1 5 10 365 10 PRT mycoplasma genitalium Sequence located in MG111 at 154-163 and may interact with Sequence 366 in this patent. 365 Phe Arg Asn Leu Leu Asn Lys Arg Tyr Gly 1 5 10 366 10 PRT mycoplasma genitalium Sequence located in MG204 at 11-20 and may interact with Sequence 365 in this patent. 366 Lys Ala Ile Glu Glu Val Phe Ala Val Ser 1 5 10 367 10 PRT mycoplasma genitalium Sequence located in MG113 at 276-285 and may interact with Sequence 368 in this patent. 367 Ser Asn Asp Ile Ile Ser Asn Leu Lys Thr 1 5 10 368 10 PRT mycoplasma genitalium Sequence located in MG229 at 266-275 and may interact with Sequence 367 in this patent. 368 Gly Ile Val Asp Asp Ala Ile Lys Phe Ser 1 5 10 369 10 PRT mycoplasma genitalium Sequence located in MG113 at 423-432 and may interact with Sequence 370 in this patent. 369 Gly Phe Gly Leu Gly Phe Asp Arg Leu Leu 1 5 10 370 10 PRT mycoplasma genitalium Sequence located in MG386 at 68-77 and may interact with Sequence 369 in this patent. 370 Lys Glu Thr Val Lys Ser Lys Ser Lys Ser 1 5 10 371 10 PRT mycoplasma genitalium Sequence located in MG114 at 51-60 and may interact with Sequence 372 in this patent. 371 Leu Asp Asn Gln Leu Gly Val Leu Ala Asn 1 5 10 372 10 PRT mycoplasma genitalium Sequence located in MG227 at 253-262 and may interact with Sequence 371 in this patent. 372 Gln Val Val Leu Lys Ser Asp Lys Ser Ile 1 5 10 373 10 PRT mycoplasma genitalium Sequence located in MG115 at 99-108 and may interact with Sequence 374 in this patent. 373 Ala Gly Ser Lys Ala Val Glu Asn Lys Ala 1 5 10 374 10 PRT mycoplasma genitalium Sequence located in MG348 at 57-66 and may interact with Sequence 373 in this patent. 374 Ser Thr Thr Phe Arg Asn Leu Val Phe Gly 1 5 10 375 10 PRT mycoplasma genitalium Sequence located in MG115 at 98-107 and may interact with Sequence 376 in this patent. 375 Ile Ala Gly Ser Lys Ala Val Glu Asn Lys 1 5 10 376 10 PRT mycoplasma genitalium Sequence located in MG348 at 56-65 and may interact with Sequence 375 in this patent. 376 Asn Ser Thr Thr Phe Arg Asn Leu Val Phe 1 5 10 377 10 PRT mycoplasma genitalium Sequence located in MG117 at 46-55 and may interact with Sequence 378 in this patent. 377 Phe Leu Ile Phe Asn Asn Phe Asn Lys Leu 1 5 10 378 10 PRT mycoplasma genitalium Sequence located in MG252 at 84-93 and may interact with Sequence 377 in this patent. 378 Gln Leu Val Lys Val Val Glu Asn Lys Lys 1 5 10 379 10 PRT mycoplasma genitalium Sequence located in MG118 at 262-271 and may interact with Sequence 380 in this patent. 379 Asn Leu Gly Ser Gly Ile Gly Thr Ser Asn 1 5 10 380 10 PRT mycoplasma genitalium Sequence located in MG431 at 67-76 and may interact with Sequence 379 in this patent. 380 Ile Glu Ser Gly Ser Tyr Thr Gly Thr Val 1 5 10 381 10 PRT mycoplasma genitalium Sequence located in MG119 at 516-525 and may interact with Sequence 382 in this patent. 381 Asn Lys Ala Ile Leu Leu Val Ser Tyr Glu 1 5 10 382 10 PRT mycoplasma genitalium Sequence located in MG370 at 261-270 and may interact with Sequence 381 in this patent. 382 Leu Val Gly Asp Lys Lys Tyr Ser Leu Ile 1 5 10 383 10 PRT mycoplasma genitalium Sequence located in MG119 at 517-526 and may interact with Sequence 384 in this patent. 383 Lys Ala Ile Leu Leu Val Ser Tyr Glu Leu 1 5 10 384 10 PRT mycoplasma genitalium Sequence located in MG370 at 260-269 and may interact with Sequence 383 in this patent. 384 Gln Leu Val Gly Asp Lys Lys Tyr Ser Leu 1 5 10 385 10 PRT mycoplasma genitalium Sequence located in MG120 at 305-314 and may interact with Sequence 386 in this patent. 385 Ser Ala Ile Ser Ala Val Pro Ala Thr Gly 1 5 10 386 10 PRT mycoplasma genitalium Sequence located in MG384 at 34-43 and may interact with Sequence 385 in this patent. 386 Pro Gly Gly Gly Asn Gly Gly Asn Gly Gly 1 5 10 387 10 PRT mycoplasma genitalium Sequence located in MG121 at 123-132 and may interact with Sequence 388 in this patent. 387 Phe Ser Asp Thr Thr Leu Arg Val Arg Tyr 1 5 10 388 10 PRT mycoplasma genitalium Sequence located in MG355 at 525-534 and may interact with Sequence 387 in this patent. 388 Glu Ala Val Arg Arg Lys Pro Tyr Ser Val 1 5 10 389 10 PRT mycoplasma genitalium Sequence located in MG122 at 480-489 and may interact with Sequence 390 in this patent. 389 Lys Phe Ser Phe Glu Lys Ile Ser Val Asn 1 5 10 390 10 PRT mycoplasma genitalium Sequence located in MG434 at 85-94 and may interact with Sequence 389 in this patent. 390 Val Asn Gly Tyr Phe Leu Lys Ala Lys Leu 1 5 10 391 10 PRT mycoplasma genitalium Sequence located in MG122 at 639-648 and may interact with Sequence 392 in this patent. 391 Gly Cys Ser Asp Phe Pro Lys Cys Lys Tyr 1 5 10 392 10 PRT mycoplasma genitalium Sequence located in MG440 at 99-108 and may interact with Sequence 391 in this patent. 392 Ser Thr Gly Val Lys Gly Leu Arg Leu Val 1 5 10 393 10 PRT mycoplasma genitalium Sequence located in MG127 at 79-88 and may interact with Sequence 394 in this patent. 393 Thr Asn Ser Val Ser Val Glu Glu Leu Ser 1 5 10 394 10 PRT mycoplasma genitalium Sequence located in MG209 at 259-268 and may interact with Sequence 393 in this patent. 394 Gly Gln Phe Leu His Ala Asn Arg Ile Cys 1 5 10 395 10 PRT mycoplasma genitalium Sequence located in MG127 at 80-89 and may interact with Sequence 396 in ihis patent. 395 Asn Ser Val Ser Val Glu Glu Leu Ser Ile 1 5 10 396 10 PRT mycoplasma genitalium Sequence located in MG209 at 258-267 and may interact with Sequence 395 in this patent. 396 Tyr Gly Gln Phe Leu His Ala Asn Arg Ile 1 5 10 397 10 PRT mycoplasma genitalium Sequence located in MG127 at 57-66 and may interact with Sequence 398 in this patent. 397 Ile Leu Ser Leu Ser Glu Asp Gly Thr Glu 1 5 10 398 10 PRT mycoplasma genitalium Sequence located in MG430 at 350-359 and may interact with Sequence 397 in this patent. 398 Asn Glu Thr Lys Thr Leu Ile Pro Ser Leu 1 5 10 399 10 PRT mycoplasma genitalium Sequence located in MG128 at 151-160 and may interact with Sequence 400 in this patent. 399 Leu Ala Lys Ser Ala Lys Gly Ala Val Ile 1 5 10 400 10 PRT mycoplasma genitalium Sequence located in MG463 at 146-155 and may interact with Sequence 399 in this patent. 400 Asp Tyr Ser Ala Phe Gly Ala Phe Cys Gln 1 5 10 401 10 PRT mycoplasma genitalium Sequence located in MG130 at 385-394 and may interact with Sequence 402 in this patent. 401 Ala Arg Ile Gly Ala Arg Ser Asp Ser Ser 1 5 10 402 10 PRT mycoplasma genitalium Sequence located in MG130 at 385-394 and may interact with Sequence 401 in this patent. 402 Ala Arg Ile Gly Ala Arg Ser Asp Ser Ser 1 5 10 403 10 PRT mycoplasma genitalium Sequence located in MG130 at 207-216 and may interact with Sequence 404 in this patent. 403 Lys Tyr Glu Val Asn Val Leu Thr Glu Ser 1 5 10 404 10 PRT mycoplasma genitalium Sequence located in MG360 at 390-399 and may interact with Sequence 403 in this patent. 404 Leu Ile Phe Asp Ile Asn Glu Ser Phe Gly 1 5 10 405 10 PRT mycoplasma genitalium Sequence located in MG132 at 4-13 and may interact with Sequence 406 in this patent. 405 Asn Thr Thr Ser Ser Cys Ile Phe Cys Asp 1 5 10 406 10 PRT mycoplasma genitalium Sequence located in MG182 at 46-55 and may interact with Sequence 405 in this patent. 406 Ile Gly Ser Gly Arg Thr Asp Lys Gly Val 1 5 10 407 10 PRT mycoplasma genitalium Sequence located in MG134 at 70-79 and may interact with Sequence 408 in this patent. 407 Ile Ile Glu Ala Thr Asn Glu Ala Val Ser 1 5 10 408 10 PRT mycoplasma genitalium Sequence located in MG189 at 100-109 and may interact with Sequence 407 in this patent. 408 Asp Asn Phe Ser Arg Val Leu Ser Asp Gly 1 5 10 409 10 PRT mycoplasma genitalium Sequence located in MG135 at 132-141 and may interact with Sequence 410 in this patent. 409 Asp Ile Val Asn Phe Ile Phe Val Gly Thr 1 5 10 410 10 PRT mycoplasma genitalium Sequence located in MG468 at 1500-1509 and may interact with Sequence 409 in this patent. 410 Ser Ser Asp Glu Tyr Glu Ile Asp Tyr Val 1 5 10 411 10 PRT mycoplasma genitalium Sequence located in MG136 at 286-295 and may interact with Sequence 412 in this patent. 411 Ser Leu Cys Glu Ser Leu Asn Gln Phe Ser 1 5 10 412 10 PRT mycoplasma genitalium Sequence located in MG157 at 138-147 and may interact with Sequence 411 in this patent. 412 Arg Gln Ala Leu Thr Lys Val Leu Lys Ala 1 5 10 413 10 PRT mycoplasma genitalium Sequence located in MG139 at 202-211 and may interact with Sequence 414 in this patent. 413 Ser Glu Ser Thr Asn Ala Glu Val Pro Gly 1 5 10 414 10 PRT mycoplasma genitalium Sequence located in MG411 at 517-526 and may interact with Sequence 413 in this patent. 414 Ser Trp Asp Leu Arg Ile Ser Ala Phe Ala 1 5 10 415 10 PRT mycoplasma genitalium Sequence located in MG139 at 293-302 and may interact with Sequence 416 in this patent. 415 Ile Lys Asn Tyr Pro Asp Arg Asn Ile Leu 1 5 10 416 10 PRT mycoplasma genitalium Sequence located in MG450 at 32-41 and may interact with Sequence 415 in this patent. 416 Asp Leu Ile Ile Gly Ile Pro Ile Asp Lys 1 5 10 417 10 PRT mycoplasma genitalium Sequence located in MG140 at 264-273 and may interact with Sequence 418 in this patent. 417 Leu Leu Lys Asp Arg Arg Asp Leu Leu Leu 1 5 10 418 10 PRT mycoplasma genitalium Sequence located in MG218 at 651-660 and may interact with Sequence 417 in this patent. 418 Lys Glu Leu Val Ala Ser Val Glu Lys Gln 1 5 10 419 10 PRT mycoplasma genitalium Sequence located in MG140 at 329-338 and may interact with Sequence 420 in this patent. 419 Asn Leu Val Leu Asn Asn Lys Lys Val Leu 1 5 10 420 10 PRT mycoplasma genitalium Sequence located in MG390 at 598-607 and may interact with Sequence 419 in this patent. 420 Ile Lys Asn Lys Val Ile Leu Leu Asp Glu 1 5 10 421 10 PRT mycoplasma genitalium Sequence located in MG140 at 328-337 and may interact with Sequence 422 in this patent. 421 Val Asn Leu Val Leu Asn Asn Lys Lys Val 1 5 10 422 10 PRT mycoplasma genitalium Sequence located in MG390 at 597-606 and may interact with Sequence 421 in this patent. 422 Asn Ile Lys Asn Lys Val Ile Leu Leu Asp 1 5 10 423 10 PRT mycoplasma genitalium Sequence located in MG141 at 508-517 and may interact with Sequence 424 in this patent. 423 Lys Lys Asp Gln Val Asp Asn Asn Gln Thr 1 5 10 424 10 PRT mycoplasma genitalium Sequence located in MG302 at 34-43 and may interact with Sequence 423 in this patent. 424 Gly Leu Val Ile Ile Asn Leu Val Phe Leu 1 5 10 425 10 PRT mycoplasma genitalium Sequence located in MG141 at 164-173 and may interact with Sequence 426 in this patent. 425 Val Gly Glu Val Ile Glu Ala Lys Val Glu 1 5 10 426 10 PRT mycoplasma genitalium Sequence located in MG316 at 206-215 and may interact with Sequence 425 in this patent. 426 His Ala Leu Asn Asn Phe Gly Phe Asn Phe 1 5 10 427 10 PRT mycoplasma genitalium Sequence located in MG144 at 37-46 and may interact with Sequence 428 in this patent. 427 Asp Phe Glu Lys Thr Val Thr Leu Thr Arg 1 5 10 428 10 PRT mycoplasma genitalium Sequence located in MG274 at 252-261 and may interact with Sequence 427 in this patent. 428 Ile Glu Phe Phe Ser Tyr Arg Gln Gly Pro 1 5 10 429 10 PRT mycoplasma genitalium Sequence located in MG146 at 65-74 and may interact with Sequence 430 in this patent. 429 Asn His Tyr Ser Ser Cys Leu Ile Thr Ile 1 5 10 430 10 PRT mycoplasma genitalium Sequence located in MG468.1 at 235-244 and may interact with Sequence 429 in this patent. 430 Asn Arg Asp Lys Gly Thr Thr Ile Val Ile 1 5 10 431 10 PRT mycoplasma genitalium Sequence located in MG147 at 64-73 and may interact with Sequence 432 in this patent. 431 Glu Glu Ile Ile Val Phe Val Val Gly Ser 1 5 10 432 10 PRT mycoplasma genitalium Sequence located in MG266 at 340-349 and may interact with Sequence 431 in this patent. 432 Gly Ala His Asn Glu Asn Asp Asn Phe Phe 1 5 10 433 10 PRT mycoplasma genitalium Sequence located in MG148 at 213-222 and may interact with Sequence 434 in this patent. 433 Ala Asp Tyr Ile Phe Ser Phe Phe Gly Glu 1 5 10 434 10 PRT mycoplasma genitalium Sequence located in MG233 at 19-28 and may interact with Sequence 433 in this patent. 434 Phe Ala Glu Lys Gly Lys Asp Ile Val Cys 1 5 10 435 10 PRT mycoplasma genitalium Sequence located in MG148 at 214-223 and may interact with Sequence 436 in this patent. 435 Asp Tyr Ile Phe Ser Phe Phe Gly Glu Lys 1 5 10 436 10 PRT mycoplasma genitalium Sequence located in MG233 at 18-27 and may interact with Sequence 435 in this patent. 436 Leu Phe Ala Glu Lys Gly Lys Asp Ile Val 1 5 10 437 10 PRT mycoplasma genitalium Sequence located in MG149 at 180-189 and may interact with Sequence 438 in this patent. 437 Ile Phe Leu Val Ile Asp Tyr Lys Lys Asp 1 5 10 438 10 PRT mycoplasma genitalium Sequence located in MG149 at 180-189 and may interact with Sequence 437 in this patent. 438 Ile Phe Leu Val Ile Asp Tyr Lys Lys Asp 1 5 10 439 10 PRT mycoplasma genitalium Sequence located in MG149 at 181-190 and may interact with Sequence 440 in this patent. 439 Phe Leu Val Ile Asp Tyr Lys Lys Asp Ser 1 5 10 440 10 PRT mycoplasma genitalium Sequence located in MG149 at 179-188 and may interact with Sequence 439 in this patent. 440 Gly Ile Phe Leu Val Ile Asp Tyr Lys Lys 1 5 10 441 10 PRT mycoplasma genitalium Sequence located in MG158 at 16-25 and may interact with Sequence 442 in this patent. 441 Ser Tyr Glu Gly His Thr Lys Gly Asn Gly 1 5 10 442 10 PRT mycoplasma genitalium Sequence located in MG407 at 118-127 and may interact with Sequence 441 in this patent. 442 Ala Ile Leu Ser Val Ser Leu Ala Val Ser 1 5 10 443 10 PRT mycoplasma genitalium Sequence located in MG158 at 15-24 and may interact with Sequence 444 in this patent. 443 Val Ser Tyr Glu Gly His Thr Lys Gly Asn 1 5 10 444 10 PRT mycoplasma genitalium Sequence located in MG407 at 117-126 and may interact with Sequence 443 in this patent. 444 Asn Ala Ile Leu Ser Val Ser Leu Ala Val 1 5 10 445 10 PRT mycoplasma genitalium Sequence located in MG161 at 14-23 and may interact with Sequence 446 in this patent. 445 Thr Gly Ala Lys Gln Val Gly Ile Ile Lys 1 5 10 446 10 PRT mycoplasma genitalium Sequence located in MG422 at 23-32 and may interact with Sequence 445 in this patent. 446 Arg Thr Ser Phe Leu Asp Ala Asn Tyr Phe 1 5 10 447 10 PRT mycoplasma genitalium Sequence located in MG161 at 13-22 and may interact with Sequence 448 in this patent. 447 Asn Thr Gly Ala Lys Gln Val Gly Ile Ile 1 5 10 448 10 PRT mycoplasma genitalium Sequence located in MG422 at 22-31 and may interact with Sequence 447 in this patent. 448 Ile Arg Thr Ser Phe Leu Asp Ala Asn Tyr 1 5 10 449 10 PRT mycoplasma genitalium Sequence located in MG162 at 20-29 and may interact with Sequence 450 in this patent. 449 Gly Ser Gly Ile Val Leu Lys Val Leu Thr 1 5 10 450 10 PRT mycoplasma genitalium Sequence located in MG334 at 430-439 and may interact with Sequence 449 in this patent. 450 Ser Lys Asn Leu Gln Asn Tyr Thr Arg Ser 1 5 10 451 10 PRT mycoplasma genitalium Sequence located in MG163 at 98-107 and may interact with Sequence 452 in this patent. 451 Ser Phe Leu Glu Lys Leu Ile Tyr Ile Ala 1 5 10 452 10 PRT mycoplasma genitalium Sequence located in MG307 at 835-844 and may interact with Sequence 451 in this patent. 452 Gly Asn Ile Asp Glu Leu Phe Lys Lys Ala 1 5 10 453 10 PRT mycoplasma genitalium Sequence located in MG167 at 95-104 and may interact with Sequence 454 in this patent. 453 Ser Lys Tyr His Gly Arg Ile Ala Ala Leu 1 5 10 454 10 PRT mycoplasma genitalium Sequence located in MG251 at 326-335 and may interact with Sequence 453 in this patent. 454 Ala Leu Ile Val Ser Ser Tyr Arg Arg Glu 1 5 10 455 10 PRT mycoplasma genitalium Sequence located in MG169 at 40-49 and may interact with Sequence 456 in this patent. 455 Lys Ala Arg Lys Ser Gly Leu Thr Arg Leu 1 5 10 456 10 PRT mycoplasma genitalium Sequence located in MG169 at 40-49 and may interact with Sequence 455 in this patent. 456 Lys Ala Arg Lys Ser Gly Leu Thr Arg Leu 1 5 10 457 10 PRT mycoplasma genitalium Sequence located in MG170 at 73-82 and may interact with Sequence 458 in this patent. 457 Gly Gly Gly Gly Leu Asn Gln Leu Ser Leu 1 5 10 458 10 PRT mycoplasma genitalium Sequence located in MG180 at 235-244 and may interact with Sequence 457 in this patent. 458 Lys Gly Lys Leu Val Lys Ala Ala Ser Pro 1 5 10 459 10 PRT mycoplasma genitalium Sequence located in MG171 at 52-61 and may interact with Sequence 460 in this patent. 459 Arg Lys Ile Ala Ala Ile Ile Ser Gln Gly 1 5 10 460 10 PRT mycoplasma genitalium Sequence located in MG468 at 75-84 and may interact with Sequence 459 in this patent. 460 Ser Leu Thr Asn Asp Ser Gly Tyr Phe Ser 1 5 10 461 10 PRT mycoplasma genitalium Sequence located in MG171 at 53-62 and may interact with Sequence 462 in this patent. 461 Lys Ile Ala Ala Ile Ile Ser Gln Gly Gly 1 5 10 462 10 PRT mycoplasma genitalium Sequence located in MG468 at 74-83 and may interact with Sequence 461 in this patent. 462 Ala Ser Leu Thr Asn Asp Ser Gly Tyr Phe 1 5 10 463 10 PRT mycoplasma genitalium Sequence located in MG171 at 54-63 and may interact with Sequence 464 in this patent. 463 Ile Ala Ala Ile Ile Ser Gln Gly Gly Tyr 1 5 10 464 10 PRT mycoplasma genitalium Sequence located in MG468 at 73-82 and may interact with Sequence 463 in this patent. 464 Ile Ala Ser Leu Thr Asn Asp Ser Gly Tyr 1 5 10 465 10 PRT mycoplasma genitalium Sequence located in MG171 at 55-64 and may interact with Sequence 466 in this patent. 465 Ala Ala Ile Ile Ser Gln Gly Gly Tyr Val 1 5 10 466 10 PRT mycoplasma genitalium Sequence located in MG468 at 72-81 and may interact with Sequence 465 in this patent. 466 Tyr Ile Ala Ser Leu Thr Asn Asp Ser Gly 1 5 10 467 10 PRT mycoplasma genitalium Sequence located in MG171 at 56-65 and may interact with Sequence 468 in this patent. 467 Ala Ile Ile Ser Gln Gly Gly Tyr Val Asp 1 5 10 468 10 PRT mycoplasma genitalium Sequence located in MG468 at 71-80 and may interact with Sequence 467 in this patent. 468 Val Tyr Ile Ala Ser Leu Thr Asn Asp Ser 1 5 10 469 10 PRT mycoplasma genitalium Sequence located in MG172 at 27-36 and may interact with Sequence 470 in this patent. 469 Phe Thr Ile Glu Lys Leu Leu Gly Lys Lys 1 5 10 470 10 PRT mycoplasma genitalium Sequence located in MG328 at 45-54 and may interact with Sequence 469 in this patent. 470 Glu Arg Asn Leu Leu Glu Lys Thr Phe Phe 1 5 10 471 10 PRT mycoplasma genitalium Sequence located in MG149.1 at 51-60 and may interact with Sequence 472 in this patent. 471 Ala Leu Leu Ile Tyr Leu Leu Ala Ser Val 1 5 10 472 10 PRT mycoplasma genitalium Sequence located in MG341 at 564-573 and may interact with Sequence 471 in this patent. 472 Asn Arg Gly Gln Gln Ile Asn Glu Glu Gly 1 5 10 473 10 PRT mycoplasma genitalium Sequence located in MG149.1 at 52-61 and may interact with Sequence 474 in this patent. 473 Leu Leu Ile Tyr Leu Leu Ala Ser Val Asp 1 5 10 474 10 PRT mycoplasma genitalium Sequence located in MG341 at 563-572 and may interact with Sequence 473 in this patent. 474 Val Asn Arg Gly Gln Gln Ile Asn Glu Glu 1 5 10 475 10 PRT mycoplasma genitalium Sequence located in MG174 at 27-36 and may interact with Sequence 476 in this patent. 475 Cys Lys Thr Lys Lys His Lys Gln Arg Gln 1 5 10 476 10 PRT mycoplasma genitalium Sequence located in MG323.1 at 137-146 and may interact with Sequence 475 in this patent. 476 Leu Ala Leu Leu Val Phe Leu Ser Phe Arg 1 5 10 477 10 PRT mycoplasma genitalium Sequence located in MG174 at 28-37 and may interact with Sequence 478 in this patent. 477 Lys Thr Lys Lys His Lys Gln Arg Gln Gly 1 5 10 478 10 PRT mycoplasma genitalium Sequence located in MG323.1 at 136-145 and may interact with Sequence 477 in this patent. 478 Ser Leu Ala Leu Leu Val Phe Leu Ser Phe 1 5 10 479 10 PRT mycoplasma genitalium Sequence located in MG176 at 58-67 and may interact with Sequence 480 in this patent. 479 Val Ala Ala Asp Lys Val Ala Lys Thr Val 1 5 10 480 10 PRT mycoplasma genitalium Sequence located in MG468 at 1392-1401 and may interact with Sequence 479 in this patent. 480 Asn Ser Leu Arg Asn Leu Ile Ser Ser Asp 1 5 10 481 10 PRT mycoplasma genitalium Sequence located in MG177 at 242-251 and may interact with Sequence 482 in this patent. 481 Ser Val Asn Glu Ser Ile Lys Asn Leu Thr 1 5 10 482 10 PRT mycoplasma genitalium Sequence located in MG340 at 187-196 and may interact with Sequence 481 in this patent. 482 Gly Tyr Ile Phe Arg Asn Leu Ile Lys Ser 1 5 10 483 10 PRT mycoplasma genitalium Sequence located in MG179 at 62-71 and may interact with Sequence 484 in this patent. 483 Ala Gly Glu Ile Lys Ile Phe Gly Lys Thr 1 5 10 484 10 PRT mycoplasma genitalium Sequence located in MG339 at 44-53 and may interact with Sequence 483 in this patent. 484 Gly Ser Leu Asn Leu Asp Glu Ala Leu Gly 1 5 10 485 10 PRT mycoplasma genitalium Sequence located in MG179 at 216-225 and may interact with Sequence 486 in this patent. 485 Gly Lys Leu Ile Lys Gln Gly Lys Pro Val 1 5 10 486 10 PRT mycoplasma genitalium Sequence located in MG420 at 215-224 and may interact with Sequence 485 in this patent. 486 Asp Gly Leu Ser Leu Leu Asp Gln Leu Ala 1 5 10 487 10 PRT mycoplasma genitalium Sequence located in MG180 at 54-63 and may interact with Sequence 488 in this patent. 487 Gly Asp Ser Gly Ser Gly Lys Ser Thr Leu 1 5 10 488 10 PRT mycoplasma genitalium Sequence located in MG208 at 70-79 and may interact with Sequence 487 in this patent. 488 Thr Ile Gly Pro Gly Ser Phe Thr Gly Gln 1 5 10 489 10 PRT mycoplasma genitalium Sequence located in MG180 at 53-62 and may interact with Sequence 490 in this patent. 489 Ile Gly Asp Ser Gly Ser Gly Lys Ser Thr 1 5 10 490 10 PRT mycoplasma genitalium Sequence located in MG321 at 410-419 and may interact with Sequence 489 in this patent. 490 Gly Gly Leu Ser Ala Ser Ala Val Pro Tyr 1 5 10 491 10 PRT mycoplasma genitalium Sequence located in MG181 at 156-165 and may interact with Sequence 492 in this patent. 491 Val Lys Gly Ile Asp Ser Leu Ala Ser Met 1 5 10 492 10 PRT mycoplasma genitalium Sequence located in MG307 at 649-658 and may interact with Sequence 491 in this patent. 492 His Leu Pro Tyr Val Arg Lys Ser Gly His 1 5 10 493 10 PRT mycoplasma genitalium Sequence located in MG182 at 90-99 and may interact with Sequence 494 in this patent. 493 Lys Thr Leu Val Leu Val Asn Asp Ser Phe 1 5 10 494 10 PRT mycoplasma genitalium Sequence located in MG341 at 706-715 and may interact with Sequence 493 in this patent. 494 Leu Arg Glu Asp Glu His Ile Ile Ala Glu 1 5 10 495 10 PRT mycoplasma genitalium Sequence located in MG182 at 45-54 and may interact with Sequence 496 in this patent. 495 Val Ile Gly Ser Gly Arg Thr Asp Lys Gly 1 5 10 496 10 PRT mycoplasma genitalium Sequence located in MG369 at 365-374 and may interact with Sequence 495 in this patent. 496 Asp Asp Thr Gly Ala Pro Ser Val Phe Ser 1 5 10 497 10 PRT mycoplasma genitalium Sequence located in MG187 at 286-295 and may interact with Sequence 498 in this patent. 497 Leu Lys Gln Leu Lys Arg Leu Ile Lys Val 1 5 10 498 10 PRT mycoplasma genitalium Sequence located in MG231 at 139-148 and may interact with Sequence 497 in this patent. 498 Asn Phe Asn Lys Ala Leu Lys Leu Leu Lys 1 5 10 499 10 PRT mycoplasma genitalium Sequence located in MG187 at 78-87 and may interact with Sequence 500 in this patent. 499 Glu Arg Lys Leu Gly Leu Val Phe Gln Asn 1 5 10 500 10 PRT mycoplasma genitalium Sequence located in MG437 at 78-87 and may interact with Sequence 499 in this patent. 500 Ile Leu Lys Asn Lys Pro Lys Leu Ser Leu 1 5 10 501 10 PRT mycoplasma genitalium Sequence located in MG188 at 255-264 and may interact with Sequence 502 in this patent. 501 Glu Asn Lys Pro Glu Glu Ala Val Ala Asn 1 5 10 502 10 PRT mycoplasma genitalium Sequence located in MG345 at 643-652 and may interact with Sequence 501 in this patent. 502 Ile Arg Asn Ser Leu Leu Arg Phe Ile Leu 1 5 10 503 10 PRT mycoplasma genitalium Sequence located in MG189 at 104-113 and may interact with Sequence 504 in this patent. 503 Arg Val Leu Ser Asp Gly Lys Tyr Leu Asn 1 5 10 504 10 PRT mycoplasma genitalium Sequence located in MG386 at 356-365 and may interact with Sequence 503 in this patent. 504 Thr Asn Glu Thr Ile Pro Leu Ile Glu Ile 1 5 10 505 10 PRT mycoplasma genitalium Sequence located in MG191 at 962-971 and may interact with Sequence 506 in this patent. 505 Asn Ala Ala Leu Leu His Thr Tyr Gly Phe 1 5 10 506 10 PRT mycoplasma genitalium Sequence located in MG321 at 605-614 and may interact with Sequence 505 in this patent. 506 Val Ser Ser Lys Gln Val Ser Val Thr Lys 1 5 10 507 10 PRT mycoplasma genitalium Sequence located in MG191 at 1411-1420 and may interact with Sequence 508 in this patent. 507 Ile Ile Asn Arg Thr Gly Ile Ser Asn Ala 1 5 10 508 10 PRT mycoplasma genitalium Sequence located in MG360 at 60-69 and may interact with Sequence 507 in this patent. 508 Asn Tyr Val Ala Arg Ser Tyr Gly Ile Arg 1 5 10 509 10 PRT mycoplasma genitalium Sequence located in MG191 at 1395-1404 and may interact with Sequence 510 in this patent. 509 Lys Lys Val Asp Val Leu Thr Lys Ala Val 1 5 10 510 10 PRT mycoplasma genitalium Sequence located in MG429 at 436-445 and may interact with Sequence 509 in this patent. 510 Asp Cys Leu Gly Lys His Val Asp Phe Phe 1 5 10 511 10 PRT mycoplasma genitalium Sequence located in MG191 at 1396-1405 and may interact with Sequence 512 in this patent. 511 Lys Val Asp Val Leu Thr Lys Ala Val Gly 1 5 10 512 10 PRT mycoplasma genitalium Sequence located in MG429 at 435-444 and may interact with Sequence 511 in this patent. 512 Ala Asp Cys Leu Gly Lys His Val Asp Phe 1 5 10 513 10 PRT mycoplasma genitalium Sequence located in MG191 at 1397-1406 and may interact with Sequence 514 in this patent. 513 Val Asp Val Leu Thr Lys Ala Val Gly Ser 1 5 10 514 10 PRT mycoplasma genitalium Sequence located in MG429 at 434-443 and may interact with Sequence 513 in this patent. 514 Ala Ala Asp Cys Leu Gly Lys His Val Asp 1 5 10 515 10 PRT mycoplasma genitalium Sequence located in MG191 at 14-23 and may interact with Sequence 516 in this patent. 515 Ala Phe Leu Thr Ala Ala Leu Thr Leu Gly 1 5 10 516 10 PRT mycoplasma genitalium Sequence located in MG456 at 309-318 and may interact with Sequence 515 in this patent. 516 Pro Glu Ser Lys Ser Ser Ser Gln Lys Ser 1 5 10 517 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 518 in this patent. 517 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 518 10 PRT mycoplasma genitalium Sequence located in MG338 at 358-367 and may interact with Sequence 517 in this patent. 518 Thr Thr Thr Thr Thr Thr Thr Gly Gly Thr 1 5 10 519 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 520 in this patent. 519 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 520 10 PRT mycoplasma genitalium Sequence located in MG338 at 357-366 and may interact with Sequence 519 in this patent. 520 Thr Thr Thr Thr Thr Thr Thr Thr Gly Gly 1 5 10 521 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 522 in this patent. 521 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 522 10 PRT mycoplasma genitalium Sequence located in MG338 at 356-365 and may interact with Sequence 521 in this patent. 522 Thr Thr Thr Thr Thr Thr Thr Thr Thr Gly 1 5 10 523 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 524 in this patent. 523 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 524 10 PRT mycoplasma genitalium Sequence located in MG338 at 355-364 and may interact with Sequence 523 in this patent. 524 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 525 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 526 in this patent. 525 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 526 10 PRT mycoplasma genitalium Sequence located in MG338 at 354-363 and may interact with Sequence 525 in this patent. 526 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 527 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 528 in this patent. 527 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 528 10 PRT mycoplasma genitalium Sequence located in MG338 at 358-367 and may interact with Sequence 527 in this patent. 528 Thr Thr Thr Thr Thr Thr Thr Gly Gly Thr 1 5 10 529 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 530 in this patent. 529 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 530 10 PRT mycoplasma genitalium Sequence located in MG338 at 357-366 and may interact with Sequence 529 in this patent. 530 Thr Thr Thr Thr Thr Thr Thr Thr Gly Gly 1 5 10 531 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 532 in this patent. 531 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 532 10 PRT mycoplasma genitalium Sequence located in MG338 at 356-365 and may interact with Sequence 531 in this patent. 532 Thr Thr Thr Thr Thr Thr Thr Thr Thr Gly 1 5 10 533 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 534 in this patent. 533 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 534 10 PRT mycoplasma genitalium Sequence located in MG338 at 355-364 and may interact with Sequence 533 in this patent. 534 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 535 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 536 in this patent. 535 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 536 10 PRT mycoplasma genitalium Sequence located in MG338 at 354-363 and may interact with Sequence 535 in this patent. 536 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 537 10 PRT mycoplasma genitalium Sequence located in MG192 at 411-420 and may interact with Sequence 538 in this patent. 537 Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 538 10 PRT mycoplasma genitalium Sequence located in MG338 at 359-368 and may interact with Sequence 537 in this patent. 538 Thr Thr Thr Thr Thr Thr Gly Gly Thr Ser 1 5 10 539 10 PRT mycoplasma genitalium Sequence located in MG192 at 411-420 and may interact with Sequence 540 in this patent. 539 Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 540 10 PRT mycoplasma genitalium Sequence located in MG338 at 357-366 and may interact with Sequence 539 in this patent. 540 Thr Thr Thr Thr Thr Thr Thr Thr Gly Gly 1 5 10 541 10 PRT mycoplasma genitalium Sequence located in MG192 at 411-420 and may interact with Sequence 542 in this patent. 541 Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 542 10 PRT mycoplasma genitalium Sequence located in MG338 at 356-365 and may interact with Sequence 541 in this patent. 542 Thr Thr Thr Thr Thr Thr Thr Thr Thr Gly 1 5 10 543 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 544 in this patent. 543 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 544 10 PRT mycoplasma genitalium Sequence located in MG338 at 358-367 and may interact with Sequence 543 in this patent. 544 Thr Thr Thr Thr Thr Thr Thr Gly Gly Thr 1 5 10 545 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 546 in this patent. 545 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 546 10 PRT mycoplasma genitalium Sequence located in MG338 at 357-366 and may interact with Sequence 545 in this patent. 546 Thr Thr Thr Thr Thr Thr Thr Thr Gly Gly 1 5 10 547 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 548 in this patent. 547 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 548 10 PRT mycoplasma genitalium Sequence located in MG338 at 356-365 and may interact with Sequence 547 in this patent. 548 Thr Thr Thr Thr Thr Thr Thr Thr Thr Gly 1 5 10 549 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 550 in this patent. 549 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 550 10 PRT mycoplasma genitalium Sequence located in MG338 at 355-364 and may interact with Sequence 549 in this patent. 550 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 551 10 PRT mycoplasma genitalium Sequence located in MG192 at 410-419 and may interact with Sequence 552 in this patent. 551 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 552 10 PRT mycoplasma genitalium Sequence located in MG338 at 354-363 and may interact with Sequence 551 in this patent. 552 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 553 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 554 in this patent. 553 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 554 10 PRT mycoplasma genitalium Sequence located in MG338 at 358-367 and may interact with Sequence 553 in this patent. 554 Thr Thr Thr Thr Thr Thr Thr Gly Gly Thr 1 5 10 555 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 556 in this patent. 555 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 556 10 PRT mycoplasma genitalium Sequence located in MG338 at 357-366 and may interact with Sequence 555 in this patent. 556 Thr Thr Thr Thr Thr Thr Thr Thr Gly Gly 1 5 10 557 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 558 in this patent. 557 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 558 10 PRT mycoplasma genitalium Sequence located in MG338 at 356-365 and may interact with Sequence 557 in this patent. 558 Thr Thr Thr Thr Thr Thr Thr Thr Thr Gly 1 5 10 559 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 560 in this patent. 559 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 560 10 PRT mycoplasma genitalium Sequence located in MG338 at 355-364 and may interact with Sequence 559 in this patent. 560 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 561 10 PRT mycoplasma genitalium Sequence located in MG192 at 409-418 and may interact with Sequence 562 in this patent. 561 Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 562 10 PRT mycoplasma genitalium Sequence located in MG338 at 354-363 and may interact with Sequence 561 in this patent. 562 Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr 1 5 10 563 10 PRT mycoplasma genitalium Sequence located in MG192 at 716-725 and may interact with Sequence 564 in this patent. 563 Ser Ser Leu Lys Pro Ser His Asp Gly Lys 1 5 10 564 10 PRT mycoplasma genitalium Sequence located in MG355 at 203-212 and may interact with Sequence 563 in this patent. 564 Leu Thr Ile Met Arg Gly Leu Lys Thr Arg 1 5 10 565 10 PRT mycoplasma genitalium Sequence located in MG192 at 407-416 and may interact with Sequence 566 in this patent. 565 Tyr Asp Ser Ser Ser Ser Ser Ser Ser Ser 1 5 10 566 10 PRT mycoplasma genitalium Sequence located in MG362 at 39-48 and may interact with Sequence 565 in this patent. 566 Ile Val Ala Ala Gly Ala Ala Gly Ala Thr 1 5 10 567 10 PRT mycoplasma genitalium Sequence located in MG192 at 406-415 and may interact with Sequence 568 in this patent. 567 Gly Tyr Asp Ser Ser Ser Ser Ser Ser Ser 1 5 10 568 10 PRT mycoplasma genitalium Sequence located in MG362 at 38-47 and may interact with Sequence 567 in this patent. 568 Pro Ile Val Ala Ala Gly Ala Ala Gly Ala 1 5 10 569 10 PRT mycoplasma genitalium Sequence located in MG192 at 236-245 and may interact with Sequence 570 in this patent. 569 Asp Ser Ser Gly Trp Ser Ser Thr Glu Glu 1 5 10 570 10 PRT mycoplasma genitalium Sequence located in MG383 at 180-189 and may interact with Sequence 569 in this patent. 570 Ile Thr Arg Ala Pro Thr Ala Ser Leu Phe 1 5 10 571 10 PRT mycoplasma genitalium Sequence located in MG194 at 106-115 and may interact with Sequence 572 in this patent. 571 Leu Tyr Gln Val Ile Asp Asn Leu Val Glu 1 5 10 572 10 PRT mycoplasma genitalium Sequence located in MG194 at 106-115 and may interact with Sequence 571 in this patent. 572 Leu Tyr Gln Val Ile Asp Asn Leu Val Glu 1 5 10 573 10 PRT mycoplasma genitalium Sequence located in MG194 at 181-190 and may interact with Sequence 574 in this patent. 573 Thr Asn Asn Pro Asp Ile Arg Val Val Ser 1 5 10 574 10 PRT mycoplasma genitalium Sequence located in MG194 at 181-190 and may interact with Sequence 573 in this patent. 574 Thr Asn Asn Pro Asp Ile Arg Val Val Ser 1 5 10 575 10 PRT mycoplasma genitalium Sequence located in MG194 at 182-191 and may interact with Sequence 576 in this patent. 575 Asn Asn Pro Asp Ile Arg Val Val Ser Leu 1 5 10 576 10 PRT mycoplasma genitalium Sequence located in MG194 at 180-189 and may interact with Sequence 575 in this patent. 576 Lys Thr Asn Asn Pro Asp Ile Arg Val Val 1 5 10 577 10 PRT mycoplasma genitalium Sequence located in MG194 at 168-177 and may interact with Sequence 578 in this patent. 577 Thr Ala Thr Thr Leu Lys Ala Val Arg Thr 1 5 10 578 10 PRT mycoplasma genitalium Sequence located in MG322 at 144-153 and may interact with Sequence 577 in this patent. 578 Arg Gly Gly Ser Lys Leu Gly Asn Thr Ser 1 5 10 579 10 PRT mycoplasma genitalium Sequence located in MG194 at 244-253 and may interact with Sequence 580 in this patent. 579 Arg Phe Arg Leu Ser His Phe Pro Phe Thr 1 5 10 580 10 PRT mycoplasma genitalium Sequence located in MG340 at 34-43 and may interact with Sequence 579 in this patent. 580 Ser Glu Gly Glu Val Thr Lys Ala Glu Thr 1 5 10 581 10 PRT mycoplasma genitalium Sequence located in MG196 at 31-40 and may interact with Sequence 582 in this patent. 581 Glu Asn Ser Thr Asn Leu Gly Ile Val Lys 1 5 10 582 10 PRT mycoplasma genitalium Sequence located in MG209 at 69-78 and may interact with Sequence 581 in this patent. 582 Phe Ile Thr Ser Val Glu Pro Tyr Asn Leu 1 5 10 583 10 PRT mycoplasma genitalium Sequence located in MG196 at 146-155 and may interact with Sequence 584 in this patent. 583 Val Phe Asp Asp Phe Tyr Gln Leu Val Lys 1 5 10 584 10 PRT mycoplasma genitalium Sequence located in MG252 at 82-91 and may interact with Sequence 583 in this patent. 584 Leu Asp Gln Leu Val Lys Val Val Glu Asn 1 5 10 585 10 PRT mycoplasma genitalium Sequence located in MG198 at 45-54 and may interact with Sequence 586 in this patent. 585 Ala Tyr Arg Asp Arg Arg Gln Lys Lys Arg 1 5 10 586 10 PRT mycoplasma genitalium Sequence located in MG309 at 11-20 and may interact with Sequence 585 in this patent. 586 Pro Leu Leu Leu Ser Ser Ile Ala Val Ser 1 5 10 587 10 PRT mycoplasma genitalium Sequence located in MG198 at 89-98 and may interact with Sequence 588 in this patent. 587 Ile Asn Arg Lys Val Leu Ser Glu Leu Ala 1 5 10 588 10 PRT mycoplasma genitalium Sequence located in MG463 at 8-17 and may interact with Sequence 587 in this patent. 588 Arg Lys Leu Gly Gln Asn Phe Thr Val Asn 1 5 10 589 10 PRT mycoplasma genitalium Sequence located in MG200 at 484-493 and may interact with Sequence 590 in this patent. 589 Pro Leu Val Ala Tyr Asn Gly Gly Ile Ile 1 5 10 590 10 PRT mycoplasma genitalium Sequence located in MG392 at 168-177 and may interact with Sequence 589 in this patent. 590 Gly Lys Asn Gly Val Ile Thr Thr Asp Asp 1 5 10 591 10 PRT mycoplasma genitalium Sequence located in MG200 at 483-492 and may interact with Sequence 592 in this patent. 591 Asp Pro Leu Val Ala Tyr Asn Gly Gly Ile 1 5 10 592 10 PRT mycoplasma genitalium Sequence located in MG392 at 167-176 and may interact with Sequence 591 in this patent. 592 Val Gly Lys Asn Gly Val Ile Thr Thr Asp 1 5 10 593 10 PRT mycoplasma genitalium Sequence located in MG203 at 539-548 and may interact with Sequence 594 in this patent. 593 Glu Thr Lys Asp Arg Lys Thr Val Lys Tyr 1 5 10 594 10 PRT mycoplasma genitalium Sequence located in MG406 at 8-17 and may interact with Sequence 593 in this patent. 594 Val Leu Asn Ser Leu Ser Val Leu Arg Leu 1 5 10 595 10 PRT mycoplasma genitalium Sequence located in MG204 at 576-585 and may interact with Sequence 596 in this patent. 595 Val Ser Lys Lys Pro Ile Leu Leu Glu Tyr 1 5 10 596 10 PRT mycoplasma genitalium Sequence located in MG468.1 at 139-148 and may interact with Sequence 595 in this patent. 596 Ile Phe Gln Gln Tyr Gly Leu Leu Arg Asp 1 5 10 597 10 PRT mycoplasma genitalium Sequence located in MG208 at 41-50 and may interact with Sequence 598 in this patent. 597 Asn Leu Thr Glu Leu Ala Val Tyr Tyr Leu 1 5 10 598 10 PRT mycoplasma genitalium Sequence located in MG377 at 90-99 and may interact with Sequence 597 in this patent. 598 Val Glu Gly Leu Lys Arg Asp Val Val Lys 1 5 10 599 10 PRT mycoplasma genitalium Sequence located in MG209 at 14-23 and may interact with Sequence 600 in this patent. 599 Asp Ser Leu Leu Ala Ser Leu Leu Asn Leu 1 5 10 600 10 PRT mycoplasma genitalium Sequence located in MG458 at 12-21 and may interact with Sequence 599 in this patent. 600 Gln Ile Glu Glu Gly Cys Gln Lys Ala Val 1 5 10 601 10 PRT mycoplasma genitalium Sequence located in MG212 at 240-249 and may interact with Sequence 602 in this patent. 601 Phe Asn Gln Ile Asp Ser Asn Asn Leu Ala 1 5 10 602 10 PRT mycoplasma genitalium Sequence located in MG265 at 129-138 and may interact with Sequence 601 in this patent. 602 Ser Gln Ile Val Gly Ile Asp Leu Ile Glu 1 5 10 603 10 PRT mycoplasma genitalium Sequence located in MG215 at 278-287 and may interact with Sequence 604 in this patent. 603 Leu Val Val Asn Asn Ala Asn Ser Gln Val 1 5 10 604 10 PRT mycoplasma genitalium Sequence located in MG428 at 29-38 and may interact with Sequence 603 in this patent. 604 Glu Asp Asp Ile Ile Ser Ile Ala Leu His 1 5 10 605 10 PRT mycoplasma genitalium Sequence located in MG217 at 209-218 and may interact with Sequence 606 in this patent. 605 Phe Asp Ser Tyr Asn Phe Arg Leu Asn Ser 1 5 10 606 10 PRT mycoplasma genitalium Sequence located in MG302 at 180-189 and may interact with Sequence 605 in this patent. 606 Thr Val Lys Ser Glu Ile Ile Arg Ile Lys 1 5 10 607 10 PRT mycoplasma genitalium Sequence located in MG218 at 1136-1145 and may interact with Sequence 608 in this patent. 607 Glu Ala Asn Ala Lys Lys Ala Phe Leu Ile 1 5 10 608 10 PRT mycoplasma genitalium Sequence located in MG336 at 370-379 and may interact with Sequence 607 in this patent. 608 Asn Lys Glu Ser Phe Leu Arg Val Ser Leu 1 5 10 609 10 PRT mycoplasma genitalium Sequence located in MG218 at 1323-1332 and may interact with Sequence 610 in this patent. 609 Glu Thr Glu Arg Lys Arg Ala Val Leu Glu 1 5 10 610 10 PRT mycoplasma genitalium Sequence located in MG340 at 212-221 and may interact with Sequence 609 in this patent. 610 Leu Lys Asn Ser Ser Leu Pro Phe Ser Leu 1 5 10 611 10 PRT mycoplasma genitalium Sequence located in MG222 at 91-100 and may interact with Sequence 612 in this patent. 611 Leu Ser Ile Thr Lys Phe Asp Gly Ile Leu 1 5 10 612 10 PRT mycoplasma genitalium Sequence located in MG303 at 209-218 and may interact with Sequence 611 in this patent. 612 Lys Asn Pro Ile Glu Leu Ser Asp Gly Gln 1 5 10 613 10 PRT mycoplasma genitalium Sequence located in MG226 at 95-104 and may interact with Sequence 614 in this patent. 613 Lys Ala Asn Asn Asn Ile Ile Ile Gly Leu 1 5 10 614 10 PRT mycoplasma genitalium Sequence located in MG226 at 95-104 and may interact with Sequence 613 in this patent. 614 Lys Ala Asn Asn Asn Ile Ile Ile Gly Leu 1 5 10 615 10 PRT mycoplasma genitalium Sequence located in MG226 at 400-409 and may interact with Sequence 616 in this patent. 615 Ile Ser Phe Ala Leu Val Ser Val Leu Leu 1 5 10 616 10 PRT mycoplasma genitalium Sequence located in MG231 at 269-278 and may interact with Sequence 615 in this patent. 616 Asp Thr Lys Arg Glu Asn Ala Asp Glu Lys 1 5 10 617 10 PRT mycoplasma genitalium Sequence located in MG226 at 116-125 and may interact with Sequence 618 in this patent. 617 Thr Phe Ile Ser Leu Phe Gly Leu Lys Ile 1 5 10 618 10 PRT mycoplasma genitalium Sequence located in MG352 at 68-77 and may interact with Sequence 617 in this patent. 618 Asp Phe Glu Ala Lys Gln Thr Asn Lys Ser 1 5 10 619 10 PRT mycoplasma genitalium Sequence located in MG230 at 37-46 and may interact with Sequence 620 in this patent. 619 Glu Lys Leu Gly Phe Gln His Lys Arg Ile 1 5 10 620 10 PRT mycoplasma genitalium Sequence located in MG255.1 at 7-16 and may interact with Sequence 619 in this patent. 620 Asn Ser Leu Val Leu Lys Pro Glu Leu Phe 1 5 10 621 10 PRT mycoplasma genitalium Sequence located in MG237 at 211-220 and may interact with Sequence 622 in this patent. 621 Ile Lys Lys Val Ser Gln Leu Phe Leu Lys 1 5 10 622 10 PRT mycoplasma genitalium Sequence located in MG384 at 313-322 and may interact with Sequence 621 in this patent. 622 Leu Lys Lys Glu Leu Gly Asn Leu Leu Asp 1 5 10 623 10 PRT mycoplasma genitalium Sequence located in MG242 at 424-433 and may interact with Sequence 624 in this patent. 623 Asn Asp Phe Tyr Gln Phe Glu Lys Asp Ile 1 5 10 624 10 PRT mycoplasma genitalium Sequence located in MG292 at 247-256 and may interact with Sequence 623 in this patent. 624 Asp Ile Phe Leu Lys Leu Ile Lys Ile Ile 1 5 10 625 10 PRT mycoplasma genitalium Sequence located in MG251 at 384-393 and may interact with Sequence 626 in this patent. 625 Cys Phe Glu Thr Thr Gly Ser Ile Gly Lys 1 5 10 626 10 PRT mycoplasma genitalium Sequence located in MG309 at 847-856 and may interact with Sequence 625 in this patent. 626 Ala Lys Leu Ser Arg Thr Thr Asn Ser Phe 1 5 10 627 10 PRT mycoplasma genitalium Sequence located in MG253 at 200-209 and may interact with Sequence 628 in this patent. 627 Ile Asp Tyr Cys Phe Lys Asn Glu Leu Thr 1 5 10 628 10 PRT mycoplasma genitalium Sequence located in MG356 at 223-232 and may interact with Sequence 627 in this patent. 628 Arg Lys Leu Val Phe Glu Thr Val Ile Tyr 1 5 10 629 10 PRT mycoplasma genitalium Sequence located in MG260 at 247-256 and may interact with Sequence 630 in this patent. 629 Gly Glu Thr Lys Asp Thr Thr Lys Ser Asp 1 5 10 630 10 PRT mycoplasma genitalium Sequence located in MG321 at 689-698 and may interact with Sequence 629 in this patent. 630 Ile Gly Leu Ser Ser Val Leu Gly Phe Ser 1 5 10 631 10 PRT mycoplasma genitalium Sequence located in MG260 at 138-147 and may interact with Sequence 632 in this patent. 631 Ser Arg Ile Gly Gly Ile Arg Asp Asp Gly 1 5 10 632 10 PRT mycoplasma genitalium Sequence located in MG329 at 27-36 and may interact with Sequence 631 in this patent. 632 Ala Ile Val Ser Asp Thr Pro Asn Thr Thr 1 5 10 633 10 PRT mycoplasma genitalium Sequence located in MG260 at 237-246 and may interact with Sequence 634 in this patent. 633 Ser Ser Ser Ser Ser Thr Thr Ser Thr Thr 1 5 10 634 10 PRT mycoplasma genitalium Sequence located in MG338 at 360-369 and may interact with Sequence 633 in this patent. 634 Thr Thr Thr Thr Thr Gly Gly Thr Ser Ser 1 5 10 635 10 PRT mycoplasma genitalium Sequence located in MG260 at 236-245 and may interact with Sequence 636 in this patent. 635 Ser Ser Ser Ser Ser Ser Thr Thr Ser Thr 1 5 10 636 10 PRT mycoplasma genitalium Sequence located in MG338 at 359-368 and may interact with Sequence 635 in this patent. 636 Thr Thr Thr Thr Thr Thr Gly Gly Thr Ser 1 5 10 637 10 PRT mycoplasma genitalium Sequence located in MG260 at 235-244 and may interact with Sequence 638 in this patent. 637 Arg Ser Ser Ser Ser Ser Ser Thr Thr Ser 1 5 10 638 10 PRT mycoplasma genitalium Sequence located in MG338 at 358-367 and may interact with Sequence 637 in this patent. 638 Thr Thr Thr Thr Thr Thr Thr Gly Gly Thr 1 5 10 639 10 PRT mycoplasma genitalium Sequence located in MG260 at 202-211 and may interact with Sequence 640 in this patent. 639 Ile Ala Asn Asp Ser Glu Thr Thr Lys Leu 1 5 10 640 10 PRT mycoplasma genitalium Sequence located in MG438 at 354-363 and may interact with Sequence 639 in this patent. 640 Glu Leu Ser Ser Leu Thr Val Ile Arg Asp 1 5 10 641 10 PRT mycoplasma genitalium Sequence located in MG260 at 56-65 and may interact with Sequence 642 in this patent. 641 Val Lys Lys Tyr Asn Asp Thr Lys Asp Pro 1 5 10 642 10 PRT mycoplasma genitalium Sequence located in MG447 at 304-313 and may interact with Sequence 641 in this patent. 642 Asn Leu Leu Val Val Val Ser Leu Ile Gly 1 5 10 643 10 PRT mycoplasma genitalium Sequence located in MG264 at 157-166 and may interact with Sequence 644 in this patent. 643 Pro Asn Cys Lys Ile Asp Thr Ile Phe Asn 1 5 10 644 10 PRT mycoplasma genitalium Sequence located in MG300 at 295-304 and may interact with Sequence 643 in this patent. 644 Gly Ile Thr Leu Asp Val Ser Asp Lys Ile 1 5 10 645 10 PRT mycoplasma genitalium Sequence located in MG265 at 204-213 and may interact with Sequence 646 in this patent. 645 Lys Ala Tyr Gly Leu Lys Val Leu Val Asp 1 5 10 646 10 PRT mycoplasma genitalium Sequence located in MG437 at 44-53 and may interact with Sequence 645 in this patent. 646 Ile Asn Glu Asn Phe Lys Ala Val Arg Phe 1 5 10 647 10 PRT mycoplasma genitalium Sequence located in MG265 at 11-20 and may interact with Sequence 648 in this patent. 647 Asp Gly Thr Leu Leu Ser Ser Asn Gln Ile 1 5 10 648 10 PRT mycoplasma genitalium Sequence located in MG453 at 58-67 and may interact with Sequence 647 in this patent. 648 Val Ser Ser Lys Lys Thr Ala Ile Leu Asp 1 5 10 649 10 PRT mycoplasma genitalium Sequence located in MG266 at 643-652 and may interact with Sequence 650 in this patent. 649 Phe Ala Tyr Asn Leu Phe Leu Lys Asn Ser 1 5 10 650 10 PRT mycoplasma genitalium Sequence located in MG422 at 311-320 and may interact with Sequence 649 in this patent. 650 Arg Ile Leu Glu Lys Lys Ile Val Ser Lys 1 5 10 651 10 PRT mycoplasma genitalium Sequence located in MG294 at 414-423 and may interact with Sequence 652 in this patent. 651 Lys Lys Tyr Thr Val Ala Gly Gln Ser Asn 1 5 10 652 10 PRT mycoplasma genitalium Sequence located in MG447 at 249-258 and may interact with Sequence 651 in this patent. 652 Leu Leu Val Arg Tyr Ser Ser Leu Gly Val 1 5 10 653 10 PRT mycoplasma genitalium Sequence located in MG301 at 11-20 and may interact with Sequence 654 in this patent. 653 Ala Ile Asn Gly Phe Gly Arg Ile Gly Arg 1 5 10 654 10 PRT mycoplasma genitalium Sequence located in MG395 at 209-218 and may interact with Sequence 653 in this patent. 654 Ser Asn Ile Pro Lys Thr Ala Tyr Thr Ala 1 5 10 655 10 PRT mycoplasma genitalium Sequence located in MG301 at 66-75 and may interact with Sequence 656 in this patent. 655 Lys Gln Asn Ile Leu Gln Ile Asp Arg Lys 1 5 10 656 10 PRT mycoplasma genitalium Sequence located in MG414 at 851-860 and may interact with Sequence 655 in this patent. 656 Leu Leu Val Asp Lys Leu Asn Ile Thr Leu 1 5 10 657 10 PRT mycoplasma genitalium Sequence located in MG301 at 73-82 and may interact with Sequence 658 in this patent. 657 Asp Arg Lys Lys Val Tyr Val Phe Ser Glu 1 5 10 658 10 PRT mycoplasma genitalium Sequence located in MG429 at 438-447 and may interact with Sequence 657 in this patent. 658 Leu Gly Lys His Val Asp Phe Phe Ser Ile 1 5 10 659 10 PRT mycoplasma genitalium Sequence located in MG301 at 283-292 and may interact with Sequence 660 in this patent. 659 Ser Ser Asp Val Val Ser Ser Glu Tyr Gly 1 5 10 660 10 PRT mycoplasma genitalium Sequence located in MG438 at 234-243 and may interact with Sequence 659 in this patent. 660 Ala Gly Ile Asp Asn Thr Gly Phe Val Ala 1 5 10 661 10 PRT mycoplasma genitalium Sequence located in MG303 at 34-43 and may interact with Sequence 662 in this patent. 661 Leu Phe Ser Phe Tyr Lys Lys Val Asp Lys 1 5 10 662 10 PRT mycoplasma genitalium Sequence located in MG390 at 441-450 and may interact with Sequence 661 in this patent. 662 Leu Val Asn Leu Phe Ile Glu Thr Lys Lys 1 5 10 663 10 PRT mycoplasma genitalium Sequence located in MG307 at 284-293 and may interact with Sequence 664 in this patent. 663 Gly Lys Asp Gly Leu Asn Thr Ala Lys Thr 1 5 10 664 10 PRT mycoplasma genitalium Sequence located in MG339 at 175-184 and may interact with Sequence 663 in this patent. 664 Gly Leu Arg Arg Ile Gln Ser Ile Leu Pro 1 5 10 665 10 PRT mycoplasma genitalium Sequence located in MG307 at 504-513 and may interact with Sequence 666 in this patent. 665 Gly Ser Tyr Tyr Leu Thr Lys Asn Ser Ser 1 5 10 666 10 PRT mycoplasma genitalium Sequence located in MG355 at 67-76 and may interact with Sequence 665 in this patent. 666 Thr Ala Ile Val Glu Gly Phe Val Arg Arg 1 5 10 667 10 PRT mycoplasma genitalium Sequence located in MG307 at 564-573 and may interact with Sequence 668 in this patent. 667 Leu Ile Leu Val Asn Ala Leu Ile Asn Thr 1 5 10 668 10 PRT mycoplasma genitalium Sequence located in MG414 at 495-504 and may interact with Sequence 667 in this patent. 668 Arg Ile Asp Glu Ser Ile Asp Lys Asn Glu 1 5 10 669 10 PRT mycoplasma genitalium Sequence located in MG307 at 124-133 and may interact with Sequence 670 in this patent. 669 Phe Ile Gln Gln Asp Leu Leu Asp Lys Ser 1 5 10 670 10 PRT mycoplasma genitalium Sequence located in MG463 at 68-77 and may interact with Sequence 669 in this patent. 670 Glu Tyr Leu Leu Val Glu Lys Ile Leu Thr 1 5 10 671 10 PRT mycoplasma genitalium Sequence located in MG317 at 148-157 and may interact with Sequence 672 in this patent. 671 Ile Asp Ala Gly Leu Pro Lys Ile Glu Val 1 5 10 672 10 PRT mycoplasma genitalium Sequence located in MG439 at 105-114 and may interact with Sequence 671 in this patent. 672 Asn Ile Ser Ala Lys Gly Leu Tyr Phe Asp 1 5 10 673 10 PRT mycoplasma genitalium Sequence located in MG321 at 591-600 and may interact with Sequence 674 in this patent. 673 Arg Thr Ala Ser Thr Ser Gly Ser Ser Ser 1 5 10 674 10 PRT mycoplasma genitalium Sequence located in MG321 at 591-600 and may interact with Sequence 673 in this patent. 674 Arg Thr Ala Ser Thr Ser Gly Ser Ser Ser 1 5 10 675 10 PRT mycoplasma genitalium Sequence located in MG321 at 205-214 and may interact with Sequence 676 in this patent. 675 Gly Phe Glu Thr Tyr Ile Leu Ser Ser Asn 1 5 10 676 10 PRT mycoplasma genitalium Sequence located in MG421 at 306-315 and may interact with Sequence 675 in this patent. 676 Ser Lys Leu Ser Ile Asn Gln Gly Ala Ile 1 5 10 677 10 PRT mycoplasma genitalium Sequence located in MG322 at 274-283 and may interact with Sequence 678 in this patent. 677 Leu Phe Asp Gly Phe Glu Ala Ile Lys Lys 1 5 10 678 10 PRT mycoplasma genitalium Sequence located in MG322 at 274-283 and may interact with Sequence 677 in this patent. 678 Leu Phe Asp Gly Phe Glu Ala Ile Lys Lys 1 5 10 679 10 PRT mycoplasma genitalium Sequence located in MG324 at 23-32 and may interact with Sequence 680 in this patent. 679 Ala Ile Leu Ile Gly Ser Asp Gln Asn Arg 1 5 10 680 10 PRT mycoplasma genitalium Sequence located in MG324 at 23-32 and may interact with Sequence 679 in this patent. 680 Ala Ile Leu Ile Gly Ser Asp Gln Asn Arg 1 5 10 681 10 PRT mycoplasma genitalium Sequence located in MG325 at 2-11 and may interact with Sequence 682 in this patent. 681 Ala Val Lys Arg Ser Thr Arg Leu Gly Cys 1 5 10 682 10 PRT mycoplasma genitalium Sequence located in MG468 at 1110-1119 and may interact with Sequence 681 in this patent. 682 Ala Ala Gln Thr Ser Thr Ser Leu Asn Arg 1 5 10 683 10 PRT mycoplasma genitalium Sequence located in MG327 at 126-135 and may interact with Sequence 684 in this patent. 683 Gln Thr Ser Phe Ser Val Asn Lys Lys Arg 1 5 10 684 10 PRT mycoplasma genitalium Sequence located in MG469 at 136-145 and may interact with Sequence 683 in this patent. 684 Pro Leu Phe Ile Tyr Gly Glu Thr Gly Leu 1 5 10 685 10 PRT mycoplasma genitalium Sequence located in MG330 at 113-122 and may interact with Sequence 686 in this patent. 685 Asn Lys Asn Ile Val Met Asp Gly Arg Asp 1 5 10 686 10 PRT mycoplasma genitalium Sequence located in MG393 at 3-12 and may interact with Sequence 685 in this patent. 686 Ile Thr Pro Ile His Asp Asn Val Leu Val 1 5 10 687 10 PRT mycoplasma genitalium Sequence located in MG330 at 114-123 and may interact with Sequence 688 in this patent. 687 Lys Asn Ile Val Met Asp Gly Arg Asp Ile 1 5 10 688 10 PRT mycoplasma genitalium Sequence located in MG393 at 2-11 and may interact with Sequence 687 in this patent. 688 Asn Ile Thr Pro Ile His Asp Asn Val Leu 1 5 10 689 10 PRT mycoplasma genitalium Sequence located in MG330 at 82-91 and may interact with Sequence 690 in this patent. 689 Thr Thr Gln Ser Val Ala Asn Ile Ala Ser 1 5 10 690 10 PRT mycoplasma genitalium Sequence located in MG448 at 116-125 and may interact with Sequence 689 in this patent. 690 Gly Gly Leu Arg Tyr Cys Ile Asn Ser Ala 1 5 10 691 10 PRT mycoplasma genitalium Sequence located in MG334 at 228-237 and may interact with Sequence 692 in this patent. 691 Asp Val Cys Leu Leu Val Asn Pro Lys Asp 1 5 10 692 10 PRT mycoplasma genitalium Sequence located in MG360 at 340-349 and may interact with Sequence 691 in this patent. 692 Ile Asn Thr Glu Lys Asn Val Arg Leu Ile 1 5 10 693 10 PRT mycoplasma genitalium Sequence located in MG335.2 at 210-219 and may interact with Sequence 694 in this patent. 693 Phe Ile Asp Val Ile Gly Thr Asn Tyr Phe 1 5 10 694 10 PRT mycoplasma genitalium Sequence located in MG421 at 683-692 and may interact with Sequence 693 in this patent. 694 Glu Ile Ile Gly Ala Asn Asn Ile Asp Lys 1 5 10 695 10 PRT mycoplasma genitalium Sequence located in MG338 at 485-494 and may interact with Sequence 696 in this patent. 695 Val Tyr Val Arg Gly Asp Asp Ala Ile Tyr 1 5 10 696 10 PRT mycoplasma genitalium Sequence located in MG357 at 240-249 and may interact with Sequence 695 in this patent. 696 Asp Ile Asp Pro Ala Ile Val Ser Tyr Ile 1 5 10 697 10 PRT mycoplasma genitalium Sequence located in MG338 at 484-493 and may interact with Sequence 698 in this patent. 697 Pro Val Tyr Val Arg Gly Asp Asp Ala Ile 1 5 10 698 10 PRT mycoplasma genitalium Sequence located in MG357 at 239-248 and may interact with Sequence 697 in this patent. 698 Gly Asp Ile Asp Pro Ala Ile Val Ser Tyr 1 5 10 699 10 PRT mycoplasma genitalium Sequence located in MG338 at 171-180 and may interact with Sequence 700 in this patent. 699 Asn Ser Ser Asp Thr Ser Val Ala Thr Thr 1 5 10 700 10 PRT mycoplasma genitalium Sequence located in MG412 at 68-77 and may interact with Sequence 699 in this patent. 700 Gly Gly Ser Asn Ala Gly Ile Arg Ala Ile 1 5 10 701 10 PRT mycoplasma genitalium Sequence located in MG342 at 45-54 and may interact with Sequence 702 in this patent. 701 Phe Tyr Ser Val Asp Leu Glu Ala Thr Asn 1 5 10 702 10 PRT mycoplasma genitalium Sequence located in MG392 at 220-229 and may interact with Sequence 701 in this patent. 702 Val Ser Ser Leu Lys Ile Asn Thr Ile Lys 1 5 10 703 10 PRT mycoplasma genitalium Sequence located in MG351 at 34-43 and may interact with Sequence 704 in this patent. 703 Ile Leu Phe Gly Ser Glu Ser Tyr Pro Gln 1 5 10 704 10 PRT mycoplasma genitalium Sequence located in MG459 at 3-12 and may interact with Sequence 703 in this patent. 704 Leu Arg Val Gly Leu Gly Ser Lys Lys Tyr 1 5 10 705 10 PRT mycoplasma genitalium Sequence located in MG354 at 9-18 and may interact with Sequence 706 in this patent. 705 Gln Leu Ile Ser Phe Phe Asn Gln Ala Cys 1 5 10 706 10 PRT mycoplasma genitalium Sequence located in MG442 at 235-244 and may interact with Sequence 705 in this patent. 706 Arg Gly Leu Ile Lys Lys Ala Asn Glu Leu 1 5 10 707 10 PRT mycoplasma genitalium Sequence located in MG360 at 347-356 and may interact with Sequence 708 in this patent. 707 Arg Leu Ile Gly Ile Ser Phe Phe Asp Leu 1 5 10 708 10 PRT mycoplasma genitalium Sequence located in MG386 at 563-572 and may interact with Sequence 707 in this patent. 708 Lys Ile Lys Glu Thr Asn Ser Asp Glu Ser 1 5 10 709 10 PRT mycoplasma genitalium Sequence located in MG365 at 8-17 and may interact with Sequence 710 in this patent. 709 Gly Thr Ser Thr Leu Ser Lys Lys Cys Leu 1 5 10 710 10 PRT mycoplasma genitalium Sequence located in MG457 at 273-282 and may interact with Sequence 709 in this patent. 710 Pro Gly Thr Gly Lys Thr Leu Leu Ala Lys 1 5 10 711 10 PRT mycoplasma genitalium Sequence located in MG366 at 440-449 and may interact with Sequence 712 in this patent. 711 Lys Lys Val Tyr Phe Asp Phe Glu Thr Ile 1 5 10 712 10 PRT mycoplasma genitalium Sequence located in MG407 at 429-438 and may interact with Sequence 711 in this patent. 712 Leu Leu Tyr Ile Glu Ile Glu Leu Gly Asp 1 5 10 713 10 PRT mycoplasma genitalium Sequence located in MG366 at 53-62 and may interact with Sequence 714 in this patent. 713 Pro Val Phe Glu Leu Asp Val Leu Glu Leu 1 5 10 714 10 PRT mycoplasma genitalium Sequence located in MG423 at 113-122 and may interact with Sequence 713 in this patent. 714 Arg Asp Lys Leu Glu Ile His Glu Leu Lys 1 5 10 715 10 PRT mycoplasma genitalium Sequence located in MG376 at 17-26 and may interact with Sequence 716 in this patent. 715 Ser His Lys Lys Thr Gly Phe Leu Val Thr 1 5 10 716 10 PRT mycoplasma genitalium Sequence located in MG376 at 17-26 and may interact with Sequence 715 in this patent. 716 Ser His Lys Lys Thr Gly Phe Leu Val Thr 1 5 10 717 10 PRT mycoplasma genitalium Sequence located in MG379 at 152-161 and may interact with Sequence 718 in this patent. 717 Gly Thr Tyr Leu Arg Ser Lys Thr Tyr Cys 1 5 10 718 10 PRT mycoplasma genitalium Sequence located in MG421 at 504-513 and may interact with Sequence 717 in this patent. 718 Arg Ile Arg Leu Ala Thr Gln Ile Gly Ser 1 5 10 719 10 PRT mycoplasma genitalium Sequence located in MG381 at 180-189 and may interact with Sequence 720 in this patent. 719 Phe Gly Glu Tyr Leu Ser Ser Phe His Leu 1 5 10 720 10 PRT mycoplasma genitalium Sequence located in MG451 at 286-295 and may interact with Sequence 719 in this patent. 720 Glu Val Glu Arg Gly Gln Val Leu Ala Lys 1 5 10 721 10 PRT mycoplasma genitalium Sequence located in MG390 at 388-397 and may interact with Sequence 722 in this patent. 721 Ala Ile Leu Gly Leu Gly Val Ile Gly Ile 1 5 10 722 10 PRT mycoplasma genitalium Sequence located in MG468 at 267-276 and may interact with Sequence 721 in this patent. 722 Ser Asp Glu Thr Lys Ala Asp Asn Thr Asp 1 5 10 723 10 PRT mycoplasma genitalium Sequence located in MG390 at 387-396 and may interact with Sequence 724 in this patent. 723 Phe Ala Ile Leu Gly Leu Gly Val Ile Gly 1 5 10 724 10 PRT mycoplasma genitalium Sequence located in MG468 at 266-275 and may interact with Sequence 723 in this patent. 724 Lys Ser Asp Glu Thr Lys Ala Asp Asn Thr 1 5 10 725 10 PRT mycoplasma genitalium Sequence located in MG391 at 392-401 and may interact with Sequence 726 in this patent. 725 Ser Ala Arg Gly Ala Gly Ser Ser Arg Ala 1 5 10 726 10 PRT mycoplasma genitalium Sequence located in MG391 at 392-401 and may interact with Sequence 725 in this patent. 726 Ser Ala Arg Gly Ala Gly Ser Ser Arg Ala 1 5 10 727 10 PRT mycoplasma genitalium Sequence located in MG393 at 85-94 and may interact with Sequence 728 in this patent. 727 Gly Asn Lys Tyr Lys Ile Ile Gly Phe Glu 1 5 10 728 10 PRT mycoplasma genitalium Sequence located in MG394 at 359-368 and may interact with Sequence 727 in this patent. 728 Phe Lys Thr Asn Asp Phe Ile Phe Val Ala 1 5 10 729 10 PRT mycoplasma genitalium Sequence located in MG395 at 456-465 and may interact with Sequence 730 in this patent. 729 Ser Glu Lys Asn Lys Thr Arg Thr Thr Asn 1 5 10 730 10 PRT mycoplasma genitalium Sequence located in MG398 at 5-14 and may interact with Sequence 729 in this patent. 730 Arg Phe Leu Val Leu Ser Pro Ser Gly Ile 1 5 10 731 10 PRT mycoplasma genitalium Sequence located in MG395 at 455-464 and may interact with Sequence 732 in this patent. 731 Glu Ser Glu Lys Asn Lys Thr Arg Thr Thr 1 5 10 732 10 PRT mycoplasma genitalium Sequence located in MG398 at 4-13 and may interact with Sequence 731 in this patent. 732 Leu Arg Phe Leu Val Leu Ser Pro Ser Gly 1 5 10 733 10 PRT mycoplasma genitalium Sequence located in MG397 at 303-312 and may interact with Sequence 734 in this patent. 733 Ser Ser Lys Glu Lys Ser Ile Asn Leu Val 1 5 10 734 10 PRT mycoplasma genitalium Sequence located in MG468 at 1655-1664 and may interact with Sequence 733 in this patent. 734 Asn Gln Val Asp Ala Phe Leu Leu Gly Thr 1 5 10 735 10 PRT mycoplasma genitalium Sequence located in MG411 at 29-38 and may interact with Sequence 736 in this patent. 735 Leu Phe Ile Ser Phe Phe Val Phe Leu Leu 1 5 10 736 10 PRT mycoplasma genitalium Sequence located in MG412 at 92-101 and may interact with Sequence 735 in this patent. 736 Lys Glu Tyr Ala Lys Glu Asn Glu Lys Lys 1 5 10 737 10 PRT mycoplasma genitalium Sequence located in MG411 at 535-544 and may interact with Sequence 738 in this patent. 737 Ile Phe Lys Ile Val Leu Pro Ser Ala Leu 1 5 10 738 10 PRT mycoplasma genitalium Sequence located in MG421 at 16-25 and may interact with Sequence 737 in this patent. 738 Lys Gly Ala Arg Glu Asn Asn Leu Lys Asn 1 5 10 739 10 PRT mycoplasma genitalium Sequence located in MG412 at 61-70 and may interact with Sequence 740 in this patent. 739 Val Glu Ile Ser Val Gln Ala Gly Gly Ser 1 5 10 740 10 PRT mycoplasma genitalium Sequence located in MG468 at 1113-1122 and may interact with Sequence 739 in this patent. 740 Thr Ser Thr Ser Leu Asn Arg Asn Phe Asn 1 5 10 741 10 PRT mycoplasma genitalium Sequence located in MG421 at 39-48 and may interact with Sequence 742 in this patent. 741 Thr Gly Leu Ser Gly Ser Gly Lys Ser Ser 1 5 10 742 10 PRT mycoplasma genitalium Sequence located in MG421 at 39-48 and may interact with Sequence 741 in this patent. 742 Thr Gly Leu Ser Gly Ser Gly Lys Ser Ser 1 5 10 743 10 PRT mycoplasma genitalium Sequence located in MG421 at 492-501 and may interact with Sequence 744 in this patent. 743 Arg Arg Ala Ser Thr Leu Ser Gly Gly Glu 1 5 10 744 10 PRT mycoplasma genitalium Sequence located in MG425 at 48-57 and may interact with Sequence 743 in this patent. 744 Pro Thr Gly Thr Gly Lys Thr Ala Ala Phe 1 5 10 745 10 PRT mycoplasma genitalium Sequence located in MG421 at 491-500 and may interact with Sequence 746 in this patent. 745 Ala Arg Arg Ala Ser Thr Leu Ser Gly Gly 1 5 10 746 10 PRT mycoplasma genitalium Sequence located in MG425 at 47-56 and may interact with Sequence 745 in this patent. 746 Ser Pro Thr Gly Thr Gly Lys Thr Ala Ala 1 5 10 747 10 PRT mycoplasma genitalium Sequence located in MG422 at 673-682 and may interact with Sequence 748 in this patent. 747 Leu Lys Lys Thr Asn Lys Lys Ile Lys Arg 1 5 10 748 10 PRT mycoplasma genitalium Sequence located in MG441 at 50-59 and may interact with Sequence 747 in this patent. 748 Ser Leu Tyr Leu Leu Val Arg Leu Phe Gln 1 5 10 749 10 PRT mycoplasma genitalium Sequence located in MG439 at 47-56 and may interact with Sequence 750 in this patent. 749 Ala Val Thr Phe Leu Lys Lys Gly Tyr Ser 1 5 10 750 10 PRT mycoplasma genitalium Sequence located in MG439 at 47-56 and may interact with Sequence 749 in this patent. 750 Ala Val Thr Phe Leu Lys Lys Gly Tyr Ser 1 5 10 751 10 PRT mycoplasma genitalium Sequence located in MG439 at 157-166 and may interact with Sequence 752 in this patent. 751 Thr Gly Ile Val Gly Ser Asp Asn Thr Ser 1 5 10 752 10 PRT mycoplasma genitalium Sequence located in MG439 at 157-166 and may interact with Sequence 751 in this patent. 752 Thr Gly Ile Val Gly Ser Asp Asn Thr Ser 1 5 10 753 10 PRT mycoplasma genitalium Sequence located in MG457 at 564-573 and may interact with Sequence 754 in this patent. 753 Glu Ile Thr Thr Gly Ala Ser Ser Asp Phe 1 5 10 754 10 PRT mycoplasma genitalium Sequence located in MG457 at 564-573 and may interact with Sequence 753 in this patent. 754 Glu Ile Thr Thr Gly Ala Ser Ser Asp Phe 1 5 10 755 10 PRT mycoplasma genitalium Sequence located in MG015 at 184-193 and may interact with Sequence 2 in this patent. 755 Ser Phe Ala Phe Leu Lys Lys Ser Lys Thr 1 5 10 756 10 PRT mycoplasma genitalium Sequence located in MG015 at 184-193 and may interact with Sequence 1 in this patent. 756 Ser Phe Ala Phe Leu Lys Lys Ser Lys Thr 1 5 10 757 10 PRT mycoplasma genitalium Sequence located in MG049 at 102-111 and may interact with Sequence 4 in this patent. 757 Gly Asp Pro Leu Arg Ala Lys Trp Ile Ala 1 5 10 758 10 PRT mycoplasma genitalium Sequence located in MG049 at 102-111 and may interact with Sequence 3 in this patent. 758 Gly Asp Pro Leu Arg Ala Lys Trp Ile Ala 1 5 10 759 10 PRT mycoplasma genitalium Sequence located in MG065 at 104-113 and may interact with Sequence 6 in this patent. 759 Glu Thr Val Ile Ala Ser Tyr Asn Ser Phe 1 5 10 760 10 PRT mycoplasma genitalium Sequence located in MG065 at 104-113 and may interact with Sequence 5 in this patent. 760 Glu Thr Val Ile Ala Ser Tyr Asn Ser Phe 1 5 10 761 10 PRT mycoplasma genitalium Sequence located in MG271 at 243-252 and may interact with Sequence 8 in this patent. 761 Leu Phe Tyr Thr Val Asn Gly Val Glu Gln 1 5 10 762 10 PRT mycoplasma genitalium Sequence located in MG271 at 243-252 and may interact with Sequence 7 in this patent. 762 Leu Phe Tyr Thr Val Asn Gly Val Glu Gln 1 5 10 763 10 PRT mycoplasma genitalium Sequence located in MG276 at 85-94 and may interact with Sequence 10 in this patent. 763 Ala Asn Lys Leu Pro Gly Gln Leu Ile Ser 1 5 10 764 10 PRT mycoplasma genitalium Sequence located in MG276 at 85-94 and may interact with Sequence 9 in this patent. 764 Ala Asn Lys Leu Pro Gly Gln Leu Ile Ser 1 5 10 765 10 PRT mycoplasma genitalium Sequence located in MG027 at 94-103 and may interact with Sequence 12 in this patent. 765 Ser Gly Lys Lys Ile Asp Leu Leu Thr Thr 1 5 10 766 10 PRT mycoplasma genitalium Sequence located in MG027 at 94-103 and may interact with Sequence 11 in this patent. 766 Ser Gly Lys Lys Ile Asp Leu Leu Thr Thr 1 5 10 767 10 PRT mycoplasma genitalium Sequence located in MG088 at 3-12 and may interact with Sequence 14 in this patent. 767 Lys Asn Arg Ala Leu Lys Arg Thr Val Leu 1 5 10 768 10 PRT mycoplasma genitalium Sequence located in MG088 at 3-12 and may interact with Sequence 13 in this patent. 768 Lys Asn Arg Ala Leu Lys Arg Thr Val Leu 1 5 10 769 10 PRT mycoplasma genitalium Sequence located in MG088 at 4-13 and may interact with Sequence 16 in this patent. 769 Asn Arg Ala Leu Lys Arg Thr Val Leu Pro 1 5 10 770 10 PRT mycoplasma genitalium Sequence located in MG088 at 2-11 and may interact with Sequence 15 in this patent. 770 Arg Lys Asn Arg Ala Leu Lys Arg Thr Val 1 5 10 771 10 PRT mycoplasma genitalium Sequence located in MG130 at 385-394 and may interact with Sequence 18 in this patent. 771 Ala Arg Ile Gly Ala Arg Ser Asp Ser Ser 1 5 10 772 10 PRT mycoplasma genitalium Sequence located in MG130 at 385-394 and may interact with Sequence 17 in this patent. 772 Ala Arg Ile Gly Ala Arg Ser Asp Ser Ser 1 5 10 773 10 PRT mycoplasma genitalium Sequence located in MG149 at 180-189 and may interact with Sequence 20 in this patent. 773 Ile Phe Leu Val Ile Asp Tyr Lys Lys Asp 1 5 10 774 10 PRT mycoplasma genitalium Sequence located in MG149 at 180-189 and may interact with Sequence 19 in this patent. 774 Ile Phe Leu Val Ile Asp Tyr Lys Lys Asp 1 5 10 775 10 PRT mycoplasma genitalium Sequence located in MG149 at 181-190 and may interact with Sequence 22 in this patent. 775 Phe Leu Val Ile Asp Tyr Lys Lys Asp Ser 1 5 10 776 10 PRT mycoplasma genitalium Sequence located in MG149 at 179-188 and may interact with Sequence 21 in this patent. 776 Gly Ile Phe Leu Val Ile Asp Tyr Lys Lys 1 5 10 777 10 PRT mycoplasma genitalium Sequence located in MG169 at 40-49 and may interact with Sequence 24 in this patent. 777 Lys Ala Arg Lys Ser Gly Leu Thr Arg Leu 1 5 10 778 10 PRT mycoplasma genitalium Sequence located in MG169 at 40-49 and may interact with Sequence 23 in this patent. 778 Lys Ala Arg Lys Ser Gly Leu Thr Arg Leu 1 5 10 779 10 PRT mycoplasma genitalium Sequence located in MG194 at 106-115 and may interact with Sequence 26 in this patent. 779 Leu Tyr Gln Val Ile Asp Asn Leu Val Glu 1 5 10 780 10 PRT mycoplasma genitalium Sequence located in MG194 at 106-115 and may interact with Sequence 25 in this patent. 780 Leu Tyr Gln Val Ile Asp Asn Leu Val Glu 1 5 10 781 10 PRT mycoplasma genitalium Sequence located in MG194 at 181-190 and may interact with Sequence 28 in this patent. 781 Thr Asn Asn Pro Asp Ile Arg Val Val Ser 1 5 10 782 10 PRT mycoplasma genitalium Sequence located in MG194 at 181-190 and may interact with Sequence 27 in this patent. 782 Thr Asn Asn Pro Asp Ile Arg Val Val Ser 1 5 10 783 10 PRT mycoplasma genitalium Sequence located in MG194 at 182-191 and may interact with Sequence 30 in this patent. 783 Asn Asn Pro Asp Ile Arg Val Val Ser Leu 1 5 10 784 10 PRT mycoplasma genitalium Sequence located in MG194 at 180-189 and may interact with Sequence 29 in this patent. 784 Lys Thr Asn Asn Pro Asp Ile Arg Val Val 1 5 10 785 10 PRT mycoplasma genitalium Sequence located in MG226 at 95-104 and may interact with Sequence 32 in this patent. 785 Lys Ala Asn Asn Asn Ile Ile Ile Gly Leu 1 5 10 786 10 PRT mycoplasma genitalium Sequence located in MG226 at 95-104 and may interact with Sequence 31 in this patent. 786 Lys Ala Asn Asn Asn Ile Ile Ile Gly Leu 1 5 10 787 10 PRT mycoplasma genitalium Sequence located in MG321 at 591-600 and may interact with Sequence 34 in this patent. 787 Arg Thr Ala Ser Thr Ser Gly Ser Ser Ser 1 5 10 788 10 PRT mycoplasma genitalium Sequence located in MG321 at 591-600 and may interact with Sequence 33 in this patent. 788 Arg Thr Ala Ser Thr Ser Gly Ser Ser Ser 1 5 10 789 10 PRT mycoplasma genitalium Sequence located in MG322 at 274-283 and may interact with Sequence 36 in this patent. 789 Leu Phe Asp Gly Phe Glu Ala Ile Lys Lys 1 5 10 790 10 PRT mycoplasma genitalium Sequence located in MG322 at 274-283 and may interact with Sequence 35 in this patent. 790 Leu Phe Asp Gly Phe Glu Ala Ile Lys Lys 1 5 10 791 10 PRT mycoplasma genitalium Sequence located in MG324 at 23-32 and may interact with Sequence 38 in this patent. 791 Ala Ile Leu Ile Gly Ser Asp Gln Asn Arg 1 5 10 792 10 PRT mycoplasma genitalium Sequence located in MG324 at 23-32 and may interact with Sequence 37 in this patent. 792 Ala Ile Leu Ile Gly Ser Asp Gln Asn Arg 1 5 10 793 10 PRT mycoplasma genitalium Sequence located in MG376 at 17-26 and may interact with Sequence 40 in this patent. 793 Ser His Lys Lys Thr Gly Phe Leu Val Thr 1 5 10 794 10 PRT mycoplasma genitalium Sequence located in MG376 at 17-26 and may interact with Sequence 39 in this patent. 794 Ser His Lys Lys Thr Gly Phe Leu Val Thr 1 5 10 795 10 PRT mycoplasma genitalium Sequence located in MG391 at 392-401 and may interact with Sequence 42 in this patent. 795 Ser Ala Arg Gly Ala Gly Ser Ser Arg Ala 1 5 10 796 10 PRT mycoplasma genitalium Sequence located in MG391 at 392-401 and may interact with Sequence 41 in this patent. 796 Ser Ala Arg Gly Ala Gly Ser Ser Arg Ala 1 5 10 797 10 PRT mycoplasma genitalium Sequence located in MG421 at 39-48 and may interact with Sequence 44 in this patent. 797 Thr Gly Leu Ser Gly Ser Gly Lys Ser Ser 1 5 10 798 10 PRT mycoplasma genitalium Sequence located in MG421 at 39-48 and may interact with Sequence 43 in this patent. 798 Thr Gly Leu Ser Gly Ser Gly Lys Ser Ser 1 5 10 799 10 PRT mycoplasma genitalium Sequence located in MG439 at 47-56 and may interact with Sequence 46 in this patent. 799 Ala Val Thr Phe Leu Lys Lys Gly Tyr Ser 1 5 10 800 10 PRT mycoplasma genitalium Sequence located in MG439 at 47-56 and may interact with Sequence 45 in this patent. 800 Ala Val Thr Phe Leu Lys Lys Gly Tyr Ser 1 5 10 801 10 PRT mycoplasma genitalium Sequence located in MG439 at 157-166 and may interact with Sequence 48 in this patent. 801 Thr Gly Ile Val Gly Ser Asp Asn Thr Ser 1 5 10 802 10 PRT mycoplasma genitalium Sequence located in MG439 at 157-166 and may interact with Sequence 47 in this patent. 802 Thr Gly Ile Val Gly Ser Asp Asn Thr Ser 1 5 10 803 10 PRT mycoplasma genitalium Sequence located in MG457 at 564-573 and may interact with Sequence 50 in this patent. 803 Glu Ile Thr Thr Gly Ala Ser Ser Asp Phe 1 5 10 804 10 PRT mycoplasma genitalium Sequence located in MG457 at 564-573 and may interact with Sequence 49 in this patent. 804 Glu Ile Thr Thr Gly Ala Ser Ser Asp Phe 1 5 10 

We claim:
 1. A set of peptide ligands; said set consisting of specific complementary peptides to proteins encoded by genes of the genome of a microbe.
 2. A set of peptide ligands according to claim 1, wherein the genome is of a pathogenic microbe.
 3. A set of peptide ligands according to claim 2, wherein the pathogenic microbe is selected from the group consisting of Borrelia burgdorferi, Chlamydia Pneumoniae, Chlamydia Trachomatis, Echerichia Coli, Haemophilus Influenzae, Helicobacter Pylori, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Rickettsia Prowazekii and Treponema Pallidum.
 4. A set of peptide ligands according to claim 3, wherein the sequences of the peptides in the set are intra-molecular complementary peptide sequences and are selected from the group consisting of Borrelia burgdorferi, Chlamydia Pneumoniae, Chlamydia Trachomatis, Echerichia Coli, Haemophilus Influenzae, Helicobacter Pylori, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Rickettsia Prowazekii and Treponema Pallidum.
 5. A set of peptide ligands according to claim 3, wherein the sequences of the peptides in the set are inter-molecular complementary peptide sequences and are selected from the group consisting of Borrelia burgdorferi, Chlamydia Pneumoniae, Chlamydia Trachomatis, Echerichia Coli, Haemophilus Influenzae, Helicobacter Pylori, Mycobacterium tuberculosis, Mycoplasma genitalium, Mycoplasma pneumoniae, Rickettsia Prowazekii and Treponema Pallidum.
 6. A novel peptide having a sequence which is a member of a set according to any preceding claim, capable of antagonising or agonising a specific interaction of a protein with another protein or receptor.
 7. Use of a set of peptides according to any of claims 1 to 5 in an assay for screening and identification of one or more peptides according to claim
 6. 8. Use according to claim 7 wherein the identified peptide(s) is an anti-infective drug candidate.
 9. Use according to claim 7 wherein the identified peptide(s) is an anti-infective pro-drug.
 10. A partly or wholly non-peptide mimetic of a peptide drug candidate or pro-dlrug according to claim 6, 8 or 9, identified by use of the set of peptides a ccording to claim
 7. 11. A method for identifying a peptide drug candidate or pro-drug which is anti-infective against a microbe, which method includes the steps of (i) identifying a set of specific complementary peptides according to any of claims 1 to 5; (ii) screening the set for specific protein interaction activity; and (iii) identifying one or more peptide(s) according to claim
 6. 12. A method for processing sequence data comprising the steps of; selecting a first protein sequence and a second protein sequence; selecting a frame size corresponding to a number of sequence elements such as amino acids or triplet codons, a score threshold, and a frame existence probability threshold; comparing each frame of the first sequence with each frame of the second sequence by comparing pairs of sequence elements at corresponding positions within each such pair of frames to evaluate a complementary relationship score for each pair of frames; storing details of any pairs of frames for which the score equals or exceeds the score threshold; evaluating for each stored pair of frames the probability of the existence of that complementary pair of frames existing, on the basis of the number of possible complementary sequence elements existing for each sequence element in the pair of frames; and discarding any stored pairs of frames for which the evaluated probability is greater than the probability threshold; wherein each frame is a peptide sequence of defined length.
 13. A method according to claim 12, in which the first sequence is identical to the second sequence and a frame at a given position in the first sequence is only compared with frames in the second sequence at the same given position or at later positions in the second sequence, in order to eliminate repetition of comparisons.
 14. A method according to claim 12 or 13, in which the sequence elements at corresponding positions within each of a pair of frames are compared sequentially, each such pair of sequence elements generating a score which is added to an aggregate score for the pair of frames.
 15. A method according to claim 14, in which if the aggregate score reaches the score threshold before all the pairs of sequence elements in the pair of frames have been compared, details of the pair of frames are immediately stored and a new pair of frames is selected for comparison.
 16. A method according to any preceding claim, in which the sequence elements are amino acids and pairs of amino acids are compared by using an antisense score list.
 17. A method according to any of claims 12 to 15, in which the sequence elements are triplet codons and pairs of codons in corresponding positions within each of the pairs of triplet codons are compared by using an antisense score list.
 18. A method for processing sequence data substantially as described herein with reference to FIGS. 1 to
 6. 19. A pair of frames or a list of pairs of frames being the product of the method of any of claims 12 to 18, optionally carried on a computer-readable medium.
 20. A frame being the product of the method of any of claims 12 to 18, optionally carried on a computer-readable medium.
 21. A peptide, pair of complementary peptides, or set of peptides, being the peptide(s) having the sequence of the frame(s) of claim 19 or
 20. 